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Abstract 
Diabetes mellitus triples the risk of developing coronary heart disease (CHD). 
The manifestations of CHD are more severe in patients with diabetes with both 
more extensive and more diffuse disease. Outcomes in patients with diabetes 
are significantly worse both in terms of Major Adverse Cardiovascular Events 
(MACE) overall and specifically following revascularisation procedures such as 
percutaneous coronary intervention (PCI). Furthermore patients with chronic 
kidney disease (CKD) are excluded from the vast majority of cardiology trials and 
therefore there is a lack of data for these patients. Contrast induced acute kidney 
injury (AKI) is an important complication following procedures in the cardiac 
catheterisation laboratory and patients with diabetes are at particular risk. 
Patients with diabetes and CKD are a particular challenge. They have an 
extremely high incidence of co-morbidities such as CHD and peripheral vascular 
disease (PVD). When renal function is already impaired by other pathological 
processes, the kidney is much less capable of tolerating the stress of excreting a 
contrast load. If AKI develops, there is a risk of further loss of nephron units and 
irreversible reduction in residual renal function. Earlier identification of patients 
as risk of developing AKI will allow earlier therapeutic intervention which might 
translate into improved clinical outcomes for these patients. 
The study aimed to evaluate the incidence of contrast induced AKI in a high risk 
population (diabetes and CKD) undergoing coronary angiography and PCI. 
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From a literature review Neutrophil Gelatinase Associated Lipocalin (NGAL) and 
Interleukin-18 (IL-18) were identified as promising candidates for inclusion in a 
‘renal injury’ biomarker panel for development of AKI early post coronary 
angiography or PCI. It was then determined if concentrations of these markers 
changed significantly at various time intervals post procedure. The aim was to 
establish a panel of markers with the best predictive ability for identifying 
development of AKI.  
208 patients with a known diagnosis of diabetes mellitus and CKD (eGFR < 60 
ml/min) were recruited over a one year period at The London Chest Hospital. 39 
patients (18.8%) developed contrast induced AKI. There were no significant 
differences between patients who did/did not develop AKI with respect to 
baseline demographics, cardiac risk factors and co-morbidities. There was a 
significant trend towards patients in the AKI group having a higher NYHA Class 
(p=0.048) and this was further supported by echocardiogram and other imaging 
data. Additional reinforcement came from the higher rate of loop diuretic 
prescription (59% vs 26.9%) in the AKI group, p=0.012.  
59 patients underwent renal angiography at the time of their coronary procedure. 
There was no association between presence of structural renal disease and 
development of AKI. 7 patients (12.5%) had moderate or severe renal artery 
stenosis with 1 patient requiring further renal angioplasty due to the presence of 
a critical lesion.  
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There was no association between severity of CAD as assessed by the SYNTAX 
score and development of AKI. However the Clinical SYNTAX score (CSS) was 
significantly higher in patients who developed AKI (82.7 vs. 35.4, p=0.036). The 
CSS also had a reasonable accuracy for predicting AKI with a C statistic = 0.64 
on ROC analysis. The Mehran risk score also performed well at identifying 
patients with AKI with a C statistic of 0.69. ROC curve analysis did not suggest 
that either NGAL or IL-18 in isolation were particularly beneficial markers of AKI 
in our patient cohort as our best C statistic was 0.634 for serum NGAL, 2h post 
procedure. However on exploratory analysis a 20% rise in urine NGAL at 2h, 
combined with a 20% rise in urine IL-18 at 2 hours and the Mehran risk score 
had a C statistic of 0.77. Simple scoring systems such as the Mehran score and 
CSS are useful tools for risk stratifying patients in both the clinical and research 
settings. 
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Chapter One: Introduction  
1.1 The diabetic coronary disease epidemic 
The developed world is in the midst of a worldwide epidemic of diabetes mellitus, almost 
totally attributable to an increase in Type 2 diabetes mellitus (T2DM). It is estimated that 
approximately 8% of the adult population in the developed world have T2DM and it is 
predicted that the prevalence will at least double over the next 12 - 15 years to 
approximately 300 million affected by 2025 (1-3). Yet these projections are likely to 
underestimate the scale of the problem as it has been estimated that up to 50% of the 
general population may be affected but undiagnosed (4-6). Furthermore up to double 
the number of patients who have T2DM have insulin resistance syndrome, associated 
with an elevated risk of development of T2DM (7). Causative factors include increasing 
obesity, sedentary lifestyles with decreasing rates of physical activity, increasing dietary 
calorie intake and an aging population (8).  
Atherosclerosis is often present in patients at the time of diagnosis of T2DM, a finding 
that suggests that the preceding ‘pre-diabetic’ period is a key stage in plaque 
development. Coronary heart disease (CHD) is the leading cause of death in patients 
with diabetes and additionally is associated with increased morbidity and increased 
rates of stroke and peripheral vascular disease; together these are defined as 
macrovascular disease (9-13). Overall the age adjusted mortality rates associated with 
CHD have declined over the last 20 years but this has not been reflected in patients with 
T2DM (14-16). Data from the MRFIT (Multiple Risk Factor Intervention Trial) trial data 
(13) shows that men with T2DM have a threefold higher absolute risk of 
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cardiovascular death than those without diabetes and this is present even after adjusting 
for age, race, cholesterol, blood pressure, smoking and socio-economic status.  
T2DM trebles the risk of developing CHD and once this has developed the risk of acute 
coronary syndromes (ACS) doubles with an additional doubling of clinical risk once a 
coronary event has occurred (17-20). The Framingham study (10) found that even after 
adjustment for other factors, diabetic patients had increased mortality and a higher 
incidence of reinfarction and heart failure in both the acute and post-infarct setting. One 
year mortality post MI is double in diabetic compared to non-diabetic patients (21). 
Approximately 20% of patients in the United Kingdom undergoing cardiac 
catheterisation procedures have a diagnosis of diabetes (7;22) and in recent 
randomised trials diabetic patients accounted for over 20% of revascularisation 
procedures (23-26). At the London Chest Hospital, patients with diabetes account for 
approximately 30% of revascularisation procedures reflecting the demographics of our 
institution’s referral base (22). Outcomes following coronary revascularisation (either by 
percutaneous coronary intervention, (PCI) or coronary artery bypass grafting (CABG) 
are significantly worse in patients with diabetes compared with non-diabetic patients (26-
34).  
Patients with diabetes have a higher rate of repeat revascularisation procedures 
following the index procedure. In addition to the increased risk associated with diabetes 
itself, the manifestations of CHD in diabetic patients are more severe with both more 
extensive and diffuse disease of the coronary arteries (34;35). Data from the BARI 
(Bypass Angioplasty Revascularisation Investigation) Trial (35) showed that diabetic 
patients had a higher incidence than non-diabetic patients of triple vessel disease 
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(TVD) (46% vs. 40%, p<0.05) and left ventricular function (LV function) below 50% (31% 
vs. 20%, p<0.001) resulting in a significantly lower 5 year survival. 
1.2 Why is diabetic coronary disease different? 
The metabolic abnormalities that characterise diabetes are summarised in Figure 1. 
Figure 1: Summary of key metabolic abnormalities in diabetes mellitus 
 
(adapted from D’Souza et al Mol Cell Biochem 2009 (36)). The metabolic abnormalities which characterise diabetes, 
particularly hyperglycaemia, free fatty acids and insulin resistance stimulate molecular mechanisms causing alterations in 
the structure and function of blood vessels. These mechanisms include increased oxidative stress, alterations of 
intercellular signal transduction (e.g. activation of PKC) and activation of RAGE. The result is decreased availability of 
NO, increased production of ET-1, activation of transcription factors such as NF-κB and AP-1 and increased generation of 
pro-thrombotic factors such as TF and PAI-1. (Abbreviations: ROS: Reactive Oxygen Species, PKC: Protein Kinase C, 
RAGE: Receptor for Advanced Glycation End Products, NO: Nitric oxide, ET-1: Endothelin-1, NF-κB: Nuclear Factor 
Kappa B, AP-1: Activator Protein-1, TF: Tissue Factor, PAI-1: Plasminogen activator inhibitor-1). 
 
27 
Several biological mechanisms exist that account for the premature development of 
atherosclerosis and the increased risk of CHD in patients with diabetes. This is due to a 
combination of general risk factors such as hypertension and hyperlipidaemia which are 
more prevalent in diabetes (37), and specific risks resulting from the triad of 
hyperinsulinaemia, insulin resistance and hyperglycaemia (38). These risks are 
summarised in Table 1.  
Table 1: Factors which increase risk of CHD in Diabetes 
Factor Effect 
Dyslipidaemia Increased LDL and triglyceride rich VLDL 
Reduced HDL 
Endothelial dysfunction Increased expression of cellular adhesion molecules 
Impaired vasomotor activity due to decreased availability 
of nitric oxide 
Oxidative stress Increased concentrations of markers such as oxidised LDLs 
and F2-isoprostanes 
Inflammation Increased expression of markers such as fibrinogen and 
CRP 
Abnormalities of coagulation and 
fibrinolysis 
Overproduction of fibrinogen 
Expression of PAI-1 
Reduced t-PA 
Glycation of proteins Formation of proatherogenic advanced glycation end 
products (AGE) in LDL and collagen within the arterial wall 
(Adapted from Kapur and Qureshi Chapter 21: Oxford Textbook of Interventional Cardiology (39). Abbreviations: HDL: 
high density lipoprotein; LDL: Low Density Lipoprotein, VLDL: Very Low Density Lipoprotein; CRP: C-Reactive Protein; 
tPA: tissue plasminogen activator; PAI-1: Plasminogen activator inhibitor -1). 
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1.2.1 Dyslipidaemia 
Diabetic patients have a characteristic but abnormal lipid profile probably due to a 
combination of insulin resistance and a general failure of insulin activity. This results in 
an increase in release from adipose tissue of free fatty acids, increased transport of free 
fatty acids to the liver and increased synthesis of VLDL (40;41). Other findings include 
elevated concentrations of small dense LDLs, triglyceride-rich VLDLs and low 
concentrations of HDL. This abnormal profile is associated with significantly increased 
cardiovascular risk (42;43). Triglyceride levels appear to be directly linked to the degree 
of glucose intolerance and glycaemic control but these have less of an effect on HDL 
and LDL levels (44).  
1.2.2 Endothelial dysfunction 
Endothelial dysfunction is a very early marker of atherosclerosis and is a key feature of 
the severe arteriopathy that can occur in the pre-diabetic state. The combination of 
hyperglycaemia, hypertension, dyslipidaemia and insulin resistance cause endothelial 
damage and the resulting endothelial dysfunction is a consequence of both 
microvascular and macrovascular complications developing (45-47). Further evidence 
supporting the hypothesis that macrovascular disease can arise in the pre-diabetic 
period is that these patients have an increased concentration of endothelial dysfunction 
markers including soluble vascular adhesion molecule (sVCAM), soluble intercellular 
adhesion molecule (sICAM), endothelin (ET)-1 and von Willebrand’s Factor (vWF) (48).  
 
29 
Whilst it is well established that a clustering of traditional cardiovascular risk factors 
occurs in the pre-diabetic period, it seems that the state of insulin resistance additionally 
contributes to the increase in cardiovascular risk (49). Hyperglycaemia activates the 
protein kinase C (PKC) pathway and this is associated with both increased vascular 
contractility and endothelial dysfunction as well as a host of other abnormal cellular 
functions (50). It is thought that there is a link between endothelial dysfunction and 
inflammatory cytokines; both Interleukin-6 (IL-6) and C-reactive protein (CRP) have 
been linked to the development of central adiposity and diabetes mellitus (51-53). 
Further studies have demonstrated that use of pharmacological agents or reduction in 
visceral fat leads to a reduction in circulating concentrations of cytokines and soluble 
markers of endothelial activation resulting in an overall improvement in endothelial 
function (54). 
Other risk factors include oxidative stress (increased concentrations of markers 
including oxidized LDLs and F2-isoprostanes) and glycation of proteins resulting in 
formation of advanced glycation end-products (AGEs) in both LDL and within the 
collagen of the arterial wall which have a number of pro-atherogenic effects (55) - (56). 
Hyperglycaemia results in endothelial and platelet dysfunction causing impaired 
vasodilatation and accelerated atherogenesis (57). 
1.2.3 Platelet hyper-reactivity 
Patients with diabetes have increased risk of thrombogenic events due to increased 
platelet activity and this can be targeted by pharmacological interventions. Platelets in 
patients with diabetes are larger and have an increased number of glycoprotein (GP) 
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IIb/IIIa receptors (58) and also aggregate more easily to known agonists in vitro than 
platelets from non-diabetic patients (59). These platelets circulate in an activated state, 
possibly due to hyperglycaemia resulting in increased production of F2-isoprostane (57). 
Hyperglycaemia may also promote platelet mediated thrombosis – serum glucose levels 
have been shown to be an important multi-variate predictor of platelet dependent 
thrombosis (60). The role of platelets in thrombus formation is summarized in Figure 2. 
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Figure 2: The role of platelets in thrombus formation 
 
 
(adapted from Bhatt et al Nature Reviews Drug Discovery 2003 (61).)  (a) Circulating platelets are usually maintained in 
an inactivated state by PC and NO released by endothelial cells lining the blood vessel walls. Endothelial cells also 
express CD39 on their surface which inhibits platelet activation by converting ADP, a potent inducer of platelet activation 
to AMP. (b, c) At sites of injury to the blood vessel wall, platelets adhere to the exposed sub-endothelium, through a 
complex series of interactions between collagen, vWF, fibronectin and their receptors on platelets. Both thrombin and 
ADP cause active conformation of platelets. (d) Activated platelets secrete ADP, PDGF, and fibrinogen from storage 
granules. TBX-A2 is produced. (e) GPIIb/IIIa receptors on the surface of activated platelets bind fibrinogen, fibrinogen 
bridges form between the platelets and platelet aggregation occurs. This and the simultaneous formation of a fibrin mesh 
(not illustrated) lead to the formation of a platelet thrombus. (f) Clot retraction then occurs leading to formation of a stable 
thrombus. (Abbreviations: PC: Prostacyclin; NO: Nitric oxide; ADP: Adenosine diphosphate; AMP: Adenosine 
monophosphate; vWF: von Willebrand’s Factor; GPIIB/IIIA: Glycoprotein IIB/IIIA; PDGF: Platelet Derived Growth Factor; 
TBX-A2: Thromboxane-A2). 
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Endothelial dysfunction leads to a reduction in formation of both prostacyclin and NO; 
both are agents with potent anti-platelet aggregating properties and are released from 
intact endothelium. In diabetic patients and insulin resistance, the synthesis of agents 
which have pro-aggregating properties such as adenosine diphosphate (ADP) and 
thromboxane is upregulated, resulting in a further mechanism for platelet mediated 
athero-thrombosis (62). This forms the basis for the pronounced clinical benefit that 
patients with diabetes derive from antiplatelet therapies including aspirin (63-65), 
thienopyridine derivatives such as clopidogrel (66) and prasugrel (67) and GP IIb/IIIa 
inhibitors (68). 
The GP IIb/IIIa receptor on the platelet surface binds fibrinogen. Once activated these 
receptors act as adhesion molecules resulting in platelet cross-linking, a key component 
of platelet aggregation (Figure 3). GP IIb/IIIa receptor inhibitors block platelet 
aggregation by binding to these receptors and disrupting the final common pathway 
(69). The use of GP IIb/IIIa inhibitors in patients with diabetes undergoing PCI has been 
shown to result in improved survival over both the short and long term (70;71).  
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Figure 3: Platelet Activation and Aggregation and Inhibition of Platelet Aggregation 
by Inhibitors of Glycoprotein IIB/IIIA Receptors 
 
(Adapted from Yeghiazarians et al N Engl J Med 2000 (72)). Activation causes changes in the shape of platelets and 
conformational changes in glycoprotein IIb/IIIa receptors. Ligand-receptive glycoprotein IIb/IIIa receptors bind fibrinogen 
molecules. These form bridges between adjacent platelets and facilitate platelet aggregation. Inhibitors of glycoprotein 
IIB/IIIA receptors also bind to glycoprotein IIb/IIIa receptors preventing the fibrinogen from binding and preventing platelet 
aggregation. 
1.2.4 Haemostatic abnormalities 
A number of different haemostatic abnormalities are associated with diabetes. These 
include elevated levels of vWF, coagulation factors VII, VIII, X and fibrinogen (73-76). 
Reduced levels of protein C and antithrombin are also seen which are potent inhibitors 
of coagulation and therefore further contribute to the increased propensity for 
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coagulation (77). 
Figure 4: The fibrinolytic pathway 
 
(Adapted from Deitcher et al clevelandclinicmed.com (78)). Physiological fibrinolysis is initiated by endothelial cell-derived 
tPA mediated conversion of plasminogen to plasmin. Plasmin can degrade fibrinogen and fibrin, thus limiting the size of a 
thrombus and helping to clear a thrombus once the vascular injury has been repaired. The fibrinolytic pathways are 
regulated by the inhibitory proteins α2-antiplasmin and PA-I1. (Abbreviations: tPA: Tissue plasminogen activator; PAI-1: 
Plasminogen Activator Inhibitor-1). 
In patients with diabetes and associated insulin resistance, suppression of the fibrinolytic 
pathway (Figure 4) occurs leading to increased concentrations of PAI-1 (79). There is a 
strong relationship between features of the metabolic syndrome and elevated PAI-1 
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levels with the correlation with triglyceride levels being particularly marked (79). 
Interestingly this is not seen in patients with T1DM in whom there is no consistent defect 
in fibrinolysis. Studies suggest that these patients have an increase in fibrinolytic activity 
and tPA concentrations and either normal or reduced levels of PAI-1 (80;81). Key 
processes involved in the formation of a pro-thrombotic state in diabetes are 
summarized in Figure 5:  
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Figure 5: Schematic diagram of the key processes involved in the development of a 
pro-thrombotic state in diabetes 
        
(adapted from D’Souza et al Mol Cell Biochem 2009 (36)). Diabetes mellitus accelerates the athero-thrombotic process 
by decreasing fibribinolytic capacity and mediating a shift to a pro-coagulant state characterized by increased 
inflammatory mediators, PAI-1, plasma fibrinogen, vWF and thrombin. (a) Endothelial dysfunction and NO deficit in 
diabetes impair endogenous inhibition resulting in enhanced platelet susceptibility to aggregate in response to release of 
agonists from the inflammed endothelium. T-lymphocytes stimulate plaque macrophages resulting in increased 
expression of the potent procoagulant Tissue Factor. This highlights the relationship between arterial inflammation and 
athero-thrombosis. (b) Post-plaque rupture, adhesion molecules (e.g. vWF and collagen) activate circulating platelets 
resulting in aggregation. Tissue Factor is released from the lipid core and the subendothelial matrix activates the 
coagulation casade with thrombin generation and fibrin formation. The overall effect is the generation of an environment 
which facilitates the generation and persistence of coronary thrombi and may precipitate acute coronary syndromes. 
(Abbreviations: TF: Tissue Factor; vWF: von Willebrand’s Factor; tPA: Tissue Plasminogen Activator; PAI-1: Plasminogen 
Activator Inhibitor-1; NO: Nitric oxide; ROS: Reactive Oxygen Species).  
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1.2.5 Adverse arterial remodelling 
In patients with diabetes an accelerated process of both atherosclerosis and restenosis 
occurs (39;82). In the early stages of atherosclerotic plaque formation a process of 
negative arterial modelling occurs with lack of collateral vessel formation and an 
increased risk of late vessel occlusion following balloon angioplasty although this is not 
the case with intracoronary stenting (34;83-85). The lack of ability in patients with 
diabetes to collateralize occluded arteries is linked to the endothelial dysfunction 
described previously. Decreased expression of vascular endothelial growth factor 
(VEGF) in the myocardium and also low levels of the VEGF receptor have been 
implicated in this process (86).  
Patients with diabetes lack an adaptive arterial response and vessel contracture occurs 
to the extent that a lower plaque burden can cause a more significant stenosis in 
diabetic patients when compared to non-diabetic subjects (87). Patients with diabetes 
therefore display a tendency to have smaller arteries, with lesions of longer length and 
diffuse disease which provide a host of challenges to performing successful 
revascularization (39). 
1.2.6 Accelerated atherosclerosis 
Both endothelial dysfunction and the pro-thrombotic state which occur in patients with 
diabetes and have been previously described, contribute to the aggressive 
atherosclerotic process observed (summarized in Figure 6). Hyperglycaemia via a 
number of chemical pathways, leads to the formation of AGEs. Engagement of 
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RAGE, the cell surface receptor for AGEs activates an inflammatory process involving 
endothelial cells, smooth muscle cells and macrophages. These cells all play key roles 
in the process of atherogenesis and further multiply the inflammatory stimuli to the 
arterial wall. RAGE therefore plays a key role in the progression of atheroma and plaque 
vulnerability in diabetic patients (55;88;89). Administration of soluble RAGE has been 
shown to retard the progression of already established atheroma, reducing lesion size 
and altering plaque characteristics with reduced inflammation and increased stability 
(90). 
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Figure 6: Schematic diagram of the inflammatory mechanisms involved in plaque 
formation in diabetes accelerated atherosclerosis 
 
Adapted from D’Souza et al Mol Cell Biochem 2009 (36). This figure illustrates the key interactions between the inflammatory 
infiltrate and the vascular wall in diabetes-accelerated atherosclerosis with a temporal sequence from left to right. Multiple 
atherosclerotic risk factors increase oxidative stress in vascular cells, activating signalling molecules such as NF-κB. This results 
in endothelial dysfunction characterised by decreased NO synthesis and increased entry of modified circulating lipoproteins into 
the vessel wall. In response to this inflammatory stimulus, the dysfunctional endothelium generates up-regulation of adhesion 
molecules (VCAM, ICAM), facilitating adherence and trans-endothelial migration of leucocytes into the tunica intima. In the intima, 
inflammatory mediators e.g. M-CSF augment expression of scavenger receptors which detect and internalise modified lipoprotein 
particles by macrophages. Ultimately this results in foam cell formation and initation of the atherosclerotic plaque. As the lesion 
evolves, lymphocytes and resident cells of the vascular wall secrete cytokines and growth factors. This encourages migration of 
vascular cells into the intima and penetration through the elastic lamina and collagenous matrix of the evolving plaque. MMP 
secreted by macrophages degrade the ECM which plays a key role in plaque stability. T-lymphocytes produce IFN-γ which limits 
collagen production. The overall result is a vulnerable plaque with extensive inflammatory infiltrate, a lipid core and a thin fibrous 
cap which is highly susceptible to rupture. (Abbreviations: ICAM: Inter-Cellular Adhesion Molecule, NO: Nitric oxide,  VCAM: 
Vascular Cell Adhesion Molecule; NF-ΚB: Nuclear Factor Kappa B; M-CSF:Macrophage Colony Stimulating Factor; MMP: Matrix 
Metallo-Proteinases). 
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Haemoglobin A1c (HbA1c) is a protein (haemoglobin) that has undergone non-
enzymatic glycation and provides a surrogate marker for glycaemic control over the 
previous 3 month period (the life-span of a red blood cell). Furthermore HbA1c 
correlates with AGE levels. The multi-factorial complexity of diabetic vascular disease 
suggests the need for tight glycaemic control and an overall strategy of risk factor 
modification (91;92). However uncertainties remain over very aggressive regimes with 2 
recent trials showing that intensive therapy may be associated with increased mortality 
(93;94). 
1.2.7 Cellular proliferation and restenosis 
A number of studies have demonstrated that diabetes is an independent risk factor for 
restenosis following balloon angioplasty (83;84) with reported rates ranging from 35-
71%. Restenosis occurs due to 3 factors: abrupt vessel closure, adverse arterial 
remodelling and neo-intimal proliferation.  
Arterial remodeling and acute recoil of balloon injured vessels play a significant role in 
the restenosis process following balloon angioplasty with a lesser contribution from neo-
intimal proliferation (95;96). In diabetic patients, collagen rich sclerotic content is 
increased in restenotic lesions undergoing remodeling and elastic recoil. This suggests 
that there is an aggressive fibrotic rather than proliferative response occurring in post 
angioplasty stenosis in diabetic vessels (97). Late vessel occlusion following balloon 
angioplasty is associated with a marked reduction in ejection fraction (98) and is a key 
determinant of long term mortality in patients with diabetes (99). Data from studies using 
intravascular ultrasound (IVUS) suggest that intimal hyperplasia is responsible for the 
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increased restenosis rates seen in diabetic patients (82). The advent of coronary 
stenting led to an overall reduction in restenosis rates in both diabetic and non-diabetic 
populations by eliminating abrupt vessel closure and vessel remodeling following PCI 
and also reduced the rate of occlusive stenosis in diabetic patients closer to the levels 
seen in non-diabetic patients (100;101).  
Both insulin and glucose have been put forward as key players in the neo-intimal 
proliferation causing restenosis in patients with diabetes although no direct link has been 
identified associating glycaemic control with restenosis. Insulin is a weak growth factor 
and co-expression of insulin-like growth factor-1 (IGF-1) and platelet derived growth 
factors which both have powerful mitogenic effects may play a contributory role (102). 
 
1.3 Cardiovascular disease in patients with CKD 
Patients with CKD, when compared to age-matched controls have a much higher rate of 
cardiovascular mortality and this is multi-factorial in aetiology (103). It has been shown 
that the relative risk of all-cause death is increased by approximately three-fold in 
patients with a serum creatinine > 150 µmol/l (104). For patients on dialysis this risk is 
even higher – ten-fold to a hundred-fold higher than for age and sex-matched controls in 
the general population (105). Possibly due to this high mortality patients with severe 
CKD have predominantly been excluded from trials investigating interventions to 
ameliorate cardiovascular risk (106). A number of clinical trials currently underway are 
seeking to address this (107-109). Patients with CKD are in a persistent catabolic state 
resulting in a systemic syndrome of malnutrition, chronic inflammation and 
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atherosclerosis, with upregulation of many acute phase proteins and cytokines (110). 
This becomes particularly prevalent once patients reach CKD Stage 5 (estimated 
glomerular filtration rate (eGFR) < 15 ml/min) (111).  
A computerised database (NEOERICA) from primary care in the United Kingdom has 
demonstrated the influence of CKD on the prevalence of cardiovascular comorbidities 
(112). The authors found that the prevalence of CHD is approximately 25% in a patient 
population with CKD Stage 3 (eGFR 30 – 59 ml/min) – Stage 5 (eGFR < 15 ml/min) and 
this is more than double that for patients with normal renal function. This increased 
prevalence is also seen in congestive cardiac failure (CCF), peripheral vascular disease 
(PVD) and cerebrovascular disease. Data from the Framingham Heart Study shows that 
when patients progress from normal renal function to a eGFR < 45 ml/min the burden of 
any cardiovascular disease is significantly higher (113) and this increased 
cardiovascular risk predicts a more rapid decline in renal function when adjusted for 
baseline eGFR (114). This may occur through an ‘upregulated pro-inflammatory’ state 
as has been described above (111). At the time of referral to a nephrologist 
approximately 1/3 of patients with CKD already have manifestations of CHD (103).  
Data from the NEOERICA study (112) also demonstrated that > 50% of patients ≥ 85 
years have CKD and questions remain as to whether this is simply part of a normal 
ageing process. If so, this might suggest that a proportion of CKD is not clinically 
relevant as many of these patients are not symptomatic and cardiovascular risk 
modification strategies in this age group do not have clear benefits in terms of 
improvement in morbidity and mortality (103). It is important to note however that 
conditions such as diabetes which contribute to the development of both 
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cardiovascular and renal disease may not present with typical symptoms of coronary 
ischaemia (115). The clinical challenge is therefore to establish on an individual patient 
basis the importance of impaired renal function and address cardiovascular risk 
modification appropriately.  
1.3.1 Cardiovascular Risk Factors in Patients with CKD 
Patients with CKD have higher rates of cardiovascular morbidity and mortality than are 
predicted by the Framingham model of cardiovascular risk (116). As has been described 
previously renal dysfunction leads to a catabolic state which leads to chronic 
inflammation resulting in accelerated atherosclerosis and the development of 
cardiovascular disease (117).  
Hypertension, dyslipidaemia, diabetes and obesity are well established risk factors for 
cardiovascular disease and are highly prevalent in populations with CKD (107;118). 
Other cardiovascular risk factors have been identified to occur more frequently in 
patients with CKD than in a general population including anaemia, abnormal metabolism 
of calcium and phosphorous, carnitine deficiency, hyperhomocysteinemia, proteinuria, 
inflammation and oxidative stress and high lipoprotein a levels and small lipoprotein a 
(LpA) size (reviewed (103;107)). However the relative contribution of traditional and non-
traditional risk factors to the risk of developing cardiovascular disease is not fully 
understood. In order to be of clinical relevance individual risk factors must be applicable 
to a general population. For example elevated levels of homocysteine are associated 
with increased risk of cardiovascular events in patients with CKD (119-122). Levels can 
be controlled with dietary supplementation of pyridoxine, Vitamin B12 and folic acid 
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(reviewed (123)). Measurement of homocysteine levels is not currently a part of routine 
clinical practice as such modification has not been able to demonstrate a consistent 
benefit in reducing cardiovascular risk in renal patients (124-127). 
1. 3.1.1 Diabetes and CKD 
Patients with diabetes and CKD are a particular challenge: they have a higher incidence 
of cardiovascular co-morbidities such as CHD and PVD than any other patient group 
with CKD (128;129). Mortality in diabetes patients becomes markedly elevated with the 
onset of proteinuria (130;131) and it is thought that this acts as a surrogate marker for 
endothelial dysfunction and therefore increased cardiovascular disease (132). In 
patients with diabetes, microalbuminuria is an independent predictor of increased 
cardiovascular mortality (129;133); the presence of microalbuminuria increases the risk 
of fatal CHD by a factor of 2 to 4. One possible explanation for this is that the early 
stages of diabetic nephropathy are associated with the co-existence of multiple 
cardiovascular risk factors including hypertension, dyslipidaemia and a hypercoagulable 
state (134). 
Hypertension is a frequent co-morbidity in diabetic nephropathy even when creatinine 
levels remain within normal limits and can further exacerbate coronary disease in 
diabetic patients. Microalbuminuria is associated with a pro-atherogenic lipid profile 
including elevated concentrations of LDL and chylomicron remnants, decreased 
concentrations of HDL and increased concentrations of LpA (135-137). PAI-1 activity, 
factor VII and plasma fibrinogen are all up-regulated in patients with T1DM and 
microalbuminuria (138;139). Diabetic nephropathy also results in accelerated 
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accumulation of AGEs in both the circulation and tissue which correlates with the 
severity of renal impairment (88).  
Strategies to modulate cardiovascular risk in diabetic patients include general measures 
such as weight loss and blood pressure control and glycaemic control (140). In an 
attempt to reduce the risk of cardiovascular disease, a number of different trials have 
looked at various different glucose lowering strategies. However, the effect of glucose 
lowering on cardiovascular outcomes remains an area of contentious debate as 
evidenced by the class IIb recommendation from the joint American Diabetes 
Association (ADA), American Heart Association and American College of Cardiology 
(141). One concern is that glucose lowering may be a weaker intervention than 
previously envisaged with individual trials being underpowered to detect changes in a 
chosen end-point. Another is that current therapies may negate the effects of glucose 
lowering e.g. weight gain which has ‘knock on’ effects on blood pressure and lipids 
(142). The largest study of intensive glucose lowering regimes compared to standard 
treatment for cardiovascular outcomes, combined data from 5 randomised controlled 
trials on 33040 patients (143). There were 1497 non-fatal MI, 2318 coronary events, 
1127 strokes, 2892 deaths and 1391 cases of new or progressive heart failure. A 0.9% 
lowering in HbA1c (7.5% vs. 6.6%) was associated with a 17% reduction in non-fatal MI, 
a 15% reduction in coronary events and a trend towards decreased stroke risk. There 
was no association between intensive and standard treatment and mortality and heart 
failure. A recent meta-analysis adds data on 8 extra studies with 1493 additional 
participants (144). The cardiovascular data are broadly consistent with earlier reports, 
demonstrating a 15% reduction in non-fatal MI but no clear effect on other 
cardiovascular disease outcomes. There were 54 non-fatal MI, 209 deaths and 187 
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cases of new or worsening heart failure. It is important to note that the sensitivity 
analysis of intensive glucose lowering and heart failure events is dominated by one 
study, the PROspective pioglitazone Clinical Trial in macroVascular Events (PROactive) 
(145). The data are also consistent with earlier evidence that the cardiovascular benefit 
of intensive glucose lowering in isolation appears to be modest at best and that this is 
less efficacious and more difficult to achieve then interventions targeting lipid and blood 
pressure control; it would therefore suggest that a combined approach targeting all 3 risk 
factors is the optimal strategy (146). Further studies will be necessary to ascertain 
whether an absolute HbA1c target should be achieved or whether attempts should be 
targeted at a target percentage reduction from baseline.  
Even more uncertainty exists as to the best index of glycaemic control in patients with 
advanced CKD (147). A large epidemiological study did not demonstrate a relationship 
between HbA1c and death in patients on dialysis (148). Conversely, a recent study from 
the United States in > 20 000 patients undergoing dialysis, showed that HbA1c levels 
were incrementally associated with a higher risk of cardiovascular death but only after 
adjustment for confounding variables (including age, length of time on dialysis and 
markers of nutrition and inflammation) (149). HbA1c may be unreliable in uraemia due to 
the unpredictable influences of carbamylated haemoglobin and/or variable red blood cell 
survival and may underestimate true glycaemic control. Glycated albumin is a possible 
alternative that requires further investigation (150). 
Interventions in diabetic patients with renal impairment have concentrated on reducing 
conversion of normalbuminuria to microalbuminuria (151;152), delaying the onset of 
diabetic nephropathy in patients with microalbuminuria (153;154) and delaying further 
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deterioration in renal impairment once diabetic nephropathy has occurred (155;156). 
The main pathway targeted by these interventions is the renin angiotensin system (RAS) 
(Figure 7). Once diabetic nephropathy is established intervention with agents that block 
the RAS system have not been shown to impact on cardiovascular risk (155). This 
highlights the importance of instituting treatment at the early stages of kidney damage in 
order to improve cardiovascular outcome in patients with diabetes. 
Figure 7: Schematic diagram depicting the Renin Angiotensin System 
 
 
(adapted from Taal and Brenner Kidney International 2000 (157)). Abbreviations: ACE: Angiotensin Converting Enzyme; 
ECM: Extracellular matrix; mφ: Macrophage; PAI-1: Plasminogen Activator Inhibitor-1; PG: Prostaglandin; Pgc: glomerular 
capillary hydraulic pressure; RBF: Renal blood flow; TGF-β:Transforming Growth Factor-β; AT1: Angiotensin II Type 1; 
AT2: Angiotensin II Type 2). 
1.3.1.2 Hypertension and CKD 
Renal impairment results in glomerular sclerosis and interstitial disease, activation of the 
RAS and leads to the development of fluid overload and increased arterial stiffness 
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resulting in hypertension. Essential hypertension itself, causes microvascular damage to 
the renal vascular bed and resulting renal impairment leads via RAS activation to further 
exacerbation of hypertension (103). Renal physiology is altered with increased filtration 
fraction of sodium and increased renovascular resistance (158). The majority of patients 
with CKD are hypertensive and prevalence rises with increasing severity of CKD: at 
eGFR <30 ml/min >90% of patients are hypertensive (111). As CKD progresses the 
diurnal variation in blood pressure starts to change, resulting in loss of the physiological 
nocturnal ‘dip’ and this is a marker for the development of left ventricular hypertrophy 
(LVH) (159). In dialysis patients the relationship between systolic blood pressure and 
death has a ‘U’-shaped distribution, with both low and high levels of blood pressure 
associated with increased mortality  
When hypertension is treated rates of progression of CKD significantly decrease 
(155;156;160-162). Again the key pathway targeted by therapeutic agents is the RAS 
showing the importance of blocking the formation of angiotensin II (Figure 8) which is 
both an endothelial growth factor in the renal vascular bed and also a powerful 
vasoconstrictor (163;164).  
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Figure 8: Diagrammatic representation of the central role of angiotensin II in the 
pathogenesis of progressive renal injury  
 
(adapted from Taal et al Kidney International 2000 (157)). The role of angiotensin II in the pathogenesis of progressive 
renal injury and fibrosis following nephron loss. (Abbreviations: ECM: Extracellular matrix; mφ: Macrophage; PAI-1: 
Plasminogen Activator Inhibitor-1; Pgc: glomerular capillary hydraulic pressure; RBF: TGF-β:Transforming Growth Factor-
β). 
The ideal blood pressure level to aim for in patients with CKD remains an area of 
controversy. A meta-analysis looking at randomized controlled trials of ACE-inhibitors 
demonstrated that systolic blood pressure > 120 mmHg was associated with increased 
risk of progressive renal dysfunction. However this was also seen with systolic blood 
pressures < 110 mm Hg, probably due to relative hypoperfusion of the kidney with low 
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systolic blood pressure secondary to heart failure (165). The current British Renal 
Association Guidelines (166) reinforce the guidance from the National Institute of 
Clinical Excellence (NICE) (167) and suggest aiming for a target blood pressure of < 
140/90 mmHg in patients without significant proteinuria and < 130/80 mmHg in patients 
with proteinuria or diabetes mellitus. 
1.3.1.3 Dyslipidaemia 
Dyslipidaemia is a common finding in patients with CKD Stage 3-4. The abnormal lipid 
profile is characterized by elevated serum triglyceride and VLDL cholesterol levels, 
decreased serum HDL cholesterol levels and normal or decreased serum LDL levels 
(168). Patients with impaired renal function also have increased levels of plasma LpA 
which is associated with an increased risk of cardiovascular disease (169;170). 
A meta-analysis of randomized clinical trials of statins vs. placebo in over 6500 patients 
with CKD showed that statin use resulted in a significant reduction in lipid concentrations 
and the incidence of cardiovascular events. Moreover, statins were well tolerated 
without increased rates of adverse events such as liver dysfunction (171). A secondary 
analysis from the Treating to New Targets study demonstrated that 80 mg daily of 
atorvastatin significantly reduced cardiovascular events in patients with CKD as 
compared to a 10 mg dose and again was well-tolerated (172). On initial reflection these 
observations suggest that statins should be used in Stage 3-4 CKD in much the same 
way as they are used in the general population. It is important to note however that the 
vast majority of patients in these trials had GFR > 30 ml/min/1.73 m2 (CKD Stages 1-3). 
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To date (2011), there have been only three randomized clinical trials of statin therapy in 
patients on dialysis completed and published in the international literature. The 4D Study 
(Die Deutsche Diabetes Dialyse Studie) found no significant benefit of statin therapy on 
cardiovascular outcomes despite significant reductions in LDL cholesterol. The 
AURORA (A Study to Evaluate the Use of Rosuvastatin in Subjects on Regular 
Haemodialysis) Trial was an international multicentre randomized double-blind trial of 
2776 patients undergoing haemodialysis. Patients were randomly assigned to 10 mg 
rosuvastatin or placebo. The primary endpoint was the time to a major cardiovascular 
event (defined as non-fatal myocardial infarction (MI), non-fatal stroke or death from 
cardiovascular causes. Mean length of follow-up was 3.2 years. Rosuvastatin had no 
significant effect on the composite primary end-point. Furthermore whilst rosuvastatin 
lowered lipid levels there was no relationship between the primary cardiovascular end-
point and either baseline LDL cholesterol or levels at 3 months. The SHARP (Study of 
Heart And Renal Protection) trial recently reported on the safety and efficacy of the 
combination of simvastatin with ezetimibe, an agent which decreases absorption of 
cholesterol from the intestine, in patients with CKD (173). 9270 patients with CKD (3023 
on dialysis) with no known history of previous MI or coronary revascularisation 
procedures were randomly assigned to either the combination of simvastatin 20 mg and 
ezetimibe 10 mg daily versus matching placebo. The main pre-specified outcome was 
first major atherosclerotic event. Simvastatin-ezetimibe significantly reduced the 
incidence of atherosclerotic events but had no effect on survival. Further trials will be 
necessary to fully determine the role of statins and other lipid lowering agents in patients 
with CKD (108). 
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1.3.1.4 Vascular Calcification 
Atherosclerotic disease in the general population is manifest by intimal fibro-fatty plaque 
formation which may then become calcified. The medial layer of elastic arteries may 
also become involved in atherosclerosis with thickening and development of 
calcification, a phenomenon known as ‘medial calcinosis’ (174;175). This results in 
increased pulse wave velocity, elevated pulse pressure and development of systolic 
hypertension (176;177). Medial calcinosis is more common in diabetes patients, the 
elderly and patients with CKD and is known to be associated with increased 
cardiovascular mortality (178;179).  
There is currently an incomplete understanding of the pathophysiology of vascular 
calcification in CKD. Arterial calcification involves the transformation of vascular smooth 
muscle cells into bone forming osteoblast-like cells expressing bone matrix proteins 
which are involved in arterial calcification (180). Several other factors (including 
hyperphosphataemia, hyperparathyroidism, hyperhomocysteineaemia and elevated 
levels of AGEs) are elevated in patients with CKD and can accelerate vascular 
calcification (103). Abnormal bone mineralization also contributes with both high and low 
bone turnover states occurring in patients with renal dysfunction (181). In high bone 
turnover states, both osteoblast and osteoclast activity are increased, preventing 
adequate mineralization of newly formed bone. In low (‘adynamic’) bone turnover 
excessive hypercalcaemia is a frequent occurrence as the skeleton cannot act as an 
efficient buffer for calcium or phosphate. This situation can be further exacerbated by 
oral phosphate binders, taken by patients to attempt to prevent gastrointestinal 
phosphate absorption which may contain calcium. 
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In dialysis patients links exist between decreased bone mineral density and increased 
coronary artery calcification (182). Both high and low bone turnover states can lead to 
development of vascular calcification and whilst controlling phosphate levels is of critical 
importance, phosphate binders with high calcium content are arguably not desirable.   
Adynamic bone disease often occurs in patients with relatively low levels of parathyroid 
hormone (PTH), < 150 pg.ml and may result in part from 1,25-dihydroxyvitamin D3 
deficiency (183). The most frequent bone abnormality in patients with CKD is high 
turnover bone disease. In pre-dialysis CKD patients, > 90% have this form of bone 
histology compared to < 5% who exhibit the adynamic modality (184). Recent data 
suggest that adynamic bone disease may also constitute a risk factor for CVD if there is 
con-comitant aluminium or calcium overload, due to the inability of the bone to buffer 
calcium (178;185). Whether induction of adynamic bone disease by low PTH levels, 
without evidence of aluminium or calcium is related to increased cardiovascular 
morbidity and mortality remains an area of debate. Recent studies of dialysis patients 
undergoing parathyroidectomy showed improvement in long-term survival following 
parathyroid gland removal (186). Further studies will be necessary to confirm the 
survival benefits associated with lower PTH levels (187). 
Fibroblast growth factor 23 (FGF-23) has recently been discovered to have a role in the 
regulation of phosphate and mineral metabolism. Its main physiological role is in 
modulating phosphate excretion (188) . Levels are associated with both progression of 
CKD and mortality in diabetes patients (189). Loss of FGF-23 is implicated in vascular 
calcification and therefore genetic variation may influence calcification in CKD (103). 
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There is relatively little data in this area regarding dialysis and low clearance patients 
although there is some evidence that in new-onset haemodialysis patients progression 
of coronary calcification is less aggressive in those taking non-calcium containing 
phosphate binders e.g. sevelamer (190). A mortality benefit has not yet been shown in 
the overall dialysis population. There is evidence for a reduction in mortality in patients 
aged > 65 years after 2 years of sevelamer therapy compared to patients on a calcium 
based phosphate binder (191). 
1.3.1.5 Left ventricular hypertrophy in CKD 
Even in the very early stages of renal impairment there is a higher prevalence of LVH 
than occurs in the general population. A prospective echocardiographic study of patients 
attending a low clearance clinic demonstrated LVH in 27% of patients with a creatinine 
clearance (CrCl) > 50 ml/min. In patients with CrCl 25 – 50 ml/min and < 25 ml/min the 
prevalence was 31% and 45% respectively (192). 
The cardiomyopathy of renal failure results from a combination of pressure overload and 
volume overload. In the early stages these are physiological ‘adaptive’ compensations to 
attempt to maintain adequate stroke volume. Arterial stiffness and calcification lead to 
the development of hypertension and development of concentric LVH. Activation of the 
RAS leads to salt and water retention, resulting in volume overload and left ventricular 
dilatation and this process is exacerbated by anaemia. The resulting cardiomyopathy 
leads to the development of both systolic and diastolic dysfunction (193).  
1.3.1.6 Other risk factors 
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Proteinuria 
Proteinuria is associated with both traditional and non-traditional risk factors for 
development of cardiovascular disease (107). Patients with proteinuria suffer particularly 
rapid deterioration in renal function and therefore might be more susceptible to the 
putative accelerated atherosclerosis that is attributable to low GFR. Albuminuria may 
additionally indicate diffuse endothelial dysfunction or be a surrogate marker for 
atherosclerotic plaque burden (134). Proteinuria is also associated with abnormalities of 
fibrinolysis, predisposing affected individuals to abnormal coagulation and thrombosis 
(194). Proteinuria is thought to directly increase cardiovascular risk rather than being a 
marker for increased pre-existing vascular burden as interventions that produce 
significant reductions in albuminuria are associated with substantial cardiovascular 
benefit (195).  
Coagulation 
Patients with CKD are more likely to express markers of a procoagulant state than a 
general population, despite having a higher risk of bleeding (107). Patients with Stage 3-
4 CKD have higher levels of fibrinogen (a marker of coagulability associated with an 
increased risk of myocardial infarction) than is seen in patients with normal renal 
function (196). A meta-analysis of trials in which the primary outcome was failure of 
vascular access showed that anti-platelet therapy significantly reduced the risk of 
serious vascular events (197).  
Anaemia 
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Anaemia is associated with a number of unfavourable conditions including 
cardiomyopathy and LVH (198). Several recent studies have compared ‘partial’ and 
‘complete’ correction of anaemia with erythropoietin in patients with CKD and have failed 
to demonstrate a consistent benefit in terms of improved quality of life (107). At least 2 
trials have been terminated prematurely because of concerns regarding futility or 
adverse events (199) (200). No trial to date has shown that erythropoiesis-stimulating 
therapy results in improved cardiovascular outcomes when compared to placebo in 
patients with CKD (201) (202).  
 
1.3.2 Strategies for management of cardiovascular risk factors 
in CKD 
Strategies for the management of cardiovascular risk in patients with CKD are 
summarized in Table 2.  
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Table 2: Strategies for Cardiovascular Risk Modification in patients with CKD 
Risk Factor Stage of CKD 
 3 – 4 5D (Dialysis) 
Smoking Recommend cessation Recommend cessation 
Diet Ensure sodium intake < 2.4 g /day Ensure sodium intake < 2.4 g /day 
Exercise Aim for 30 – 60 minutes of moderate 
intensity dynamic exercise 4 – 7 days/week 
Aim for 30 – 60 minutes of moderate 
intensity dynamic exercise 4 – 7 
days/week 
Hypertension Treatment goal: BP <130/80 mmHg 
Pharmacotherapy: 
Proteinuric CKD: (urine albumin:creatinine 
ratio ≥ 30 mg/mmol) should include and 
ACE-I or ARB 
Non-proteinuric CKD: (urine 
albumin:creatinine ratio < 30 mg/mmol) 
treat with either an ACE-I or ARB , a thiazide 
diuretic, a β-blocker (in patients < 60 years) 
or a long acting CCB 
Treatment goal: Predialysis and 
postdialysis BP should be < 140/90 mmHg 
and <130/80 mm Hg respectively. 
Consider nocturnal dialysis if BP or ECF 
volume are difficult to control 
Pharmacotherapy: ACE-I and ARB are 
preferred. 
Diuretics are not recommended. Sotalol is 
contraindicated. Spironolactone with 
caution to avoid ↑K
+
 
Diabetes mellitus Treatment goal: HbA1c < 7%, FPG 4-7 
mmol/l 
Pharmacotherapy: Metformin is acceptable 
in stable Stage 1-3 CKD, Repaglinide is 
acceptable and needs no dose adjustment, 
short-acting sulphonylureas e.g. gliclazide 
are preferred over longer acting agents. 
Sulphonylureas and insulin require dose 
adjustment 
Treatment goal: Optimal HbA1c is 
unknown 
Pharmacotherapy: Metformin should be 
discontinued, sulphonylureas and insulin 
require dose adjustment 
Dyslipidaemia Treatment goal: LDL cholesterol targets 
should follow guidelines for the general 
population 
Pharmacotherapy: Statin 
Dose adjustment required for fibrates only 
Treatment goal: unknown 
Pharmacotherapy: Statin if benefits 
outweigh risks 
Dose adjustment required for fibrates 
only 
Anaemia Treatment goal: 10-12 g/dl 
Balance CV risks against QoL benefits on an 
individual basis 
Pharmacotherapy: Iron supplementation, 
Erythropoiesis stimulating agents 
Treatment goal: 10-12 g/dl 
Balance CV risks against QoL benefits on 
an individual basis 
Pharmacotherapy: Iron supplementation, 
Erythropoiesis stimulating agents 
Other Aspirin daily if high CV risk or established CV 
disease and no contraindication 
Aspirin daily if high CV risk or established 
CV disease and no contraindication 
(adapted from Rucker and Tonelli Nature Review Nephrology 2009 (107) and incorporating current guidelines(166;203-
206). Abbreviations: CKD: Chronic kidney disease; BP: Blood pressure; ACE-I: Angiotensin Converting Enzyme Inhibitor; 
ARB: Angiotensin II Receptor Blocker; CCB: Calcium channel blocker; FPG: Fasting Plasma Glucose; CV: Cardio-
Vascular; QoL: Quality of Life). 
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1.4 Classification of Kidney Disease 
1.4.1 Chronic Kidney Disease 
CKD is an area of intensive clinical and epidemiological research (207). A number of 
different definitions of CKD are used in the literature which can cause difficulties with 
data comparison and also may call into question the validity and reliability of research 
findings (208-210). In 2002 the National Kidney Foundation’s Kidney Disease Outcomes 
Quality Initiative (KDOQI) formulated guidelines providing clear definitions and 
classification of CKD (211). The classification defines CKD as the presence of kidney 
damage or glomerular filtration rate (GFR) of < 60 ml/min/1.73 m2 for at least 3 months. 
CKD is further classified into 5 stages according to the estimated eGFR (Table 3). 
Table 3: The National Kidney Foundation Kidney Disease Outcomes Quality 
Initiative 
Stage Clinical Features GFR (ml/min/1.73m
2
) 
I  Kidney Damage* with normal or 
increased GFR 
≥ 90 
II  Kidney Damage* with a mild 
decrease in GFR 
60 – 89 
III Moderate decrease in GFR 30 – 59 
IV Severe decrease in GFR 15 – 29 
V Kidney Failure < 15 or dialysis 
*Kidney Damage = pathological abnormalities or markers of disease present in the urine, blood or on imaging modalities 
(Table adapted from Anderson and Glynn 2011 (207)) 
It was thought that these guidelines would establish a benchmark for both research and 
clinical practice (212). However there has been extensive criticism and calls for 
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amendments (213-215). These have included increasing the ‘chronic’ aspect of the 
definition by increasing the 3 month time frame to 6, 9 or 12 months (216). It has also 
been suggested that these guidelines ‘over-label’ elderly patients with mild impairment 
of renal function as having a disease (217). It is important to note that despite the calls 
for lengthening the chronicity aspect of the CKD definition, many large CKD prevalence 
and mortality studies including the National Health Nutrition and Examination Survey 
have chosen to use only one serum creatinine reading to define CKD, therefore not 
accounting for the inherent chronicity of this disease (218;219). 
There has also been great debate with regard to the optimal method of measuring 
kidney function. The ‘gold standard’ to assess kidney function is direct measurement of 
GFR from 24 h urine collection by isotopic techniques but this is not practical in many 
settings (207); therefore equations are used to calculate an eGFR, rather than direct 
measurement.  
The 2 equations most commonly used to estimate kidney function are the Cockcroft 
Gault equation (for determining creatinine clearance (CrCl)) (220) and the Modified Diet 
in Renal Disease (MDRD) equation (for estimating eGFR) (221). The majority of 
epidemiological studies use the MDRD equation and its use is also widespread in 
clinical laboratories (222-226). Historically the Cockcroft-Gault equation has been 
recommended for use when calculating medication dosage although recently the MDRD 
formula has been used for this purpose as well (227). However both equations have 
been criticised for biases and inaccuracy (213;228). A number of new equations have 
been proposed to attempt to overcome some of these limitations but need to be further 
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developed, validated and adopted through a process of international consensus 
(217;229-231). 
1.4.2 Acute Kidney Injury 
The results of the Cardiac Angiography in REnally impaired patients (CARE) and 
Visipaque Angiography/interventions with Laboratory Outcomes in Renal insufficiency 
(VALOR) (232;233) studies discussed in more detail in section 1.6.3, highlight how the 
definition of AKI used can affect trial outcomes and there is also a need for consistent 
terminology to ensure that research is interpretable and valid comparisons between 
trials can be made. Studies to date, have defined the development of contrast induced 
AKI as an absolute increase in serum creatinine of 44 - 88 µmol/l (234) or as a 
percentage increase from baseline (25 - 50%) (235-237). Serum creatinine levels can 
vary by 10-20% in patients with normal renal function depending on hydration status and 
hence serum creatinine is an insensitive marker of GFR in these patients (238). In a 
small subset of diabetes hyperfiltration occurs which is dependent on the degree of 
hyperglycaemia (239). Moreover changes in serum creatinine level take at least 24 h to 
become apparent after a change in GFR has occurred. Whilst creatinine clearance is a 
more sensitive marker of GFR than serum creatinine, its use is limited by practical 
considerations as discussed in the section 1.4.1. Other markers that are currently being 
assessed include iothalamate and cystatin C (240;241). 
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1.4.2.1 RIFLE and AKIN 
The RIFLE (Risk, Injury, Failure, Loss and ESRD) criteria were developed in an attempt 
to standardize and improve the care of patients with AKI (242;243). They combine the 
use of both GFR and urine output criteria and hence avoid the difficulties that may arise 
from using serum creatinine alone to stratify severity of renal impairment. Patients are 
grouped according to the RIFLE acronym: R – at Risk of AKI, I – with renal Injury, F – 
with renal Failure, L – with sustained Loss of renal function, E – End –stage renal 
disease (ESRD). This is summarised on the next page in Figure 9.
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Figure 9: The RIFLE Classification for AKI 
 
 
(Adapted from: Ricci et al Kidney International 2008 (244)). The shape of the figure denotes the fact that more patients 
(high sensitivity) will be included in the mild category, including some without actually having renal failure (less 
specificity). In contrast, at the bottom, the criteria are strict and therefore specific, but some patients will be missed. 
Abbreviations: GFR, glomerular filtration rate; UO, Urine Output; ARF, acute renal failure. 
A number of studies have shown that the RIFLE criteria correlate with outcomes in many 
different populations (244) including in-hospital (245), critical care units (246), cardiac 
surgery (247) and patients on haemodialysis (248). Whether different aetiologies of AKI 
(e.g. contrast medium) affect the clinical outcome of each degree of renal dysfunction in 
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the RIFLE criteria is not currently known but would be valuable to be addressed in future 
studies of contrast induced AKI. 
The Acute Kidney Injury Network (AKIN) was formed in 2004 and proposed a new 
definition for AKI (243). Compared with the RIFLE classification, this definition of 
contrast induced AKI requires a serum creatinine elevation of either ≥ 0.3 mg/dl or ≥ 
50% above baseline (within a 48 h period), identical grades of oliguria and a similar 
severity staging system. Retrospective studies should be conducted to initiate the 
process of validating this definition of AKI with subsequent prospective studies 
incorporating sampling of putative AKI biomarkers (249). 
 
1.5 The Diabetic Kidney 
Diabetes is the leading cause of end-stage kidney disease and has reached epidemic 
proportions worldwide (132). Patients with diabetes have up to a 40% life-time risk of 
developing diabetic nephropathy which is one of the major micro-vascular complications 
(250).  
 1.5.1 Cellular and structural abnormalities in diabetic 
nephropathy 
The kidney lesions in diabetic nephropathy are similar whether related to T1DM or 
T2DM (251). Cells involved include glomerular podocytes, mesangial and endothelial 
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cells, tubular epithelia and interstitial fibroblasts and vascular endothelia. Cellular and 
extra-cellular abnormalities occur in both the glomerular and tubule-interstitial 
compartments (252). These include hyperplasia/hypertrophy of various cells associated 
with thickening of the glomerular and tubular basement membranes and expansion of 
the tubule-interstitial and mesangial compartments (253). Other changes which occur 
include hyalinization of arterioles and thickening of the intrarenal arterial tree and its 
branches, resulting in impairment in ‘autoregulation’ of the microcirculation.  
1.5.2 Pathogenesis of diabetic nephropathy 
In one-third of patients, diabetic nephropathy is a progressive condition characterised by 
decline in GFR (Table 3) with increasing proteinuria (predominantly albuminuria) which 
acts as both a marker of disease severity, is used to guide treatment and is an 
independent risk factor for cardiovascular disease (130;131). Proteinuria also plays a 
central role in the pathogenesis of progressive renal dysfunction (summarised in Figure 
10). 
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Figure 10: Schema unifying the mechanisms of proteinuria and decrease in GFR in 
DKD  
 
(Adapted from Jefferson et al Kidney International 2008 (132)). Green arrows summarise events leading to albuminuria 
and proteinuria. Purple arrows summarise events leading to reduced GFR. The diabetic milieu acts on all cell types within 
the kidney (thick orange arrows) and these contribute either primarily or secondarily to the development of 
albuminuria/proteinuria and reduced GFR. At the level of the glomerulus, both haemodynamic effects and injury to the 
individual components of the glomerular filtration barrier primarily lead to proteinuria (green arrows). Tubulointerstitial 
injury may decrease tubular protein reuptake. Mesangial cell injury plays a secondary role with loss of glomerular filtration 
surface leading to glomerular hyperfiltration (dashed green arrows) and mesangiolysis leading to structural changes in the 
capillary loops. 
Results from several recent studies show that a number of different phenotypes of 
diabetic nephropathy exist and in fact the majority of patients do not develop this 
‘classic’ phenotype of progressive diabetic nephropathy. In some patients the 
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deterioration in renal function is characterised by a decrease in GFR and little or no 
albuminuria (254;255). 
Table 3: Classification of diabetic nephropathy 
Stage of diabetic nephropathy GFR (ml/min/1.73m
2
) Albuminuria (mg/g) 
1 ≥ 90 Absent or < 30 
2 ≥ 60 30 - 300 
3 ≥ 60 > 300 
4 < 60 > 3000 
5 < 15 Absent or present 
(Adapted from Calvin and Pflueger Nature Reviews Nephrology (238)). 
 
Diabetic nephropathy is characterised by renal vascular dysfunction with increased 
sensitivity to renal vasoconstrictors and renal ischaemia and a decrease in nitric oxide 
dependent vasodilatation (256;257). Ishimura et al showed that patients with Stage 1 
diabetic nephropathy have elevated renal resistive indices in their renal vasculature 
indicating a loss of renal vasodilatory blood flow reserve (258). Patients with diabetes 
also have a lower renal blood flow (vasodilatory) response following administration of 
intravenous (i.v.) nitrate (259). Renal blood oxygenation is lower in patients with early 
stage diabetic nephropathy than in healthy controls following a water-load suggesting 
that there is impairment of oxygen delivery to the kidney (260). The abnormal vascular 
and endothelial function that occurs in diabetes (discussed in section 1.2) is likely to 
contribute to this impairment in renal oxygenation. Other factors which may play a role 
(summarised in Figure 11) include defective nitric oxide production, increased 
concentrations of AGEs, increased generation of cytokines and increased production of 
reactive oxygen species (ROS) (252;261). Data from animal studies have shown that 
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nitric oxide dependent renal vasodilatation plays a key role in counteracting the 
vasoconstrictive effects of contrast media (262). The responsiveness of this mechanism 
is decreased in patients with diabetes (258;261;263).  
Figure 11: Summary of mechanisms leading to development of diabetic nephropathy 
and chronic renal failure  
 
(adapted from Kanwar et al Exp Biol Med 2008(252)). Various mechanisms relevant to hyperglycaemia induced and 
angiotensin II induced activation of various signalling pathways. This causes upregulation of various genes and cellular 
dysfunction, resulting in the development of diabetic nephropathy and chronic renal failure. Abbreviations: AGEs: 
Advanced Glycation End-products; PKC: Protein Kinase C; TGF-β: Transforming Growth Factor-β; ROS: Reactive 
Oxygen Species, NFκB: Nuclear Factor kappa B; RNS: Reactive Nitrogen Species; ECM: Extracellular matrix; AP1: 
Activator protein1; SP1: Specificity protein 1, VEGF: Vascular Endothelial Growth Factor, MCP-1: Monocyte 
Chemoattractant Protein-1, GTP: Guanosine Triphosphate).  
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1.6 Contrast Induced Acute Kidney Injury 
Contrast induced acute kidney injury (AKI); previously known as contrast induced 
nephropathy (CIN) is an important complication following procedures in the 
catheterisation laboratory (264-266). It is the third commonest cause of acute renal 
failure in hospitalised patients (266) and is associated with higher short and long term 
morbidity and mortality rates than are seen in patients without contrast induced AKI 
(267-271).  
‘Contrast induced AKI’ is now the preferred terminology over the more familiar term 
‘CIN’, since it reflects that deterioration in renal function following procedures using 
iodinated contrast media may be multi-factorial (267). CIN is a form of contrast induced 
AKI but is not the only mechanism for its occurrence (272). 
The most common definition used in clinical trials to define contrast induced AKI is a rise 
in serum creatinine of 44.5 μmol/l (0.5 mg/dl), or a relative increase of serum creatinine 
> 25% from baseline (273). AKI usually manifests clinically within 3 days of contrast 
administration and peaks within 3-5 days, with a return to baseline creatinine seen within 
10-21 days (273;274) although in some cases prolonged and even permanent decline in 
GFR may persist (272). Renal impairment is a frequent feature in patients with coronary 
artery disease and several studies have documented the adverse prognostic impact of 
CKD following percutaneous intervention (PCI) (275;276). As discussed in section 1.3.1 
patients with CKD are at extremely high risk for developing CAD, with subsequent poor 
prognosis. The combination of CKD and diabetes is associated with particularly poor 
outcomes, since when the renal function is already impaired, the ability of the nephrons 
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to recover from additional insults is extremely limited. This is discussed in detail in 
section 1.6.1.2. 
 
1.6.1 Incidence of AKI following Coronary Angiography or PCI 
1.6.1.1 General Population 
The incidence of contrast induced AKI is of the order of 3-15% in the general population 
undergoing procedures in the cardiac catheterisation laboratory (268;277). However, 
this rate may be much higher in some at–risk population groups (278-280).  
1.6.1.2 Chronic Kidney Disease and Diabetes Mellitus 
If renal function is already impaired by pathological processes then the kidney is far less 
able to tolerate the additional stress of excreting a contrast load (281). Pre-existing CKD 
(GFR <60 ml/min/1.73 m2 of BSA) is one of the strongest risk factors for the 
development of AKI (218). In these patients there is a considerable loss of nephron units 
and residual renal function is at risk of further deterioration from renal insults (e.g. 
iodinated contrast, athero-embolism, renal-toxic medications, and cardiopulmonary 
bypass). Other co-morbidities that have been demonstrated to be important include 
congestive heart failure, left ventricular dysfunction, hypotension, hypertension, pre-
procedure shock, acute myocardial infarction and possibly female gender (reviewed 
(281)). Diabetes mellitus has emerged as being a particularly important risk factor for 
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the development of contrast induced AKI as highlighted by data from the Mayo Clinic 
(268). In this retrospective analysis of 7586 patients, both elective and acute, 
undergoing coronary angiography and PCI at the Mayo Clinic, the authors report the 
higher risk to diabetic patients although this study was not specifically looking at contrast 
induced AKI. In patients with a baseline serum Cr <2.0 mg/dl (177 μmol/l), the diabetic 
patients had a significantly higher rate of AKI than the non-diabetic patients. Among 
patients with a serum Cr >2.0 mg/dl (177 μmol/l) all patients (both diabetic and non-
diabetic) had a significantly increased risk of AKI. If the serum Cr was <1.1 mg/dl (97.4 
μmol/l), the risk of AKI was 3.7% vs. 2.0%, p=0.05 in the diabetic vs. non diabetic 
patients and if the serum Cr was between 1.2 mg/dl (106.1 μmol/l) and 1.9 (170 μmol/l) 
the risk of AKI was 4.5% vs. 1.9%, p < 0.001. When serum Cr was >2.0 mg/dl both 
diabetic and non-diabetic patients experienced AKI at a high rate (22.4% for Cr 2.0-2.9 
mg/dl (177-256.4 μmol/l and 30.6% for Cr >3.0 mg/dl (265.2 μmol/l)). From these data 
the overall incidence of AKI in patients with diabetes is of the order of 6% - an additional 
2 fold increase over non diabetic patients in this study (268). These results are 
summarised in Table 4. 
Table 4: Observed incidence of AKI stratified by baseline serum creatinine and 
diabetic status 
Cr (mg/dl) Risk, all 
patients, % 
Risk, diabetic 
patients, % 
Risk, non-diabetic 
patients,% 
Diabetic vs. non-
diabetic patients, 
OR (95% CI) and 
p value 
0 – 1.1 2.4 (n = 3965) 3.7 (n = 809) 2.0 (n = 3156) 1.86 (1.20, 2.89) 
0.005 
1.2 – 1.9 2.5 (n = 3318) 4.5 (n = 710) 1.9 (n = 2608) 2.42 (1.54, 3.79) 
< 0.001 
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2.0 – 2.9 22.4 (n = 179) 22.4 (n = 67) 22.3 (n = 112) 1.00 (0.48, 2.08) 
0.99 
≥ 3.0 30.6 (n = 124) 33.9 (n = 62) 27.4 (n = 62) 1.36 (0.63, 2.92) 
0.44 
(Adapted from Rihal et al Circulation 2002 (268). Abbreviations: OR: Odds Ratio). 
This study also demonstrated that AKI is associated with significantly increased rates of 
mortality. 22% of patients who developed AKI died during the index hospitalisation 
compared to 1.4% of patients without AKI (p < 0.0001). Among hospital survivors with 
AKI, 1 year and 5 year estimated mortality rates were 12.1% and 44.6%, respectively, 
much greater than the 3.7% and 14.5% mortality rates in patients without AKI (p < 
0.0001). 
The findings of another, albeit smaller study, emphasise the adverse prognosis of AKI 
after PCI in patients with baseline Cr elevation (278). 46% of the 161 patients whose Cr 
increased by >25% had died by 1 year compared with 19.4% of those whose Cr did not 
rise by this amount. The BARI Trial and Registry (recruited 1988-1991) of patients with 
multivessel coronary disease (n=1829) (353 patients with diabetes, 76 patients with 
CKD - defined as serum Cr >1.5mg/dl) provides further evidence (Figure 12). Patients 
with CKD were more likely to have a history of diabetes and hypertension, and CKD was 
the strongest predictor of all-cause mortality (128) and was associated with an increased 
risk of recurrent hospitalisation and subsequent bypass surgery. 
In earlier studies the risk of AKI post contrast has been reported to be as high as 33% in 
patients with diabetes (280). It has been suggested that diabetes acts as a ‘risk 
amplifier’ (Figure 13), that is to say that at any level of decreased eGFR, patients with 
diabetes have a higher risk of AKI (282). 
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Figure 12: Freedom from all cause death for patients with CKD and DM: Data from 
the BARI Trial and Registry  
 
(Adapted from Szczech et al Circulation 2002 (128).) 7 year all-cause mortality was markedly different for patients on the 
basis of both the presence and absence of CKD and of DM. Mortality for patients with DM was 28% in those without CKD 
and 67% for patients with CKD.  
Figure 13: Risk of contrast induced AKI according to baseline renal function and 
diabetes status 
 
(Adapted from McCullough PA et al Am J Cardiol 2006 and McCullough PA J Am Coll Cardiol 2008 (267;277)). 
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1.6.1.3 Risk of contrast induced AKI requiring dialysis 
The risk of contrast induced AKI requiring treatment with dialysis is approximately 1% in 
the general population undergoing coronary angiography or PCI (283-285), 4% in 
patients with underlying renal impairment (286) and 3% in patients undergoing primary 
PCI for ACS (287) (reviewed (267)). Although relatively rare patients who require 
haemodialysis post PCI have high hospital and 1 year mortality rates (278;283); post 
PCI patients requiring dialysis have a five-fold increase in in-hospital death compared 
with those who developed AKI but did not require dialysis (36% vs. 7%, p<0.0000001); 
mortality rate at 1 year in patients requiring dialysis were 54.5% vs. 6.4% respectively, 
p<0.0001 (281). 
1.6.1.4 Outcomes following development of AKI 
Contrast induced AKI has been associated with worsening of both short and long term 
outcomes, including death from cardiovascular causes (268;288). Kimura et al (289) 
studied 2349 patients with CKD who underwent coronary angiography or PCI. 
Relationships between CKD and AKI and mortality or cardiovascular disease were 
assessed using Cox regression analysis and identified both CKD and AKI as 
independent predictors of long term mortality and cardiovascular events. The results are 
summarised in Table 5. 
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Table 5: Cox regression analysis for long term endpoints in patients with CKD 
undergoing coronary angiography 
 All patients 
End-point Parameter Unadjusted model Multi-variable model 
Death from any cause CKD 2.23 (1.62 – 3.01) 1.51 (1.07 – 2.13) 
AKI 2.61 (1.44 – 4.71) 1.53 (0.84 – 2.91) 
Composite end-point CKD 2.55 (2.10 – 3.10) 1.72 (1.40 – 2.11) 
AKI 2.59 (1.78 – 3.78) 1.64 (1.09 – 2.46) 
 
(Adapted from Kimura et al Nephrol Dial Transplant 2010 Values are described as HR (95% CI)) 
 
There has been a tendency to assume that contrast induced AKI identifies patients with 
a higher burden of comorbidity and therefore these longer term adverse outcomes 
reflect this (reviewed (290)). Recent prospective randomised trials in which a therapeutic 
intervention reduces both the incidence of contrast induced AKI and long term adverse 
events, raises the possibility that contrast induced AKI directly contributes to an 
increased risk of cardiovascular and renal sequelae (291;292). Episodes of AKI 
predispose patients to develop long term loss of renal function (293). Long term follow 
up of patients who have developed AKI shows that they experience a more precipitous 
decline in GFR than individuals who do not develop kidney injury (294). As described in 
Section 1.3, CKD is a strong risk factor for developing cardiovascular events 
(103;107;295).  
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1.6.2 Pathophysiology 
The pathophysiology of contrast induced AKI is multi-factorial in aetiology and is 
summarised in Figure 14. Athero-emboli and haemodynamic alterations leading to 
reduced renal perfusion may play a role in some cases, as may other co-morbidities that 
predispose patients receiving iodinated contrast to renal injury (267;272;296). Impaired 
renal function at baseline (eGFR < 60 ml/min) appears to be a pre-requisite for the 
development of contrast induced AKI (296). Two major hypotheses have been proposed 
to explain this finding: renal vasoconstriction and tubular injury (267;272).  
A baseline reduction in nephron number is assumed, with superimposition of acute 
vasoconstriction caused by release of renal vasoconstrictors such as adenosine and 
endothelin triggered by iodinated contrast administration. Blockade of endogenous 
vasodilators including prostaglandins and nitric oxide occurs. This results in a transient 
increase in renal blood flow followed by a sustained reduction, lasting for several hours. 
This, in association with volume depletion or reduced renal blood flow from heart failure, 
results in increased blood viscosity, predisposing to medullary hypoxia and ischaemia 
(267;272). Iodinated contrast concentrates in the renal tubules and collecting ducts 
leading to direct cellular injury and death of renal tubule cells. The degree of renal 
cytotoxicity is directly related to the length of exposure those cells have to iodinated 
contrast. The sustained reduction in renal blood flow to the outer medulla leads to 
medullary hypoxia, ischaemic injury and renal tubular cell death. Other processes 
including oxidative stress and inflammation play an additive role resulting in further 
damage. Any superimposed insult such as sustained hypotension, bleeding, athero-
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embolic shower from catheter exchange/manipulation or use of intra-aortic balloon pump 
(IABP) may further amplify this injury cascade (267). 
Figure 14: Pathophysiology of contrast induced AKI 
 
(Adapted from McCullough PA J Am Coll Cardiol 2008 (267)). 
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1.6.3 Role of Contrast Media on Risk of AKI 
Iodinated contrast agents contain radio-opaque iodine atoms attached to water soluble 
carbon based molecules. Contrast media are classified according to osmolality, 
reflecting the total particle concentration of the solution – high-osmolal (HOCM) ~ 2000 
mOsm/kg, low-osmolal (LOCM) 600-800 mOsm/kg and iso-osmolal (IOCM) 290 
mOsm/kg, with decreasing renal toxicity according to these classifications. IOCM were 
originally developed to reduce the risk of contrast induced AKI but have a higher 
viscosity than LOCM (297;298). Increased viscosity has been shown in animal studies to 
reduce renal tubular flow and decrease GFR (299). There have therefore been some 
concerns regarding whether IOCM are beneficial (297;298;300;301). 
The agents may also be described as ionic or non-ionic depending on whether the 
iodine moiety is bound to an organic (non-ionic) or ionic compound. An ionic compound 
dissociates or dissolves into charged particles when it enters a solution such as blood. 
Ionic agents were developed first and use is still relatively widespread but may cause 
additional complications. Non-ionic agents covalently bind the iodine and have fewer 
side-effects as they do not dissociate into the individual component molecules (302). 
Table 6 lists commonly used contrast agents and classifies them by both osmolality and 
ionicity. 
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Table 6: Classification of commonly used contrast agents 
Compound Generic 
Name 
Brand 
Name 
Type Iodine 
content 
(mg/ml) 
Osmolality 
(mOsm/kg) 
Level 
Ionic Diatrizoate Hypaque 50 Monomer 300 1550 High 
osmolar 
Ionic Metrizoate Isopaque 
370 
Monomer 370 2100 High 
osmolar 
Ionic Ioxaglate Hexabrix Dimer 320 580 High 
osmolar 
Non-ionic Iopamidol Isovue 370 Monomer 370 796 Low 
osmolar 
Non-ionic Iohexol Omnipaque 
350 
Monomer 350 884 Low 
osmolar 
Non-ionic Ioxilan Oxilan 350 Monomer 350 695 Low 
osmolar 
Non-ionic Iopromide Ultravist 
370 
Monomer 370 774 Low 
osmolar 
Non-ionic Iodixanol Visipaque 
320 
Dimer 320 290 Iso osmolar 
 
In the last 40 years agents have become progressively more physiological, approaching 
the point of iso-osmolality. Red blood cell deformation, systemic vasodilatation, intra-
renal vasoconstriction and direct renal tubular toxicity may all result with hyperosmolar 
contrast agents (267).  
1.6.3.1 What is the contrast agent of choice in patients with CKD? 
Early studies demonstrated a lower incidence of contrast induced AKI in patients with 
diabetic nephropathy who received an IOCM as compared to LOCM (303;304). 
However, subsequent larger scale studies did not confirm this finding (232;233). It can 
sometimes be difficult to compare studies due to the different definitions used to define 
contrast induced AKI. The double-blind, multi-centre CARE study used a definition of a 
rise in creatinine of > 50% from baseline and showed no difference in rates of AKI 
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between patients with diabetic nephropathy who received LOCM iopidamol and IOCM 
iodixanol (232). The VALOR trial looked at the incidence of AKI in patients with CKD and 
further stratified by the presence of diabetes (233). Both IOCM iodixanol and LOCM 
ioversol were assessed. AKI was defined as an absolute rise in serum creatinine ≥ 44.5 
µmol/l (0.5 mg/dl). In patients with CKD but without diabetes (n = 145), no difference 
was observed in the incidence of contrast induced AKI between the 2 treatment groups. 
However in patients with CKD and diabetes (n = 154), the incidence of AKI was lower in 
the iodixanol group than the ioversol group (12.9% vs. 2.4%, p = 0.01).  
The joint guidelines from the American College of Cardiology (ACC) and American Heart 
Association (AHA) for ACS patients with CKD, describe the usage of IOCM as a class I, 
level of evidence A recommendation (305). Use of IOCM is also recommended for renal 
dialysis patients to minimise the risk of volume overload and other complications 
between dialysis sessions. Use of LOCM is allowed for lower risk patients and i.v. 
administration.  
Many studies have demonstrated that the volume of contrast agent is an important risk 
factor for contrast induced acute kidney injury (e.g. (237;306). Even small volumes of 
contrast (~30 ml) can have adverse effects on renal function in patients at particularly 
high risk (237). In this study of 59 azotemic diabetic patients undergoing coronary 
angiography as part of pre-transplant evaluation univariate analysis demonstrated a 
significant association between dye quantity (p=0.002) and development of AKI and the 
independence of this relationship was confirmed by stepwise logistic regression. This is 
especially important in the current era of PCI where increasingly larger volumes of 
contrast are being used reflecting the increasing complexity of the interventions being 
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undertaken. This is particularly true of PCI performed in patients with diabetes who 
generally have more extensive and more severe disease (34). It has been suggested 
that as a rule, the volume of contrast in ml should not exceed twice the baseline level of 
eGFR (307). Therefore for patients with significant CKD the operator should aim to use 
<30 ml for diagnostic coronary angiography and <100 ml for PCI, computed tomography 
(CT) and other intravascular studies.  
It has been demonstrated in a number of studies that the risk of contrast induced AKI is 
higher after intra-arterial than i.v. contrast administration (308;309). However it should 
be remembered that in CT studies comparatively large volumes of contrast agent can be 
given in a compact i.v. bolus and then the risk of AKI may be increased (282).  
Serial exposure to contrast medium and subsequent administration in the AKI setting is 
believed to further worsen renal function and may result in an increased chance of 
persistent renal dysfunction developing. Current clinical practice would in this setting 
favour a limited diagnostic catheterisation and PCI in the same setting over a diagnostic 
catheterisation and then a scheduled PCI within 10 days. It is important to note that 
there are no published studies of comparative data on this strategy and furthermore the 
optimal waiting period between a first and subsequent contrast medium exposure is also 
unknown. 
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1.6.4 Risk Factors 
A number of risk factors have been identified for the development of contrast induced 
AKI. These can be divided into modifiable and non-modifiable factors and are 
summarized in Table 7. 
Table 7: Risk factors for the development of contrast induced AKI  
Fixed (non-modifiable) risk factors Modifiable risk factors 
   
Older age Volume of contrast media 
Diabetes mellitus Hypotension 
Pre-existing renal failure Anaemia and blood loss 
Advanced CCF Dehydration 
Low LVEF Low serum albumin level (<35g/l) 
Acute myocardial infarction ACE inhibitors 
Cardiogenic shock Diuretics 
Renal transplant Non-steroidal anti-inflammatory drugs 
 Nephrotoxic antibiotics 
IABP 
 
 
(adapted from Mehran et al Kidney International Suppl 2006 (310). Abbreviations: ACE Angiotensin Converting Enzyme, 
CCF Congestive Cardiac Failure, IABP Intra-Aortic Balloon Pump, LVEF Left Ventricular Ejection Fraction). 
1.6.4.1 Pre-existing renal disease 
Pre-existing renal disease, as measured by an elevated serum creatinine level, is a key 
factor in the development of contrast induced AKI. The incidence of contrast induced 
AKI in patients with underlying CKD is reported in the literature at between 14.8-55% 
(268;271;283). In one contemporary study, despite pre-hydration and the use of non-
ionic contrast media, contrast induced AKI occurred in one-third of 439 consecutive 
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patients who underwent PCI and had a baseline creatinine ≥ 1.8 mg/dl (~ 160 µmol/l) 
(271). 
The higher the baseline serum creatinine concentration, the greater the risk of contrast 
induced AKI. This was very clearly shown by Hall et al (311) (summarized in Table 8). 
Table 8: Relationship between baseline serum creatinine and risk of developing 
contrast induced AKI 
Creatinine (mg/dl) Risk of contrast induced AKI (%) 
≤ 1.2 2 
1.4-1.9 10.4 
≥ 2.0 62 
 
 
For patients with a baseline creatinine ≤ 1.2 mg/dl (≤ 107 µmol/l), the risk of contrast induced AKI was 2%. This increased 
five-fold to 10.4% for a creatinine in the range 1.4 - 1.9 mg/dl (125 – 169 µmol/l). For patients with creatinine ≥ 2.0 mg/dl 
(≥ 178 µmol/l) this rose even further to 62%. 
There are limitations with baseline creatinine as a reliable marker for identifying patients 
at risk for developing contrast-induced AKI as there is marked variation with age, muscle 
mass and gender (310). In order to evaluate renal function accurately assessment of 
creatinine clearance should be performed. It may not be practical to measure creatinine 
clearance directly but it can easily be estimated using the Cockcroft-Gault Formula (220) 
or the Modification of Diet in Renal Disease (MDRD) equation (221). A number of 
studies have demonstrated that an estimated glomerular filtration rate (eGFR) of ≤ 60 
ml/min/1.73m2 is a reliable threshold for identifying patients at high risk for development 
of AKI (310). It is therefore recommended that eGFR is calculated prior to exposure to 
contrast agent as part of the risk assessment process (220;221). 
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1.6.4.2 Diabetes mellitus 
A high proportion of patients undergoing coronary angiography or PCI have diabetes. 
This is due to the combination of the high prevalence of the disease and the wide 
spectrum of cardiovascular disease that can manifest as a consequence. The incidence 
of contrast induced AKI in diabetic patients in the literature varies from 5.7 – 29.4% 
(286;312). In diabetic patients with preserved renal function and absence of other risk 
factors, rates of contrast induced AKI are comparable to those of a non-diabetic 
population (312). In one study contrast induced AKI occurred in 27% of diabetic patients 
with a baseline serum creatinine 2.0 - 4.0 mg/dl and in 81% with serum creatinine > 4.0 
mg/dl (313). In another study of diabetic patients, contrast induced AKI occurred in 
15.1% of patients without CKD vs. 27.4% in those with CKD; de novo dialysis was 
instituted in 0.1 vs. 31% respectively (both p < 0.0001) (286).  
1.6.4.3 Older Age 
There is evidence from a number of studies that older age is an independent risk factor 
for the development of contrast induced AKI (280;314;315). The reasons for higher risk 
in the elderly have not been specifically studied. However these are likely to be multi-
factorial in origin including age related changes in renal function such as decreased 
glomerular filtration rate, tubular secretion and concentrating ability. Furthermore the 
presence of multi – vessel coronary artery disease, requiring more complex intervention 
procedures with higher volumes of contrast media and more difficult vascular access 
due to tortuosity and calcification of vessels may further amplify risk (310). 
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1.6.4.4 Volume and Type of contrast media 
The volume of contrast media used during coronary angiography or PCI is probably one 
of the most easily modifiable risk factors. There is a clear correlation between volume of 
contrast media used and risk of contrast induced AKI e.g. (237;283;315;316). Even 
relatively low amounts of contrast (< 100 ml) can result in permanent renal failure and/or 
the need for dialysis in patients with underlying CKD (237;317). One study in diabetic 
patients with CKD showed that for every 100 ml increment in contrast volume used, the 
result was a 30% increase in the odds of contrast induced AKI developing (odds ratio 
1.30, 95% CI 1.16-1.46) (286). 
Whether use of different types of contrast agent is of benefit in reducing rates of contrast 
induced AKI is an area of great debate. Katholi et al (318) and Harris et al (319) both 
showed that decrease in creatinine clearance was greater in patients receiving HOCM 
compared to LOCM. However Schwab et al (320) did not show any difference in 
nephrotoxic effects between several different studied contrast agents. In a meta-analysis 
of 45 trials, a greater increase in serum creatinine following administration of HOCM 
compared to LOCM was only seen in patients with pre-existing renal failure (321).  
There are currently a number of different LOCM available. There is some evidence that 
differences in nephrotoxic effect appear to more evident with ionic than non-ionic 
agents. The ICON study (Ionic versus non-ionic Contrast to Obviate worsening 
Nephropathy after angioplasty in chronic renal failure patients) showed that contrast 
induced AKI is less likely to develop in high risk patients (baseline serum creatinine 1.5 
– 3.5 mg/dl) when iso-osmolality, non-ionic iodixanol is used rather than low-osmolality, 
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non-ionic iohexol (322).  
In current practice, non-ionic low osmolar contrast media remain the preferred choice in 
patients with renal impairment. Further studies will be necessary to clarify the issue of 
minimizing renal damage whilst using different contrast media (310). 
1.6.4.5 Anaemia and blood loss 
It is thought that anaemia contributes to renal ischaemia and hence development of 
contrast induced AKI. Data from the interventional cardiology database at Columbia 
University in New York (323), showed that rates of AKI increased as pre-procedure 
haematocrit quintile decreased (from 10.3% in the highest quintile with haematocrit ≥ 
44.8% to 23.3% in the lowest quintile with haematocrit < 36.8%). Stratification by 
baseline eGFR and baseline haematocrit demonstrated that rates of AKI were the 
highest (28.8%) in patients with both the lowest level for both baseline eGFR and pre-
procedure haematocrit. On multivariate analysis, lower baseline haematocrit was 
identified as an independent predictor for AKI development regardless of the presence 
or absence of CKD: each 3% decrease in baseline haematocrit resulted in a significant 
increase in the odds of AKI in patients with and without CKD (11% and 23%, 
respectively). 
1.6.4.6 Other risk factors 
Congestive cardiac failure, impaired left ventricular function, dehydration, hypotension 
and the use of IABP and some drugs (non-steroidal anti-inflammatory (NSAIDs), 
diuretics and ACE inhibitors) have all been identified as risk factors for the 
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development of AKI (310;324;325). The damaging effect of hypotension on renal 
function is well known (323). IABP insertion may be linked with the development of AKI 
through a number of different mechanisms: a) athero-emboli to the renal circulation 
during insertion, b) partial occlusion of renal blood flow due to malposition, c) as a 
marker of increased vascular complications and post PCI hypotension (reviewed (310)). 
The role of ACE inhibitors is controversial. In one study patients receiving ACE inhibitors 
had a significant increase in serum creatinine post procedure compared with patients 
not receiving this medication (315). However use of ACE inhibitors only predicted the 
occurrence of contrast induced AKI on univariate but not multi-variate analysis.  
1.6.4.7 A Risk Scoring System: The Mehran Risk Score 
The development of various risk scoring systems now allows clinicians to evaluate an 
individual patient’s risk of developing AKI following PCI. In the scoring system below 
(Table 9) (326), diabetes significantly adds to the risk of developing AKI, especially 
given that many patients with DM undergoing PCI have eGFR < 60 ml/min. 
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Table 9: The Mehran Risk Score for development of contrast induced AKI  
 Score 
Risk Factor Hypotension 5 
IABP 5 
CCF 5 
Age >75 years 4 
Anaemia 3 
DM 3 
Contrast media volume 1 for every 100 ml 
Serum Cr >1.5mg/dl* 2 
*Or  eGFR <60 ml/min           40-60   2 
                     20-40                                                 4 
<20   6 
Risk Score Risk of AKI Risk of dialysis 
<5 7.5% 0.04% 
6-10 14.0% 0.12% 
11-16 26.1% 1.09% 
>16 57.3% 12.6% 
(adapted from Mehran et al J Am Coll Cardiol 2004 (326)). 8315 patients undergoing PCI at Columbia University Medical 
Centre, New York over a 6 year period were randomly assigned to a development and validation dataset. 5571 patients in 
the development dataset had their baseline clinical and procedural characteristics considered as candidate univariate 
predictors for the development of contrast induced AKI (defined as either a rise of >25% from baseline or an absolute rise 
>0.5mg /dl). Multivariate logistic regression analysis was used to identify predictors of contrast induced AKI with a p value 
< 0.0001. From the odds ratio (OR) 8 variables (hypotension, intra-aortic balloon pump (IABP), congestive cardiac failure 
(CCF), CKD, diabetes, age >75 years, anaemia and contrast volume) were identified and assigned a weighted integer. 
The sum of the integers was a total risk score for each patient. Definitions: anaemia: baseline haematocrit value < 39% 
for men and < 36% for women; CCF: New York Heart Association (NYHA) Class III/IV ± history of pulmonary oedema; 
hypotension: systolic BP < 80 mmHg for at least 1 hour requiring inotropic support or IABP. 
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1.7 Strategies for renal protection  
(Summarised in Figure 15) 
1.7.1 Intravenous hydration 
Due to the considerable morbidity and mortality associated with the development of 
renal injury post PCI, it is important to identify strategies that may confer a degree of 
renal protection. Volume expansion and treatment of dehydration has a key role in 
prevention of contrast induced AKI. Volume expansion results in increased renal peri-
tubular blood flow and reduces tubular stasis of contrast medium. It is thought that this 
limits the contact between contrast and the tubular cells therefore decreasing the direct 
cytotoxic insult. Whilst the importance of good hydration with i.v. fluids has been 
identified, there are no robust data that favour a particular regimen (327;328). Isotonic 
crystalloid (normal saline or bicarbonate solution) is probably more efficacious than half-
normal saline as it will remain in the intravascular space for a longer duration (327). It 
has been hypothesised that alkalinisation of tubular fluid might be beneficial by reducing 
the levels of pH dependent free radicals. Merten et al (328) showed that creatinine 
levels were less likely to rise >25% within 2 days following the administration of contrast 
in patients given isotonic sodium bicarbonate infusion rather than normal saline. 
However this remains a controversial intervention due to methodological concerns about 
this study (reviewed (329)). A recent meta-analysis demonstrated no benefit of hydration 
with sodium bicarbonate versus normal saline (330) and called for more good quality 
large scale trials to evaluate this further. 
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There is limited evidence to date to guide the choice of optimal rate and duration of the 
fluid regime. Maintaining urine output >150 ml/h (324) has been shown in one study to 
be associated with decreased rates of AKI. This was a prospective randomised 
controlled single-blind trial of 98 patients. Those in the control arm (n=55) were 
randomised to intravenous crystalloid (0.45% saline) at a rate of 150 ml/hour, 
commenced on arrival in the cardiac catheter lab and continued during the procedure. 
Those in the experimental arm (n=43) received the same regime of intravenous 
crystalloid, frusemide intravenously as a single dose (1 mg/kg up to a maximum of 100 
mg) and intravenous dopamine (3 µg/kg/min) which was continued during the 
procedure. The forced diuresis resulted in higher urine flow rate (163.26 +/- 54.47 vs. 
122.57 +/- 54.27 ml/hour) over the 24 h following contrast exposure (p=0.001). 2 
patients in the experimental arms versus 5 in the control arm required dialysis with all 7 
cases having urine flow rates <145 ml/h. The rates of renal failure in those with urine 
flow rates >150 ml/h in the post-procedure period were significantly lower 8/37 (21.6%) 
vs. 28/61 (45.9%), p=0.03. 
At the London Chest a pragmatic approach is taken with 2 h of intravenous normal 
saline prior to the procedure with 6 h of hydration (oral or intravenous) post-procedure in 
all patients with eGFR < 50 ml/min. (331) 
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1.7.2 N-acetylcysteine (NAC) 
NAC has the potential to decrease nephrotoxicity due to its anti-oxidant and vasodilatory 
effects. Animal studies have demonstrated that acetylcysteine decreases ischaemic 
renal failure, blocks expression of vascular cell adhesion molecule-1 (VCAM-1) and 
prevents activation of NF-κB in glomerular mesangial cells (332). A clinical trial of 83 
patients with chronic renal insufficiency (defined as a serum creatinine >1.2 mg/dl or 106 
μmol/l or a creatinine clearance <50 ml/min) undergoing CT with a low-osmolality 
contrast agent, assigned patients to receive either oral 600 mg acetylcysteine bd for 2 
days (starting the day prior to the planned procedure) or placebo. All patients received 
intravenous hydration with 0.45% saline for 12 h pre and post contrast administration. A 
standard dose of 75 ml of low-osmolality contrast agent was used. The study 
demonstrated that serum creatinine levels rose by >0.5 mg/dl in 2% of patients who 
received NAC compared with 21% of patients in the control group (p<0.01, (333)). It has 
been noted that the event rate in the control group was unexpectedly high for patients 
receiving a low osmolality contrast agent. Until recently other trials have been limited by 
low power and lack of blinding and by variation of NAC dose level and regime (reviewed 
(282)). A number of meta-analyses have been published on this subject (285;334-343) 
and seven of these found a net benefit for NAC in the prevention of AKI. A review (339) 
found marked heterogeneity in 10 of 11 meta-analyses and also that it was only in 
studies where following NAC administration serum creatinine decreased below baseline 
values that AKI rates appear to be reduced. NAC reduces skeletal muscle production of 
creatinine into the blood stream and it has been hypothesised that it may falsely lower 
post-contrast creatinine and not actually protect against AKI (282). 
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The ACT (Acetylcysteine for the prevention of Contrast induced nephropathy Trial) 
recently reported at the AHA in November 2010 (344). This randomised multi-centre 
clinical trial of 2308 patients from Brazil compared high dose NAC (1200 mg bd orally, 2 
days pre and 2 days post procedure) against placebo in patients undergoing coronary 
and vascular angiography. There was no increase in the primary endpoint of contrast 
induced AKI (12.7% in the NAC arm vs. 12.7% in the placebo arm, p = 0.97). Clinical 
endpoints at 30 days including mortality, cardiovascular mortality and dialysis were 
equivalent between the 2 groups. The study used a number of different contrast agents 
including 22% HOCM and fluid regimes were not standardised. Furthermore although 
the authors refer to the population as ‘high risk’ they only had to have one of the 
following to qualify: age >70 years, chronic renal failure (serum creatinine > 1.5 mg/dl), 
diabetes mellitus, heart failure and shock. 
Routine use of NAC is currently not recommended in the ACC/AHA guidelines but it is a 
Class IIB recommendation in chronic renal failure patients in the European Society of 
Cardiology (ESC) guidelines (345). At the London Chest oral NAC 600 mg bd is given to 
all patients with eGFR <50 ml/min undergoing coronary angiography and PCI (331) for 
48 h pre and post procedure. 
1.7.3 Statins 
Statins (3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors) have been shown to 
reduce myocardial infarction and death (346-348). It is thought that reduction of LDL is 
responsible for the majority of the observed benefit. Statins have been shown to 
demonstrate pleiotropic effects including improved endothelial function (e.g. at the 
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level of the glomerulus) and reduction in systemic inflammatory response and may have 
protective effects on the kidney. It has been shown that patients continued on statins 
during cardiovascular procedures including PCI and CABG have lower rates of AKI 
(349). Small randomised trials provide further supportive evidence although conclusive 
trials have not been reported to date (reviewed (350)). 
 
1.7.4 Other Approaches 
Forced diuresis with frusemide, mannitol or a combination of these agents has not been 
demonstrated to reduce the incidence of contrast induced AKI when compared to 
intravenous hydration alone (351;352). There have been small randomised trials of 
various vasodilators including atrial natriuretic peptide (353;354) prostaglandins (355) 
and endothelin receptor antagonists (356) but similarly none of these agents have 
demonstrated a reduction in the risk of AKI when compared to intravenous hydration. 
Aminophylline, an adenosine receptor inhibitor, has been proposed as an agent that 
may reduce the risk of contrast induced AKI but there is no conclusive supporting 
evidence for this so far (329;357;358), reviewed (329). The choice and volume of 
contrast agent utilised is also important as outlined previously (section 1.6.3).  
A novel therapeutic approach using a device allowing delivery of direct renal arterial 
infusion has recently been described (359). This has the advantage of allowing local 
drug delivery, with a high local dose whilst avoiding systemic adverse effects due to 
renal 1st pass metabolism. This study was a post-market registry which enrolled 501 
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patients at high risk for AKI. Bilateral renal artery cannulation was successful in 94.2% 
with a mean cannulation time of 2 min. Patients received an infusion of either 
fenoldopam mesylate, sodium bicarbonate, alprostadil or B type natriuretic peptide. 
Mean creatinine levels did not change significantly (baseline, 24 and 48 h post 
procedure: 1.95. 1.99 and 1.98 mg/dl, p = NS). In the 285 patients who received 
fenoldopam and were followed for 48 h, the incidence of AKI was 71% lower than 
predicted (8.1% actual vs. 28% predicted by the Mehran risk score, p < 0.0001). Only 4 
(1.4%) of patients required dialysis vs. the 2.6% predicted (p = NS). Further large 
randomised studies will be required to further validate these initial promising results. 
1.7.5 Role of Haemodialysis/Haemofiltration 
The role of haemodialysis in patients at high risk for the development of AKI remains 
unclear. Iodinated contrast is water soluble and therefore can be removed by dialysis. 
Patients already receiving renal replacement therapy (RRT) should have a dialysis 
session shortly following contrast administration to remove the contrast from the body 
and avoid possible complications of volume overload or late contrast reactions. There is 
currently no evidence that prophylactic dialysis in patients with advanced CKD (not on 
RRT) reduces the risk of AKI even when this intervention is carried out within 1 h of 
contrast administration. There may however be a role for haemofiltration in very high risk 
patients as some small studies have shown this to be beneficial (360;361). In 114 
patients with advanced kidney disease (defined as a serum creatinine > 2mg/dl (176.8 
μmol/l)) an increase in serum creatinine levels was significantly lower in patients 
randomly assigned to receive haemofiltration (n=58) pre and post contrast exposure as 
opposed to those assigned to receive fluid alone (5% vs. 50%, p<0.001). In-hospital 
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death was also significantly less frequent in those who received haemofiltration (2% vs. 
14% in the control arm p=0.02) (361). Serum creatinine is directly affected by the 
intervention, and the relationship between the intervention and reduction in mortality is 
not clear. The resources required to deliver this therapeutic intervention are 
considerable and therefore the authors concluded that this would only be a realistic 
option for the most severe cases. In order to target patients who would benefit from this 
intervention after a contrast load, earlier identification of those at risk is necessary. 
Figure 15: Strategies for renal protection 
 
(adapted from McCullough PA: Chapter 27 Contrast Induced Acute Kidney Injury, Oxford Textbook of Interventional 
Cardiology 2010 (282)).  
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1.7.6 Remote Ischaemic Pre-Conditioning 
Murry et al first proposed the hypothesis of ‘conditioning’ the myocardium to protect it 
against ischaemia-reperfusion injury (362). They observed that intermittent occlusion of 
the coronary artery to induce short bouts of myocardial ischaemia and reperfusion led to 
the development of myocardial resistance to a subsequent more prolonged episode of 
ischaemia and resulted in a significant reduction in infarction size. They termed this 
phenomenon ‘ischaemic pre-conditioning’ (IPC). The IPC stimulus results in a ‘biphasic 
response with 2 distinct ‘windows’ of myocardial protection. The first, or ‘classical IPC’ 
lasts 3-4 hours and then disappears (363). The ‘second window of protection, SWOP’ or 
delayed/late preconditioning window, reappears 24 hours later and may confer 
cardioprotection for up to 72 hours (364).  
The cardioprotective potential of IPC was first demonstrated in patients undergoing 
coronary artery bypass grafting (365;366). The IPC protocol involved cross clamping of 
the aorta and was shown to decrease myocardial injury. However the IPC technique 
used was both impractical and highly invasive. A more convenient, less invasive means 
of achieving cardioprotection may be conferred through ‘remote ischaemic 
preconditioning’ (RIPC) where brief ischaemia in a tissue/organ confers protection on a 
distant tissue or organ from a prolonged episode of ischaemia. 
RIPC was first described by Przyklenk et al in 1993 (367). The authors showed that in 
anaesthetised dogs, episodes of circumflex coronary artery occlusion interspersed with 
periods of reperfusion before a sustained occlusion of the left anterior descending (LAD) 
artery with subsequent reperfusion, resulted in a significant reduction in the size of 
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myocardial infarction in the LAD vascular bed (6 +/- 2% of the risk zone versus 16 +/-5% 
in non-pre-conditioned controls, p < 0.05). Furthermore segment shortening of the LAD 
region was improved by preconditioning the circumflex vascular bed, again reflecting 
smaller infarction size. Preconditioning the circumflex vascular bed did not affect 
collateral flow within the LAD coronary bed. The authors also demonstrated that the 
magnitude of infarction reduction (35%) was equivalent to that of standard 
preconditioning within the same vascular bed (reviewed (368)).  
Recent studies have suggested that there may be benefit from RIPC in decreasing rates 
of renal injury (369-371;371). The first of these studies, by Ali et al showed that RIPC 
reduced both myocardial and renal injury after elective abdominal aortic aneurysm repair 
(369). This was a randomised study performed in 82 patients undergoing elective 
abdominal aortic aneurysm (AAA) surgery which is a major operation associated with 
significant myocardial and renal injury. The study utilised invasive lower limb ischaemia 
with 2 cycles of intermittent cross clamping of the iliac arteries for 10 minutes followed 
by 10 minutes of reperfusion. Myocardial injury was defined as a cardiac troponin I > 
0.40 ng/ml, myocardial infarction by the ACC/AHA definitions (305) and renal injury by a 
serum creatinine >177 μmol/l. RIPC reduced the incidence of myocardial injury by 27% 
(39% versus 12%, p=0.05), myocardial infarction by 22% (27% vs 5%, p=0.006) and 
renal impairment by 23% (30% vs 7%, p=0.009).  Hoole et al extended the concept of 
RIPC using 3 cycles of upper limb ischaemia to a population undergoing elective 
percutaneous coronary intervention (370). Subjects were randomised either to 3 cycles 
of upper limb RIPC (n=104) or a control arm (n=98). RIPC significantly decreased 
median troponin I concentrations when compared to controls at 24 hours (0.06 ng/ml vs 
0.16 ng/ml, p=0.04). RIPC was associated with less chest pain and ECG changes 
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during the PCI procedure and at 6 months there were fewer major adverse cardiac 
events when compared to controls (4 versus 13, hazard ratio 0.28, p=0.018). 
In order to become adopted as an effective therapeutic strategy, it will be important to 
determine whether the myocardium is amenable to IPC in the presence of pathological 
conditions such as the metabolic syndrome and diabetes mellitus – this is currently not 
known (371;372). The data from animal models has been conflicting (reviewed (373)) 
and studies in humans have not included sufficient numbers of patients with diabetes 
(370;371;374).  
One possibility is that there is an abnormality in protein kinase signalling in the PI3k-Akt 
kinase pathway of the diabetic heart. This pathway is thought to be involved in relaying 
the cardioprotective signal in the index ischaemic phase (363) and also inhibits the 
opening of the mitochondrial transition pore (375) in the inner mitochondrial membrane. 
Opening of this pore in the first few minutes of reperfusion mediates cell death by 
uncoupling oxidative phosphorylation and inducing mitochondrial swelling (376). 
Research by Tsang et al suggests that the effect of IPC may be restored by augmenting 
the IPC stimulus (377). Administration of hypoglycaemic agents such as glimepiride or 
rosiglitazone (reviewed (378)) may also restore the effects of IPC, since they act to 
augment levels of Akt. It is however important to note that some medications e.g. 
nicorandil and anti-diabetic agents have the potential to interfere with the endogenous 
cardioprotection conferred by IPC. This includes the sulphonylurea gliblencamide which 
increases basal and postprandial insulin secretion by closing the ATP dependent 
potassium channel in pancreatic beta cells. It is also thought to antagonise IPC by 
closing similar channels in the myocardium (379). However other sulphonylureas 
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including glipizide, gliclazide and glimepiride do not antagonise IPC (reviewed (378)). 
Further studies will be necessary to evaluate the role of RIPC in ameliorating contrast 
induced AKI, particularly in patients with diabetes. 
 
1.8 Use of Biomarkers 
In both AKI and CKD, prompt recognition and early intervention can significantly improve 
the otherwise very poor prognosis. Currently, in standard clinical practice, AKI is 
diagnosed by measuring serial serum creatinine levels but this may be problematic for a 
number of reasons. Creatinine is not a reliable indicator during acute fluctuations in 
kidney function (380-382). Serum creatinine levels can vary widely even in healthy 
individuals depending upon age, sex, muscle mass and metabolism, medications, 
nutrition and hydration status reviewed (383). A number of both acute and chronic 
kidney conditions can exist with no increase in serum creatinine evident due to the 
concept of ‘renal reserve’: this estimates that at least 50% of kidney function must be 
lost before it becomes clinically evident with a rise in serum creatinine. During acute 
changes in glomerular filtration, creatinine does not provide an accurate depiction of 
kidney function until a steady-state equilibrium (between production and decreased 
excretion of creatinine) has been achieved (380), a process that takes at least several 
hours. Finally an increase in serum creatinine is a late marker of functional change in 
GFR and lags behind key structural changes occurring in the kidney during the early 
stages of AKI (249).  
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Animal studies (reviewed (383)) have demonstrated that whilst AKI can be prevented 
and/or treated by various strategies, these must be instituted very early, after the initial 
insult and before the serum creatinine starts to rise. Typically creatinine begins to rise 
between 48-72 h following this initial insult. Conventional urine markers such as casts or 
fractional excretion of sodium are insensitive and non-specific for early recognition of 
AKI (381). 
1.8.1 The need for a ‘troponin-like’ biomarker of AKI 
A biomarker for AKI that is easily measured and unaffected by other biological variables, 
with the potential for both early identification and risk stratification would be a key 
therapeutic advance in the care of hospitalised patients where the overall incidence of 
AKI is estimated at 5-7% (380-382). As already discussed this rate may be even higher 
in some at risk groups undergoing exposure to contrast agents such as those found in 
the cardiac catheter laboratory (218;268;281). The deleterious influence of AKI to clinical 
outcomes in critically ill patients is well known (384-386). AKI has also been shown to be 
a key risk factor for the development of non-renal complications and to independently 
contribute to mortality (387). Technological developments in functional genomics and 
proteomics have led to the identification of a number of novel serum and urine 
biomarkers in both AKI and CKD. Our aim is to identify a highly sensitive and specific 
biomarker or if necessary develop a ‘kidney injury risk panel’ to perform the same role. 
This would be similar to that used in diagnosing an acute coronary syndrome where one 
combination used comprises of creatinine kinase, troponin and myoglobin. 
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1.8.2 The Ideal Acute Kidney Injury Biomarker  
(adapted from Devarajan Nephrology 2010 (383)).  
There are a number of important requirements for the ideal biomarker. These are: 
1. Non-invasive using easily accessible samples such as urine or blood with the 
ability to perform either bedside testing or evaluate in a standard clinical 
laboratory 
2. Rapid and reliable measurement using established standardised clinical assay 
platforms across a range of co-morbidities e.g. diabetes, coronary heart disease 
3. Sensitive – facilitating early identification of AKI, with a wide dynamic range and 
cut off values allowing relevant risk stratification 
4. Robust biomarker performance on statistical analysis including accuracy testing 
by receiver operating characteristic curves (388-390). 
5. Highly specific for AKI, allowing the identification of AKI sub-types and different 
aetiologies 
6. Cheap and cost effective 
Biomarkers may serve a number of other purposes in AKI (388-390). They may have a 
role in identifying: 
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1. Primary anatomical location of the injury (e.g. proximal tubule, distal tubule, 
interstitium or vasculature) 
2. Duration of AKI, CKD or ‘acute on chronic’ injury 
3. Aetiology of AKI (e.g. ischaemia, sepsis, toxins, multi-factorial) 
4. Risk stratification and prognosis (e.g. duration/severity of AKI, need for 
dialysis/filtration, length of hospital stay or mortality) 
5. Response to AKI interventions 
Finally AKI biomarkers may have an important role in the development of drugs and 
therapeutic interventions to treat AKI allowing nephrologic care to be individually tailored 
to the patient. 
1.9 Biomarkers to be measured 
These markers have been chosen to allow the identification of a possible ‘panel’ to 
predict the risk of contrast induced AKI – similar to that used in ACS non-ST elevation 
myocardial infarction (NSTEMI) (CK, Myoglobin, Troponin). The markers include both 
serum and urine neutrophil gelatinase associated lipocalin (NGAL), interleukin-18 (IL-18) 
and cystatin C. All have been implicated in the development of AKI but not all have been 
studied in post contrast AKI or in patients with CKD. 
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1.9.1 Microalbuminuria 
Microalbuminuria, the pathological excretion of urinary albumin at levels below the 
threshold of detection by conventional urinary dipstick (30-300 mg/l), is thought to mark 
the onset of altered glomerular structure and function. There are some recent data from 
animal studies which suggest that the normal glomerular filter may leak albumin at 
higher levels than thought previously and albuminuria may reflect alterations in the 
proximal tubule cell retrieval pathway (391). Hence microalbuminuria may provide a 
useful marker of AKI and proximal tubule damage. There are concerns that lack of 
specificity may compromise utility as microalbuminuria may also occur in the setting of 
strenuous exercise, urinary tract infection, dehydration, fever and poor glycaemic control 
(392). 
1.9.2 Neutrophil gelatinase associated lipocalin 
NGAL is a small 25 kDa protein that was first identified bound to matrix 
metalloproteinase-9 (MMP-9) from neutrophils with a role as an innate immunity 
antibacterial factor (393). NGAL forms a barrel shaped tertiary structure with a 
hydrophobic calyx that binds small lipophilic molecules (394). The major ligands for 
NGAL are siderophores, small iron-binding molecules. Siderophores are synthesised by 
bacteria to acquire iron from their surroundings and NGAL exerts a bacteriostatic effect 
by depleting siderophores. However siderophores produced by eukaryotes play a key 
role in NGAL mediated iron shuttling that is critical in various cellular processes such as 
proliferation and differentiation (395). NGAL is expressed at very low levels in 
 
104 
several human tissues but acutely rises following injury to epithelial cells including the 
renal tubule, colon, liver and lung (383). NGAL is thought to play a role in enhancing the 
epithelial phenotype both during kidney development and following AKI (393). 
In kidney animal models, NGAL has been identified as one of the earliest genes or 
proteins to be elevated following ischaemic or nephrotoxic injury (393;396-399). From 
this animal work it was discovered that NGAL was easily detectable soon after AKI and 
this lead to a number of translational studies evaluating NGAL as a non-invasive 
biomarker of human AKI. In adults with established AKI of various aetiologies (defined 
as a doubling of serum creatinine from baseline), a marked increase in both urine and 
serum NGAL was documented by Western blotting compared with controls (398). Urine 
and serum NGAL levels correlated with serum creatinine. Furthermore kidney biopsies 
in patients with AKI demonstrated intense accumulation of immunoreactive NGAL in the 
cortical tubules. This established NGAL as a sensitive biomarker of AKI (tubular 
damage) in humans. A number of subsequent studies (reviewed (383) have identified 
NGAL as an early diagnostic urine and plasma biomarker for AKI in various clinical 
settings in both adults and children, as summarised in the tables below (Tables 10 and 
11) 
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Table 10: Urine NGAL for the early prediction of AKI  
Reference Setting Subjects (n) Sensitivity Specificity AUC-ROC (CI) 
Mishra, Lancet 
2005 
Cardiac surgery 71 1.0 0.98 0.99 (NR) 
Wagener, 
Anesthesiology 
2006 
Cardiac surgery 81 0.73 0.78 0.80 (0.57-1.03) 
Koyner, Kidney Int 
2008 
Cardiac surgery 72 0.49 0.79 0.69 (0.57-0.82) 
Wagener, Am J 
Kidney Dis. 2008 
Cardiac surgery 426 NR NR 0.61 (0.54-0.68) 
Xin, Ren Fail 2008 Cardiac surgery 33 0.71 0.73 0.88 (NR) 
Bennett, J Am Soc 
Nephrol 2008 
Cardiac surgery 196 0.82 0.9 0.93 (NR) 
Portilla, Kidney Int 
2008 
Cardiac surgery 40 1.0 1.0 1.00 (NR) 
Tuladhar, J 
Cardiovasc 
Pharmacol 2009 
Cardiac surgery 50 0.93 0.78 0.96 (0.9-1.0) 
Bachorzewska-
Gajewska, Am J 
Nephrol 2006 
Contrast 100 NR NR NR 
Ling, Nephron Clin 
Practice 2008 
Contrast 40 0.77 0.71 0.73 (0.54-0.93) 
Hirsch, Pediatr 
Nephrol 2007 
Contrast 91 0.73 1.0 0.92 (NR) 
Nickolas, Ann 
Intern Med 2008 
Emergency room 635 0.9 0.99 0.95 (0.88-1.0) 
Zappitelli, Crit 
Care 2007 
Critical care 150 0.77 0.72 0.78 (0.62-0.95) 
Makris, Clin Chem 
Lab Med 2009 
Critical care 31 0.91 0.95 0.98 (0.82-0.98) 
Siew, J Am Soc 
Nephrol 2009 
Critical care 451 NR NR 0.71 (0.63-0.78) 
Parikh, Am J 
Transplant 2006 
Kidney transplant 63 0.9 0.83 0.90 (0.71-1.0) 
Hall, J Am Soc 
Nephrol 2010 
Kidney transplant 91 0.77 0.74 0.81 (0.70-0.92) 
(adapted from Devarajan et al Nephrology 2010 (383). Abbreviations: AUC-ROC, area under the receiver-operating 
characteristic curve; CI, 95% confidence interval; NR, not-reported). 
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Table 11: Plasma NGAL for the early prediction of AKI  
Reference Setting Subjects (n) Sensitivity Specificity AUC-ROC (CI) 
Mishra, Lancet 
2005 
Cardiac surgery 71 0.7 0.94 0.91 (NR) 
Koyner, Kidney Int 
2008 
Cardiac surgery 72 NR NR 0.54 (0.4-0.67) 
Dent, Crit Care 
2007 
Cardiac surgery 120 0.84 0.94 0 96 (0.94-0.99) 
Tuladhar, J 
Cardiovasc 
Pharmacol 2009 
Cardiac surgery 50 0.8 0.67 0.85 (0.73-0.97) 
Haase-Fielitz, Crit 
Care Med 2009 
Cardiac surgery 100 0.79 0.78 0.8 (0.63-0.96) 
Malyszko, Ren Fail 
2009 
Contrast 91 0.73 1.0 0.91 (NR) 
Wheeler, Crit Care 
Med 2008 
Critical care 143 0.86 0.39 0.68 (0.56-0.79) 
Cruz, Int Care Med 
2010 
Critical care 301 0.73 0.81 0.78 (0.65-0.90) 
Bolignano, Nephrol 
Dial Transplant 
2008 
Critical care 88 0.82 0.97 0.92 (0.85-0.97) 
Niemann, Liver 
Transplant 2009 
Liver transplant 59 0.68 0.8 0.79 (NR) 
(adapted from Devarajan et al Nephrology 2010 (383). AUC-ROC, area under the receiver-operating characteristic curve; 
CI, 95% confidence interval; NR, not-reported). 
Urine and plasma levels are elevated 2 h post cardio-pulmonary bypass and 4 h post 
contrast administration in patients who subsequently develop AKI (400;401). 
Measurements may be influenced by pre-existing renal disease and systemic or urinary 
tract infections. In CKD NGAL has been demonstrated to be a marker (plasma and 
urine) of kidney disease and its severity (402;403). Further studies will be necessary to 
determine the role of NGAL in models of CKD and to define its association with CKD 
progression (380). NGAL has not been assessed post contrast in a population including 
CKD patients. 
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1.9.3 Interleukin-18 (IL-18) 
IL-18 is a pro-inflammatory cytokine that is induced in the renal tubule following AKI. It is 
produced as a 24 kDa inactive precursor which requires cleavage by caspase 1 to 
generate its biologically active form (404;405). A cleaved form is detectable in urine. IL-
18 has immunomodulatory properties and appears to play a key role in host cell defence 
against a number of infections (reviewed (392)). It has low sensitivity but high specificity 
for AKI (reviewed (401)). It is more specific to ischaemic AKI and other forms of tubular 
necrosis (406;407). Urinary levels are elevated 48 h before clinically evident AKI (rise in 
serum creatinine) (407). IL-18 does not appear to be affected by pre-renal uraemia, 
CKD or urinary tract infections and appears to offer prognostic information regarding 
severity and mortality at the time of AKI diagnosis. It has not been formally assessed as 
a marker of post contrast AKI (380). 
1.9.4 Other biomarkers of renal injury 
Other potential candidates as biomarkers of contrast induced AKI are discussed below. 
This list is not exhaustive but from review of the literature were the most promising 
markers for identifying renal injury early post procedure. 
1.9.4.1 Cystatin C 
Cystatin C is a cysteine protease inhibitor that is synthesised and released at a relatively 
constant rate by all nucleated cells. It is freely filtered by the glomerulus, completely 
reabsorbed by the proximal tubule and not secreted thereby providing a surrogate 
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marker of glomerular filtration. Plasma levels are elevated 8 hours post administration of 
contrast and urinary excretion has been shown to predict the requirement for renal 
replacement therapy in patients with established AKI approximately 1 day earlier than 
creatinine (408). It is primarily a sensitive marker of reduction in glomerular filtration and 
not a marker of kidney injury per se (380). From reviewing the literature plasma levels of 
cystatin C out-perform creatinine as a marker of kidney function. A 50% rise in cystatin 
C 2 days prior to clinical AKI has a 55% sensitivity and a 95% specificity for predicting 
AKI (409). However levels may be affected by HIV and glucocorticoid use and the 
variability and bias in using cystatin C to predict GFR were no better than equations 
using serum creatinine. It has been widely reviewed as a promising GFR marker in both 
AKI (as outlined above) and CKD but further studies are necessary to determine 
whether it is truly a better biomarker than serum creatinine and to define the populations 
in which its use is appropriate (380). 
1.9.4.2 N-acetyl-β-D-glucosaminidase  
N-acetyl-β-D-glucosaminidase (NAG) is a lysosomal enzyme and a sensitive urine 
marker of proximal tubule injury with a role in mortality risk prediction following AKI 
(410). This study also showed NAG has to be elevated in AKI following a number of 
disease states including cirrhosis and sepsis (410) In a study of 90 adult patients 
undergoing bypass surgery at Columbia University in New York, 36 patients developed 
AKI. The AUC for NAG on ROC analysis immediately and 3 hours post procedure was 
0.61 and 0.63. However when combined with NGAL and Kidney Injury Molecule-1 (KIM-
1) the AUC improved to 0.75 and 0.78 respectively (411). NAG has not been evaluated 
as a marker of contrast induced AKI. 
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1.9.4.3 Kidney Injury Molecule 1  
KIM-1 is a transmembrane protein which is not expressed in normal kidney tissue but is 
up-regulated in de-differentiated proximal tubule cells following ischaemic or nephrotoxic 
AKI and a proteolytic processed domain is easily detectable in urine (412). It readily 
distinguishes ischaemic AKI from pre-renal uraemia and chronic kidney disease (413). 
From the New York registry described in section 1.9.4.2, KIM-1 had an AUC on ROC 
analysis of 0.68 and 0.65 immediately and 3 hours post bypass surgery respectively 
(411). Elevated urine levels have been associated with adverse outcomes in 
hospitalised patients who develop AKI (410). In a small study of 70 diabetic patients with 
normal baseline renal function undergoing coronary angiography, no significant increase 
in KIM-1 was seen within the first 48 hours post procedure (414). There are some 
methodological questions that arise on reviewing this study. Data are also provided for a 
control cohort of non-diabetic patients and the rate of contrast induced AKI was higher in 
this group than in the patients with diabetes. This is surprising since as discussed in 
section 1.6.4.2 diabetes is an important risk factor for development of AKI. Furthermore 
no p values were provided to demonstrate how well matched the 2 cohorts were with 
regard to baseline characteristics, although the authors state that the groups were age 
matched. Finally for a diagnostic procedure the mean volume of contrast used was very 
high at a mean of 170.5 ml. To my knowledge there are no other studies assessing KIM-
1 as a marker of contrast induced AKI. 
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1.9.4.4 Liver Type Fatty Acid Binding Protein (L-FABP) 
This is a 14kDa protein expressed in the proximal tubule of normal kidney tissue. Its 
primary function is to facilitate intra-cellular long chain fatty acid transport. Both 
expression and urinary excretion are increased in the setting of non-diabetic CKD (415). 
Levels at 4h post bypass surgery in paediatric patients have been shown on logistic 
regression analysis to independently predict development of kidney injury with an AUC 
on ROC analysis of 0.81, sensitivity 0.714 and specificity 0.684 for a 24-fold increase in 
urinary L-FABP (416). However as the name may suggest expression is not specific to 
the kidney and this protein is expressed in a number of tissues with active fatty acid 
metabolism such as the heart and the liver (417;418). One small study (n=70) has 
evaluated L-FABP post coronary angiography in patients with normal baseline renal 
function. Urinary L-FABP levels were shown to be significantly raised at 24 hours post 
procedure (p<0.05) in patients who subsequently developed AKI (414). There are some 
methodological concerns that arise from this study as mentioned in section 1.9.4.3. To 
my knowledge there are no other studies assessing L-FABP as a marker of contrast 
induced AKI. 
1.9.4.5. Homocysteine 
Homocysteine is a known risk factor for cardiovascular disease as discussed previously 
in section 1.3.1. Recent data have shown that levels independently predict development 
of contrast induced AKI in patients undergoing PCI (419). Hyperhomocysteinemia 
induces oxidative stress and endothelial dysfunction, which are some of the proposed 
pathophysiologic mechanisms of contrast-induced AKI discussed in more detail in 
section 1.6.2. The incidence of contrast induced AKI was significantly greater in 
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patients in the third homocysteine tertile (from lowest to highest, 4.7%, 7.3%, and 
24.2%, p <0.001). Furthermore, the homocysteine levels were significantly greater in 
patients with contrast induced AKI than in those without (16.9 ± 4.9 vs. 13.5 ± 4.2 
µmol/L, p <0.001). In multiple logistic regression models, hyperhomocysteinemia was an 
independent risk factor for contrast induced AKI  
(per the SD change in the plasma homocysteine level [4.44 µmol/L], odds ratio 1.70, 
95% confidence interval 1.07 to 2.71, p = 0.025) after adjusting for major risk factors 
such as age, diabetes, and baseline cardiac and renal function. In subgroup analyses 
according to diabetes, acute coronary syndrome, or baseline estimated glomerular 
filtration rate, significant graded associations were found between the homocysteine 
level and the incidence of contrast induced AKI. This was an observational study and in 
order to identify if a true causal relationship is present, further trials with interventions to 
lower homocysteine levels will be necessary.  
 
1.10 Outline of thesis 
The aim of the work presented in this thesis was to identify early markers of kidney 
injury post i.v. contrast following coronary angiography or PCI in patients with diabetes 
and CKD. These were compared against the current ‘gold standard’ marker of renal 
injury, creatinine in order to attempt to establish a panel of ‘renal injury markers’ that 
could translate into clinical practice. Patients with diabetes and CKD are known to have 
worse cardiovascular outcomes and are at extremely high risk of developing AKI and yet 
have been excluded from many of the studies investigating biomarkers of renal injury. 
Our research group has had a longstanding interest in diabetic coronary disease and 
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this was an exciting opportunity for collaboration between the departments of cardiology 
and renal medicine at Barts and The London NHS Trust.  
This was a prospective observational study and the design is discussed in Chapter 2. All 
patients were recruited at a single site, The London Chest Hospital which is a tertiary 
centre for interventional cardiology procedures. Chapter 3 details the baseline 
characteristics and clinical procedural data collected. The influence of structural renal 
disease on the development of AKI is discussed in Chapter 4, along with assessment of 
a number of risk scores such as The Mehran Score and Syntax Score in a high risk 
cohort of patients. Chapter 5 describes the various assays and all laboratory techniques 
as well as the statistical methodology underlying Receiver Operating Characteristic 
(ROC) curve analysis, which is used to assess the predictive power of the biomarker 
panel. The results of a biomarker panel including NGAL and IL-18 are discussed in 
Chapter 6, with an exploratory analysis including the various risk scores as predictive 
markers. In each chapter a brief discussion is included at the end, with a comprehensive 
final discussion in Chapter 7. 
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Chapter 2: Study Design 
This was a single-centre prospective study of patients with diabetes with a baseline 
eGFR < 60 ml/min undergoing coronary angiography and / or PCI at The London Chest 
Hospital. AKI was defined as an increase in creatinine ≥ 44.5 µmol/l or a rise of > 25% 
from baseline. Both elective and unstable patients were included but due to other co-
existent studies in the department patients with ST elevation myocardial infarction 
(STEMI) were excluded. In a subset of patients renal angiography was performed to 
assess for structural renal disease. Informed consent was obtained in all cases. The 
study was approved by the East London and City NHS Research Ethics Committee 1 
(09/H0703/29) and registered on clinicaltrials.gov (NCT00948116). 
2.1 Study Objective 
The primary objective of this study was to identify in patients with diabetes techniques to 
predict who will develop AKI post coronary angiography PCI earlier than is currently 
possible. This is based on the hypothesis that a panel of biomarkers can predict 
development of contrast induced AKI earlier than a rise in serum creatinine. The study 
design is summarised in Figure 16 and was a single-centre observational study of 
biomarkers reflecting kidney injury in patients with diabetes mellitus undergoing 
coronary angiography and PCI. 
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Figure 16: Biomarkers Study Design 
 
Consort diagram summarising study pathway. Samples were immediately centrifuged and stored at -80°C prior to assay 
for NGAL and Interleukin-18. 
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2.2 Sample Size Calculation 
From a retrospective audit of the cardiac catheter laboratory database and a review of 
the literature we estimated that a sample size of approximately 250 patients with 
diabetes mellitus and CKD (eGFR < 60 ml/ml) would be needed. We envisaged that that 
we would encounter at least 50 cases of AKI from this cohort (based on an expected 
incidence of AKI between 15-30 % in this group). Looking for a study rate difference of 
at least 25%, for power of 95% and confidence intervals of 95% (with Fleiss correction) 
we would need at least 204 evaluable patients (to avoid Type 2 error). In view of a 
potential drop-out rate of 10-15% we therefore intended to recruit up to 250 patients 
(Power calculation performed using Arcus Medical Statistical Programme). The study 
was powered on the rate of anticipated AKI in the population rather than on the 
biomarkers diagnostic ability as the biomarkers had not been evaluated for this type of 
study population or following contrast administration at the time this study was 
conceived. 
 
2.3 Study Duration 
It was expected that the study would take between 12-18 months to recruit. 208 patients 
were recruited between 1st August 2009 and 21st July 2010. At this time recruitment 
stopped as we had reached a sufficient number of events for the study to be adequately 
powered. 
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2.4 Statistical Methods 
Baseline characteristics were assessed with paired student t tests (parametric) and 
Mann-Whitney U test (non-parametric) for continuous variables. Chi squared and where 
appropriate Fisher’s Exact test were used for categorical variables. Results are 
presented as mean (SD) for parametric variables and median (IQR) for non-parametric 
variables. Categorical variables are presented as n (%). Logistic regression analysis 
was used to establish the predictive relationship between biomarker elevation and 
development of contrast induced AKI. Where the biomarker was also a continuous 
variable linear regression analysis was used to assess the relationship between the 
biomarkers and other continuous measurements. Receiver Operating Characteristic 
(ROC) Curves were obtained by plotting sensitivity and specificity of individual markers 
at different cut-offs as has previously been described (407). All analyses were 
performed using Stata 10.1 (StataCorp, College Station, Texas). A p value <0.05 was 
considered to be statistically significant. 
 
2.5 The London Chest Hospital Heart Attack Centre Guidelines 
for the Prevention of Contrast Nephropathy 
The London Chest Hospital Heart Attack Centre Guidelines for the Prevention of 
Contrast Nephropathy are available on the Barts and The London NHS Trust Intranet 
(331). The eGFR for all patients undergoing coronary angiography or PCI must be 
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known (except in emergency cases such as primary PCI for acute STEMI) and is usually 
provided directly from the biochemistry laboratory. If it is not available then this can be 
easily calculated using the Cockcroft Gault Formula. An online calculator is available 
(http://nephron.org/cgi-bin/CGSI.cgi). Other formulas are available which do not include 
body weight (e.g. MDRD, Modification of Diet in Renal Disease, http://nephron.org/cgi-
bin/MDRD_GFR/cgi). These are described in more detail in the Appendix along with a 
copy of The London Chest Hospital Guidelines for Prevention of Contrast Nephropathy. 
2.5.1 The Cockcroft-Gault Formula 
This estimates creatinine clearance (eCCr) in ml/min as follows: 
 
Where Constant is 1.23 for men and 1.04 for women 
and was first reported in 1976 (220). This calculation is very dependent on age. For 
example a 20 year old person will have twice the creatinine clearance as an 80 year old 
for the same level of serum creatinine. It also shows that a woman will have a 15% 
lower creatinine clearance for the same level of creatinine than a man.  
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2.5.2 N-acetylcysteine 
It is currently established practice that all patients with an eGFR < 50ml/min undergoing 
coronary angiography or PCI at the London Chest Hospital receive treatment with N-
Acetylcysteine (NAC) 600 mg po bd prior to the procedure and continued for 24 hours 
following (total 4 doses). There is no evidence in the literature, nor from consensus 
expert opinion that there is any interaction between NAC and the biomarkers under 
investigation (420).  
2.5.3 Intravenous Fluids 
Patients with eGFR >50 ml/min do not require any special measures (e.g. NAC, 
hydration) and can take free fluids orally until the time of the procedure. For patients with 
eGFR ≤50 ml/min a litre of 0.9% sodium chloride should be commenced intravenously at 
least 2 h prior to the procedure and continued for a total of 8 hours. Free access to clear 
oral fluids should be available before and after the procedure. 
2.5.4 Contrast agent 
All coronary angiogram and PCI procedures were performed at The London Chest 
Hospital and used iodixanol (VISIPAQUE™, GE Healthcare, Norway) as the contrast 
agent. Iodixanol is a non-ionic, iso-osmolar agent (see section 1.6). 
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2.5.5 Medication discontinuation 
It is advised that all diabetic patients discontinue metformin for 24 hours prior to the 
procedure and for 48 h afterwards due to the risk of lactic acidosis. In patients with GFR 
<50 ml/min it is advised that consideration should be given to stopping nephrotoxic 
agents such as ACE inhibitors, diuretics or NSAIDs on an individual patient basis. 
2.6 Blood Sampling 
Blood (serum) samples were taken at the following time intervals:  
Baseline – FBC, U+E, CRP, Bone, LFT, Clotting, Glucose, HbA1c, lipids, CK, Troponin 
T (20 ml). 
Baseline, 2 hours, 4 hours and 12-24 hours post procedure biomarkers (4 x 20 ml – 
serum samples).  
Pre-discharge biomarkers CK, CK-MB, Troponin and U+E (2 x 20 ml). 
U+E 3 days post procedure (5 ml).  
Total Blood Volume:  145 ml. 
All samples except for the biomarkers were analysed as according to routine clinical 
practice in the haematology and chemical pathology departments at Barts and The 
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London NHS Trust. The process for biomarkers samples is described in section 2.8 and 
2.9. 
(FBC = Full Blood Count, U+E = Urea and Electrolytes, LFT = Liver Function Tests, CK = Creatinine Kinase, HbA1c = 
glycated haemoglobin). 
 
 
2.7 Urine Sampling 
Urine samples were taken at the following time intervals: 
Baseline – Urine albumin:creatinine ratio, biomarkers (100 ml) 
2 hours, 4 hours and 12-24 hours post procedure biomarkers (3 x 100 ml). 
Pre-discharge biomarkers (100 ml).  
Total Urine Volume: 500 ml. 
We selected these time points for blood and urine samples to assess our panel of 
markers on the day of the patient’s procedure. This is important as the majority of 
coronary angiography and an increasing number of PCI procedures are performed on a 
day case basis (22). The current ‘gold standard’ marker of AKI – serum creatinine does 
not rise until 48-72 h post procedure. We therefore wanted to ascertain whether any of 
our biomarkers rose in the period that all patients remain in hospital – i.e. up to 4 h 
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following procedure. In those patients who stay overnight for procedures it is routine for 
them to have blood tests the next day – at least to include an FBC and U + E and 
sometimes also a CK and Troponin. We therefore also took serum and urine samples 
for our biomarker panel at this time-point in order to assess if there was an additional 
value from this to our biomarker panel for predicting AKI. This was typically 12-24 h post 
procedure. An initial plan to also take a sample at 8-12 h had to be abandoned for 
logistical reasons. 
2.8 Sample Storage 
Biomarker samples were immediately centrifuged at 3000 rpm (1600 g) for 10 minutes 
and the supernatant fluid was aliquoted into 2 ml cryotubes. All samples were stored at -
80°C in allocated freezer space at the London Chest Hospital.  Batches were transferred 
on ice to Professor Yaqoob’s laboratory at The William Harvey Research Institute for 
analysis. 
2.9 Analytical Assay 
Blood (serum) samples were used for determination of biomarkers and comparison to 
serum creatinine and urine for biomarker presence and comparison to 
albumin:creatinine ratio. Commercially available ELISA (Enzyme Linked Immunosorbent 
Assay) kits (R and D Systems, Oxford, United Kingdom) were used to measure marker 
concentration. 
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ELISA, is a biochemical technique which is based on the ‘antibody sandwich principle’. 
A capture antibody, specific to the analyte of interest is bound to a microtitre plate to 
create the solid phase. Unbound antibody is removed by washing the plate and a 
blocking reagent is added. Following a wash, samples, standards and controls are then 
incubated with the solid phase antibody which captures the analyte. After washing away 
unbound analyte, a conjugated detection antibody (e.g. biotin conjugated) is added. This 
detection antibody binds to a different epitope of the molecule being measured, 
completing the sandwich. A further wash removes unbound detection antibody and a 
detection reagent e.g. streptavidin-HRP (horse-radish peroxidase) is added. The plate is 
washed and a substrate solution e.g. tetramethylbenzidine (TMB)/hydrogen peroxide is 
added; colour develops in proportion to the quantity of bound analyte (TMB/peroxide 
turns blue when modified by HRP). Colour development is stopped with the addition of 
an acidic ‘stop solution’ which turns the solution yellow. The optical density of the yellow 
colour is read on a microtitre plate reader.  
The values of the unknown samples are assigned in relation to a standard curve. 
Software allows various methods of ‘curve fitting’ to be tried e.g. linear, log-log to 
determine which curve best fits the data. Once an acceptable standard curve is obtained 
the assay is optimised to meet performance requirements. Further details of this process 
for the individual assays are given in Chapter 5. 
2.10 Inclusion Criteria 
In order to be eligible to enter the study, the patients had to meet the following criteria: 
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1. Age > 18 years, known diagnosis of diabetes mellitus or BM on arrival consistent 
with probable diagnosis of diabetes, eGFR <60 ml/min 
2. Undergoing a coronary angiography or PCI procedure 
3. Agreed to the additional collection of blood and urine samples as outlined above  
4. Agreed to access of their clinical records for the collection of relevant medical 
data 
5. No history or signs of drug abuse 
6. Able to understand and sign the written Informed Consent Form 
7. Able and willing to follow the Protocol requirements. 
2.11 Exclusion Criteria 
Patients were not admitted to the study if they met any of the following exclusion criteria: 
1. Cardiogenic shock 
2. Pregnancy 
3. Patient on renal replacement therapy (haemodialysis/CAPD/renal transplant) 
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4. Known clinically significant infection such as HIV, Hepatitis or TB. 
5. Any patient determined not able to make a reasoned, informed consent prior to 
the planned interventional procedure. 
 
2.12 SYNTAX Score 
The SYNTAX score allows quantification of the complexity of coronary artery disease by 
taking into consideration not only the number of significant lesions but also the 
complexity of each lesion independently. Higher SYNTAX scores, indicative of more 
complex disease are hypothesised to represent a bigger therapeutic challenge and 
potentially to have a poorer prognosis (421). It is important for the non-clinician and 
indeed the non-cardiologist to understand this complex scoring system and how this 
translates into interpreting the severity of CAD. Whilst on first inspection, this may 
appear to have little relevance to the main subject matter discussed in this thesis, that is 
the development of AKI post contrast, understanding is essential in order to interpret the 
data presented in Chapter 4. 
The definition of the coronary tree segments (Figure 17) is based on the classification 
proposed by the AHA (422) and modified for the ARTS I and II Trials (423).  
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Figure 17: Definition of the coronary tree segments 
 
 
(Adapted from Sianos et al EuroIntervention 2005 (421)). Abbreviations: RCA: right coronary artery, LAD: left anterior 
descending.  
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A lesion is defined as significant when it causes a ≥ 50% reduction in luminal diameter 
on visual assessment in vessels > 1.5 mm diameter. The algorithm includes occlusive 
(100% stenosis) and non-occlusive (50-99% stenosis) but does not further stratify 
percent diameter of stenoses. Various weighting factors are given to account for the 
difficulty in percutaneous treatment (summarised in Table 12). 
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Table 12: Coronary artery segment weighting factors 
Segment Number Segment Name Right dominance Left dominance 
1 RCA proximal 1 0 
2 RCA mid 1 0 
3 RCA distal 1 
0 
4 Posterior descending artery 1 n.a. 
16 Posterolateral branch from RCA 0.5 n.a. 
16a Posterolateral branch from RCA 0.5 n.a. 
16b Posterolateral branch from RCA 0.5 n.a. 
16c Posterolateral branch from RCA 0.5 n.a. 
5 Left main 5 6 
6 LAD proximal 3.5 3.5 
7 LAD mid 2.5 2.5 
8 LAD apical 1 1 
9 First diagonal 1 1 
9a First diagonal a 1 1 
10 Second diagonal 0.5 0.5 
10a Second diagonal a 0.5 0.5 
11 Proximal circumflex artery 1.5 2.5 
12 Intermediate/anterolateral 
artery 
1 1 
12a Obtuse marginal a 1 1 
12b Obtuse marginal b 1 1 
13 Distal circumflex artery 0.5 1.5 
14 Left posterolateral 0.5 1 
14a Left posterolateral a 0.5 1 
14b Left posterolateral b 0.5 1 
15 Posterior descending n.a. 1 
(Adapted from Sianos et al EuroIntervention 2005 (421)). Abbreviations: RCA: right coronary artery, LAD: left anterior 
descending. 
All other adverse lesions characteristics assessed using the SYNTAX score have an 
additive value (Table 13). 
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Table 13: Adverse characteristic lesion scoring 
Lesion Type Lesion Score 
 
Diameter reduction*  
- Total occlusion X 5 
- Significant lesion (50-99%) X 2 
 
Total Occlusion (TO)  
- Age >3 months or unknown +1 
- Blunt stump +1 
- Bridging +1 
- First segment visible beyond TO +1/ non-visible segment 
- Side branch (SB) 
-  – Yes SB < 1.5 mm** 
- Yes both SB < & ≥ 1.5 mm 
                                                                               
+1 
+1 
 
Trifurcations  
- 1 diseased segment +3 
- 2 diseased segments +4 
- 3 diseased segments +5 
- 4 diseased segments +6 
 
Bifurcations  
- Type A, B, C +1 
- Type D, E, F, G +2 
- Angulation <70° +1 
 
Aorto-ostial stenosis +1 
Severe tortuosity +2 
Length > 20 mm +1 
Heavy calcification +2 
Thrombus +1 
Diffuse disease/small vessels +1/per segment number 
(Adapted from Sianos et al EuroIntervention 2005 (421)). Key: x: multiplication, +: addition. * In the SYNTAX algorithm 
there is no question for % luminal diameter reduction. The lesions are considered as significant (50-99% luminal diameter 
reduction) or occlusive. **If all the side-branches are 1.5 mm diameter, no points are added since the lesion is considered 
as a bifurcation and it will be scored accordingly. 
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2.12.1 The SYNTAX Score Algorithm 
The Syntax Score is calculated by a computer program (available as an online 
download: http://www.syntaxscore.com/) made up of sequential and interactive self-
guided questions. These are summarised in Table 14. All patients in this study were 
scored by myself and Dr Akhil Kapur, Consultant Interventional Cardiologist. On 
completion of the algorithm a detailed report is automatically generated summarising all 
the adverse characteristics, the individual score for each lesion and the total SYNTAX 
score. For the purposes of this study we used Version 2.02 of the online calculator. The 
score can help to guide revascularisation strategy. For patients with a low SYNTAX 
score (0-22) the risk-benefit ratio favours PCI, for patients with an intermediate score 
(23-32) either PCI or CABG may be appropriate and for a high score (≥33) CABG is the 
preferred option (26).  
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Table 14: The SYNTAX Score Algorithm 
 
 
(Adapted from Sianos et al EuroIntervention 2005 (421)). Algorithm definitions are given in the Appendix. 
Patients with previous CABG cannot receive a SYNTAX score as such patients were 
excluded from the trials from which the score was developed. Our study included 41 
such patients. 
2.12.2 The Clinical SYNTAX Score 
One of the main limitations of the SYNTAX score is that anatomical (lesion based) 
scoring systems have been shown to have a lower accuracy in predicting mortality than 
systems which include clinical characteristics (424). Whilst clinical risk scores such as 
EuroSCORE have been well-validated in cardiac surgery populations (425;426), there 
are currently only very limited data of such systems for patients undergoing PCI 
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(427) (428). A simple ACEF (Age, serum Creatinine and Ejection Fraction) score has 
recently been described and validated (429) in patients undergoing elective CABG. It is 
thought that more complex scores which use multiple individual variables may reduce 
the overall accuracy of the model (430). 
In order to attempt to overcome the perceived limitations of the SYNTAX score, the 
authors of the SYNTAX trial (26), combined the SYNTAX score with a modified ACEF 
score (incorporating creatinine clearance rather than serum creatinine) creating a clinical 
SYNTAX score (CSS) (431). This was then assessed on the  Arterial Revascularisation 
Therapies Study (ARTS) II dataset (n=512) (25) for improvement in ability to predict 
mortality and MACCE (Major Adverse Cardiovascular and Cerebrovascular Events) 
(431). Clinical outcomes were assessed for MACCE and mortality at 1 and 5 years 
follow up and further stratified by CSS tertiles: CSSlow ≤ 15.6 (n=170), 15.6 < CSSmed ≤ 
27.5 (n=171) and CSShigh > 27.5 (n=171). At 1 year follow-up rates of repeat 
revascularisation and MACCE were significantly higher in the highest tertile group 
(Table 15). At 5 year follow-up, CSShigh had a similar rate of myocardial infarction, 
demonstrated a trend towards a significantly higher rate of death, and significantly 
higher rates of repeat revascularisation and overall MACCE as compared to patients in 
the lower 2 tertiles. Univariate and multivariate predictors of MACCE are summarised in 
Table 16. The C statistics for the CSS, SYNTAX Score and ACEF score were 
respectively for 5 year mortality were 0.69, 0.62 and 0.65 and for 5 year MACCE were 
0.62, 0.59 and 0.57 (p<0.05 for all). 
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Table 15: Clinical Outcomes at 1-Year Follow-Up stratified by CSS Tertile 
Variable, n (%) unless 
stated 
CSS ≤15.6 
(n=170) 
15.6 <CSS≤27.5 
(n=171) 
CSS >27.5 
(n=171) 
p value 
Hierarchical 
Death 1 (0.6) 0 (0.0) 4 (2.3)  
 
 
0.09 
Cerebrovascular 
Accident 
0 (0.0) 1 (0.6) 3 (1.8) 
MI 
          Q wave 
                  Non-Q wave 
2 (1.2) 
1 (0.6) 
1 (0.6) 
1 (0.6) 
1 (0.6) 
1 (0.60 
4 (2.3) 
2 (1.2) 
2 (1.2) 
Repeat revascularisation 
             CABG 
         PCI 
8 (4.7) 
2 (1.2) 
6 (3.5) 
0 (0.0) 
11 (6.4) 
2 (1.2) 
21 (12.3) 
5 (2.9) 
16 (9.4) 
MACCE 11 (6.5) 13 (7.6) 32 (18.7) 0.001 
Non- Hierarchical 
Cerebrovascular 
Accident 
0 (0.0) 1 (0.6) 3 (1.8) 0.33 
MI 
           Q wave 
                  Non-Q wave 
2 (1.2) 
1 (0.6) 
1 (0.6) 
1 (0.6) 
1 (0.6) 
0 (0.0 
6 (3.5) 
3 (1.8) 
3 (1.8) 
0.14 
0.63 
0.23 
Repeat revascularisation 
             CABG 
         PCI 
9 (5.3) 
7 (4.1) 
2 (1.2) 
11 (6.4) 
9 (5.3) 
3 (1.8) 
27 (15.8) 
21 (12.3) 
6 (3.5) 
0.002 
0.009 
0.41 
(Adapted from Garg et al Circ Cardiovasc Interv (431)). Abbreviations: CSS: Clinical Syntax Score, MACCE: Major 
Adverse Cardiac and Cerebrovascular Event, MI: Myocardial Infarction, CABG: Coronary Artery Bypass Grafts, PCI: 
Percutaneous Coronary Intervention. 
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Table 16: Univariate and Multivariable Predictors of MACCE at 5-Year Follow-up 
 Univariate Predictors of MACCE at 5 
years 
Multivariable Predictors of MACCE 
at 5 years 
Variable [95% CI] p value [95% CI] p value 
Age 1.02 [1.00-1.04] 0.03   
Diabetes 1.80 [1.28-2.54] 0.001 1.55 [1.09-2.19] 0.01 
Peripheral vascular 
disease 
2.01 [1.18-3.44] 0.01 1.97 [1.14-3.41] 0.02 
Log SYNTAX Score 5.62 [2.32-13.62] <0.0001   
Log ACEF 7.11 [1.56-32.45] 0.01   
Log Clinical SYNTAX 
score 
1.81 [1.42-2.29] <0.0001 1.77 [1.02-3.07] 0.04 
No. of diseased lesions 1.43 [1.17-1.73] <0.0001   
Incomplete 
revascularisation 
1.56 [1.12-2.17] 0.009 1.43 [1.01-2.02] 0.045 
(Adapted from Garg et al Circ Cardiovasc Interv (431)). Abbreviations: MACCE: Major Adverse Cardiac and 
Cerebrovascular Event, CI: Confidence Interval). 
The British Society of Echocardiography Guidelines were followed when assessing left 
ventricular (LV) function: normal ≥ 55%, mild impairment 45 – 54%, moderate 
impairment 36 – 44% and severe impairment ≤ 35% (432). Where echocardiogram data 
was not available, LV gram data (from time of angiography, if available) was used as 
follows: a score of 60% for normal/good, 50% for mild impairment, 40% for moderate 
impairment and 30% for severe impairment.  
2.13 Ethics and Clinical Trial Registration 
Following formal peer review at both The London Chest Hospital and The William 
Harvey Research Institute, the study received approval from Barts and The London NHS 
Trust Research and Development (R and D) Department (R and D 006580). 
Subsequently the study was assessed by The East London and City Research 
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Ethics Committee 1 and received formal ethical approval (NRES: 09/H0703/29). The 
study was then registered at clinicaltrials.gov (NCT 00948116). 
 
2.14 Study Organisation 
The study was sponsored by Barts and The London NHS Trust. Patients were recruited 
from The London Chest Hospital. The weekly cardiac catheter laboratory ‘admissions 
list’ was screened to identify suitable patients, in addition to a daily review of all transfers 
and admissions to the Coronary Care Unit (CCU) and cardiology wards at The London 
Chest Hospital. All baseline demographic and clinical data were recorded onto a 
specially designed paper Case Report Form (CRF). This allowed anonymised retrieval 
of data and these were then entered into a specifically designed electronic database. A 
copy of the CRF is included in the Appendix. The paper CRFs were stored in files in a 
locked office at The London Chest Hospital in accordance with good clinical practice. 
Funding for the study was from an unrestricted research grant from Boston Scientific. 
Since this was an investigator initiated study the study design data management, 
coordination and data analysis were all undertaken independently from the source of 
funding. The study commenced on 14th August 2009 and the last patient was recruited 
on 26th July 2010. The design of the study is summarised in Figure 16. 
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2.15 Limitations of Study Design 
The study described in this thesis was designed as a single centre observational study 
of biomarkers in a population with CKD and diabetes mellitus. This was part of a 
planned programme of work including 2 further studies for which I wrote 2 further 
complete protocols and successfully completed the ethics application. These further 
studies included possible therapeutic interventions to prevent / diminish AKI.  
One of the main limitations of the design was that there was no control group for this 
study. The most logical control group would have been a non-diabetic population with 
CKD but in order to have adequate power the number of patients needed would have 
been outside the scope of a single recruiter and the limited time period available, due to 
the lower incidence of AKI in this population. Other populations that could have been 
considered include those with CKD undergoing CT procedures although this would have 
reflected i.v. rather than intra-arterial contrast administration and furthermore for CT 
scanning the contrast is given in a single bolus (rather than repeated small 5 – 10 ml 
injections as is the case in the cardiac catheter lab). Finally at the time of the study 
recruiting, the CT scanner at The London Chest was being refurbished and this meant 
that all CT scans were being done at other sites several miles away. Since sample 
processing and storage were on the London Chest site this was not felt to be a feasible 
control group to be studied. It was therefore planned that on completion of the study 
outlined in this thesis, having identified the most promising 2 – 3 biomarkers from the 
candidates discussed in section 1.9 that a larger scale study would be conducted by 
myself as part of a planned post – doctoral programme of research. 
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Chapter 3: Baseline Characteristics of the Study 
Population and Clinical Procedural Data 
3.1 Study Population 
Our aim was to identify patients with diabetes mellitus and CKD (as described in 
Chapter 2) undergoing coronary angiography or PCI. Recruitment is summarised in 
Figure 18. Patients were recruited at The London Chest Hospital between 14th August 
2009 and 26th July 2010. 234 patients were screened for the study, recorded in the 
Screening Log (as described in section 2.14) and of these 208 gave written consent and 
participated. Prior to consent patients were given a study Patient Information Sheet (see 
Appendix) and details of the study, the procedures and the risks were fully explained. 
Consent was indicated in the Research Section of the routine Patient Agreement to 
Investigation or Treatment Form (Barts and The London NHS Trust Consent Form 3). 
This was then signed and dated by the patient. Completed consent forms were filed in 
the patient’s notes with a copy given to the patient. 
All data were originally entered onto a paper Case Report Form (CRF) which was 
designed to allow anonymised retrieval of data (see Appendix). The first page of the 
CRF contained the patients contact details and allowed the assignation of a study ID 
number. This first page was then kept in a separate file ensuring that all data retrieval 
was anonymised to the study ID number. The relevant sections of the form were 
completed on the day of procedure and at follow-up. Subsequently all the data were 
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entered into a specifically designed database which coded from the CRF and again 
ensured anonymisation of data. From this database all analysis was performed. 
116 patients had a coronary angiogram, 55 patients underwent PCI alone and 36 had a 
coronary angiogram with subsequent PCI on the same day. Following the study 
procedure 35 patients were referred for a PCI procedure and 27 were referred for 
CABG. 207 patients attended for Day 3 blood tests and of these 39 (18.8%) patients 
developed the main clinical end-point of contrast induced AKI.  
 
3.2 Baseline Characteristics of the Study Population 
Baseline characteristics of the study population are summarised in Table 17. The results 
are tabulated to compare those who did not develop contrast induced AKI versus those 
who did develop this event.  
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Figure 18: Consort diagram of Study Population 
 
 
Abbreviations: Angio: Coronary angiogram, PCI: Percutaneous coronary intervention, DNA: did not attend, AKI: Acute 
Kidney Injury. 
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Table 17: Baseline characteristics of study population 
 No AKI Outcome 
n = 168 
AKI Outcome 
n = 39 
p value 
Age, mean (SD) 70.8 (8.5) 71.9 (9.4) 0.500 
Male (%) 109 (64.9) 27 (69.2) 0.606 
Ethnicity (%) 
Caucasian 66 (39.3) 14 (35.9)  
 
0.838 
South Asian 81 (48.2) 18 (46.2) 
East Asian 2 (1.2) 1 (2.6) 
Afro-Caribbean 8 (4.8) 3 (7.7) 
African 7 (4.2) 1 (2.6) 
Other 4 (2.4) 2 (5.1) 
BMI, mean, SD 28.6 (5.4) 29.1 (6.1) 0.651 
Diabetes type (%) 
Type 1 3 (1.8) 0 (0) 0.401 
Type 2 165 (98.2) 39 (100) 
Years with diabetes, 
mean (SD) 
 
14.3 (10.0) 
 
14.6 (10.4) 
 
0.846 
Diabetes Treatment (%) 
Diet 16 (11.8) 6 (17.1)  
0.405 Oral 71 (52.2) 14 (40.0) 
Insulin 49 (36.0) 15 (42.9) 
Smoking Status (%) 
Current 10 (6.0) 2 (5.1)  
0.634 Ex 86 (51.2) 17 (43.6) 
Never 72 (42.9) 20 (51.3) 
Family history of CHD 
(%) 
84 (50.0) 20 (51.3) 0.885 
Hypertension (%) 154 (91.7) 34 (87.2) 0.382 
SBP, mean (SD) 134.4 (20.8) 134.4 (23.2) 0.988 
DBP, mean (SD) 70.9 (12.1) 68.4 (13.6) 0.254 
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(Table 17 continued) 
Hyperlipidaemia (%) 164 (97.6) 38 (97.4) 0.946 
Previous CVA (%) 20 (12.0) 8 (20.5) 0.161 
PVD (%) 16 (9.5) 4 (10.3) 0.889 
Lung Disease (%) 14 (8.4) 7 (18.0) 0.075 
Previous MI (%) 66 (39.3) 15 (38.5) 0.924 
Known Valvular Heart 
Disease (%) 
28 (16.7) 7 (18.0) 0.847 
Previous PCI (%) 54 (32.1) 13 (33.3) 0.886 
Previous CABG (%) 32 (19.1) 9 (23.1) 0.569 
Heart Failure (%) 32 (19.2) 7 (18.0) 0.862 
Angina (%) 143 (85.1) 35 (89.7) 0.453 
Silent ischaemia (%) 7 (4.2) 3 (7.7) 0.355 
CCS Class (%) 
0 7 (4.2) 0 (0)  
 
0.136 
I 14 (8.3) 4 (10.3) 
II 112 (66.7) 22 (56.4) 
III 34 (20.2) 12 (30.8) 
IV 1 (0.6) 0 (0) 
IVb 0 (0) 1 (2.6) 
NYHA (%) 
I 12 (7.1) 0 (0)  
 
0.048 
II 119 (70.8) 23 (59.0) 
III 35 (20.8) 15 (38.5) 
IV 2 (1.2) 1 (2.6) 
 
(Abbreviations used: NYHA: New York Heart Association classification of heart failure, CCS: Canadian Cardiovascular 
Society functional classification of angina – see Appendix) 
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Overall there were no significant differences between the 2 groups in terms of 
demographics, cardiac risk factors and co-morbidities. 204 patients had Type 2 diabetes 
with only 3 patients with Type 1 diabetes included in the study. The number of years 
patients had been diagnosed with diabetes was similar between the 2 groups at 
approximately 14.5 years. Furthermore diabetes treatment with respect to diet, oral 
medication and insulin therapy did not significantly differ between the 2 groups. It will be 
noted that the study included a high proportion of patients of South Asian origin. This 
reflects the demographics of the local population and the population of East London 
from which The London Chest Hospital receives referrals. Moreover patients of South 
Asian origin are known to be high risk for developing both diabetes and coronary artery 
disease (CHD) and this has been reported in a number of other studies (433-436).  
There was a significant trend towards patients in the AKI group having a higher NYHA 
Class (p = 0.048). This is based on patient reported symptoms and is therefore 
subjective but this was further supported by objective data from the echo reports (104 
patients) and LV gram performed at the time of procedure in 174 patients (Table 22).  
 
3.3 Medication Use 
Diabetes medication use at baseline is shown in Table 18 and other medication use in 
Table 19. 
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Table 18: Diabetes medication use at baseline 
Medication No AKI Outcome 
n = 152 (%) 
AKI Outcome 
n = 33 (%) 
p value 
Metformin 70 (41.7) 10 (25.6) 0.640 
Sulphonylureas 56 (33.3) 11 (28.2) 0.537 
Thiazolinediones 9 (5.4) 2 (5.1) 0.954 
Insulin 81 (48.2) 20 (52.3) 0.730 
There were no significant differences in prescribing of diabetes medication between the 
2 groups. Metformin was discontinued for 24 h pre-procedure and 48 h afterwards. 
Table 19: Medication use at baseline 
Medication  No AKI Outcome 
n = 168 (%) 
AKI Outcome 
n = 39 (%) 
p value 
Aspirin  162 (96.4) 37 (94.9) 0.650 
Clopidogrel 111 (66.1) 26 (66.7) 0.944 
Warfarin 10 (6.0) 1 (2.6) 0.395 
Heparin 
Low molecular weight 19 (11.3) 5 (12.8) 0.862 
Unfractionated 1 (0.6) 0 (0) 
Other anticoagulant 6 (3.6) 3 (7.7) 0.259 
Beta-blockers 117 (69.6) 24 (61.5) 0.328 
Calcium channel antagonists 
Dihydropyridine 47 (28.0) 13 (33.3) 0.506 
Non-dihydropyridine 19 (11.3) 6 (15.4) 0.482 
Nitrates 92 (54.8) 25 (64.1) 0.289 
Lipid lowering agents (LLA) 
Statin 151 (89.9) 36 (92.3)  
0.792 Statin and other LLA 6 (3.6) 1 (2.6) 
Other LLA 2 (1.2) 1 (2.6) 
ACE - Inhibitors 105 (62.5) 22 (56.4) 0.482 
Angiotensin II Receptor 
Blockers 
42 (25.0) 8 (20.5) 0.555 
Loop diuretic 62 (26.9) 23 (59.0) 0.012 
Thiazide diuretic 37 (22.0) 4 (10.3) 0.097 
Digoxin 10 (6.0) 0 (0) 0.118 
Amiodarone 2 (1.2) 0 (0) 0.494 
Thyroxine 14 (8.3) 2 (5.1) 0.500 
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There was a significantly higher rate of loop diuretic prescription in the group that 
developed AKI (59.0% vs. 26.9%, p = 0.012). This reflects the difference in NYHA 
Classification already reported (Table 17) and the more severe LV function from echo 
and LV gram data (Table 22). High numbers of patients were prescribed statin therapy 
or ACE inhibitors/Angiotensin II Receptor Blockers (AIIRBs) as is recommended in 
guidelines for this population (section 1.3). No patients in this study discontinued ACE 
inhibitors or AIIRBs prior to undergoing coronary angiography or PCI. 
 
3.4 Baseline Blood and Urine Results 
Patients were assessed for eligibility for the study based on ‘screening’ blood results 
(creatinine and eGFR) taken at the time of pre-admission appointment or from referral 
paperwork from referring centres. These results along with baseline results from the 
time of the procedure are summarised in Table 20. 
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Table 20: Screening and Baseline Blood Results 
Blood result, Median (IQR) 
No AKI outcome 
n = 168 
AKI outcome 
n = 39 p value 
Baseline results 
Glucose (mmol/l) 7.0 (5.7, 9.1) 7.5 (6.4, 10.9) 0.106 
HbA1c (%) 7.4 (6.9, 8.5) 7.6 (6.7, 8.7) 0.785 
HbA1c (mmol/mol) 57 (52, 69) 60 (50, 72) 0.794 
Hb (g/dl) 11.4 (10.3, 12.7) 11.0 (9.8, 12.4) 0.125 
HCt (units) 0.35 (0.32, 0.38) 0.33 (0.29, 0.38) 0.055 
WCC ( x 10
9
/l) 7.4 (6.5, 8.8) 7.4 (6.2, 8.5) 0.722 
Platelets ( x 10
9
/l) 212 (172, 262) 208 (166, 250) 0.423 
INR 1 (1, 1.1) 1 (1, 1.1) 0.532 
CRP (mg/l) 5 (5, 8) 6 (5, 10) 0.114 
Sodium (mmol/l) 140 (139, 142) 140 (138, 142) 0.465 
Potassium (mmol/l) 4.4 (4.1, 4.7) 4.5 (4.1, 5.1) 0.244 
Urea (mmol/l) 9.2 (7.1, 11.5) 11.4 (8.3, 16.3) 0.004 
Baseline Creatinine 
(µmol/l) 113 (94, 138) 143 (109, 156) 0.002 
Baseline GFR (ml/min) 54 (40, 63) 42 (36, 54) 0.002 
Corrected Calcium* 
(mmol/l) 2.2 (2.1, 2.3) 2.2 (2.2, 2.3) 0.297 
Phosphate (mmol/l) 1.24 (1.09, 1.41) 1.25 (1.11, 1.36) 0.886 
Albumin (g/l) 42 (39, 44) 40 (39, 44) 0.534 
ALP (units) 69 (59, 89) 74 (65, 96) 0.127 
ALT (units) 19 (15, 26) 19 (15, 27) 0.804 
Creatinine kinase (IU/l) 105 (68, 149) 90 (58, 194) 0.597 
Troponin T (µg/l) 0.01 (0.01, 0.03) 0.01 (0.01, 0.06) 0.067 
Cholesterol (mmol/l) 3.4 (3.0, 4.1) 3.5 (3.0, 4.4) 0.708 
LDL (mmol/l) 1.6 (1.3, 2.2) 1.8 (1.4, 2.3) 0.746 
HDL mmol/l) 1.09 (0.88, 1.36) 1.06 (0.81, 1.55) 0.984 
Triglyceride (mmol/l) 1.36 (1.03, 1.92) 1.44 (1.19, 1.76) 0.341 
Screening results 
Screening Creatinine 
(µmol/l) 130 (110, 155) 155 (123, 176) 0.005 
Screening GFR (ml/min) 46 (36, 54) 39 (34, 46) 0.011 
*Calcium is reported as a corrected value for serum albumin levels – see Appendix. (Abbreviations: HbA1c: glycated 
haemoglobin; Hb: haemoglobin; HCt: Haematocrit; WCC: White Cell Count; INR: International Normalised Ratio; CRP: C-
Reactive Protein; GFR: Glomerular Filtration Rate; ALP: Alkaline phosphatase; ALT: Alanine transaminase; LDL: Low 
Density Lipoprotein; HDL: High Density Lipoprotein). 
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The screening creatinine in both groups is higher than the baseline creatinine. This is to 
be expected as baseline results were taken at time of procedure and therefore would 
reflect the hydration that the majority of these patients would have received (Table 22). 
Renal function is significantly worse in the patients in the group who developed AKI 
versus the group who did not (reflected by elevation in both baseline and screening 
creatinine, elevated serum urea and decreased baseline and screening GFR). Again this 
is to be expected as pre-existing renal disease is one of the most important risk factors 
for the development of AKI (Section 1.6, Table 7 and 8).  
HbA1c does not vary significantly between the 2 groups and a reasonable level of 
glycaemic control is achieved at 7.4 – 7.6%. We reported HbA1c using both the well-
known DCCT (Diabetes Control and Complications Trial) % (437) and the new IFCC 
(International Federation of Clinical Chemistry) units of mmol/mol (438) since it has been 
recommended by the American Diabetes Association (ADA), the European Association 
for the Study of Diabetes (EASD) and the International Diabetes Federation that these 
are adopted (439). For ease of reference we have given the conversion in the Appendix.  
There is a trend towards a lower haematocrit in the patients who developed AKI (p = 
0.055). As has already been discussed (section 1.6), anaemia is a significant risk factor 
for the development of contrast induced AKI, probably due to low effective intravascular 
volume. The study also included a high proportion of patients of South Asian origin and 
due to dietary and cultural reasons in addition to CKD these patients may be particularly 
prone to anaemia (435). 
Prior to procedure patients were requested to provide a urine sample (section 2.5). An 
aliquot was centrifuged (3000 rpm, 1600 g) and frozen at -80°C with the remainder 
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sent to the clinical chemistry laboratory for assessment of urine albumin and protein 
levels. These are reported in Table 21. 
Table 21: Urine results at baseline 
Urine results, median (IQR) 
No AKI 
outcome 
n = 168 
AKI outcome 
n = 39 p value 
    
Albumin : Creatinine ratio (mmol/l) 
2.6 (1.6, 
10.2) 4 (2.6, 19.2) 0.087 
Protein : Creatinine ratio (mg/mmol) 
45 (24, 
100) 45 (22, 93) 0.521 
 
Although there was no significant difference in urine protein levels as assessed by the 
protein : creatinine ratio, a trend was observed towards a higher level of urine albumin 
measured by the albumin : creatinine ratio in the patients who developed AKI. 
 
3.5 Procedural Data 
Key data from the patients’ procedures are summarised in Table 22. The majority of the 
procedures included were elective. Due to other studies taking place in the department 
we were not able to include ACS patients with ST elevation myocardial infarction 
(STEMI) in this study which contributes to the vast majority of the emergency workload. 
We did however include both non-ST elevation myocardial infarction (NSTEMI) and 
unstable angina patients. The case mix with regard to stable and unstable cases was 
similar between the 2 groups and just over 25% of patients included had suffered a 
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recent infarct. Similar proportions of patients underwent angiography and PCI in the 2 
groups.  
A minority of patients (30 in total), underwent the study procedure as part of a planned 
staged revascularisation. There may be a number of reasons for a staged strategy 
including the presence of multi-vessel disease, complex lesion anatomy where contrast 
dose may be high or determining the culprit lesion for the patient’s ischaemic symptoms.  
Approximately 50% of procedures were performed by the radial route in both groups. 
Radial angiography as a technique was introduced to the London Chest Hospital in 2004 
and this reflects the overall proportion of cases which are done radially at our centre 
(22). Radial access is increasingly popular as it allows the patient greater movement 
after the case and facilitates procedures being done on a day case basis. Furthermore 
complications such as bleeding from the access site are much more immediately 
apparent. There was no significant difference between radial and femoral access and 
incidence of AKI (p = 0.332). 
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Table 22: Procedural Details 
 No AKI Outcome 
n = 168 
AKI Outcome 
n = 39 
p value 
Type of procedure (%) 
Elective 118 (70.2) 25 (64.1)  
0.444 Urgent 49 (29.2) 13 (33.3) 
Emergency 1 (0.6) 1 (2.6) 
Recent MI (%) 47 (28.0) 10 (25.6) 0.769 
Point of Access (%) 
Radial 92 (54.8) 18 (46.2)  
0.332 Femoral 76 (45.2) 21 (53.9) 
Type of procedure (%) 
Angio 98 (58.3) 18 (46.2)  
0.298 PCI 41 (24.4) 14 (35.9) 
Both 29 (17.3) 7 (18.0) 
Staged procedure 25 (14.9) 5 (12.8) 0.742 
Ejection Fraction, mean (SD) 48.9 (14.5) 44.4 (15.9) 0.181 
LV function* 
Normal 79 (55.6) 15 (46.9)  
 
0.027 
Mild impairment 26 (18.3) 1 (3.1) 
Moderate impairment 19 (13.4) 8 (25.0) 
Severe impairment 18 (12.7) 8 (25.0) 
LV gram 67 (39.9) 8 (20.5) 0.023 
Echo 83 (49.4) 21 (55.3) 0.514 
IV fluids (%) 119 (70.8) 34 (87.2) 0.036 
NAC (%) 122 (72.19) 34 (87.18) 0.051 
Contrast dose, median (IQR) 140 (100,210) 180 (100, 240) 0.398 
Procedure time, median 
(IQR) 
55 (40, 85) 60 (45, 80) 0.574 
Referred for further PCI 32 (19.3) 3 (7.7) 0.084 
Referred for further CABG 20 (12.1) 7 (18.0) 0.327 
(* The British Society of Echocardiography Guidelines (Cheesman et al Heart 1998 (432)) were followed when assessing 
LV function: normal: ≥ 55%, mild impairment: 45-54%, moderate impairment: 36-44%, severe impairment ≤ 35%). 
 
151 
LV function data were collated from a number of sources including pre-procedure 
echocardiograms, cardiac magnetic resonance imaging (CMR), stress echocardiogram 
and nuclear medicine scans as well as LV gram performed at the time of procedure. The 
patients who developed AKI had significantly worse LV function than those who did not 
develop this complication (p = 0.027). This supports the previous data from NYHA Class 
and diuretic prescribing mentioned earlier in this chapter. NYHA Class III-IV heart failure 
carries significant risk for developing AKI as discussed in section 1.6.  
A significantly higher proportion of patients in the non-AKI arm underwent LV gram at 
the time of procedure (p = 0.023). There are no formal guidelines at The London Chest 
Hospital regarding performing an LV gram in patients with CKD. This decision is made 
on a case by case basis at the operator’s discretion. The importance of volume of dye 
as a risk in the development of contrast induced AKI was discussed in section 1.6. Since 
the patients in the AKI group had significantly worse renal function prior to procedure, it 
may be that operators considered them to be higher risk cases and this is why a lower 
proportion of patients in this group had an LV gram during the procedure. Although the 
median contrast volume in the AKI group was numerically higher (180 ml vs. 140 ml in 
the non-AKI group), this was not a statistically significant difference (p = 0.398). In 
clinical practice every additional 10 ml of dye is felt to constitute a risk to the patient, with 
operators attempting to minimise every dose in high risk groups, however in the risk 
scoring systems such as the Mehran Risk Score (discussed in more detail in sections 
1.6.4.7 and 4.2), heightened risk is only ascribed to every additional 100 ml contrast 
(326). 
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Use of both NAC and i.v. fluids was higher in the patients who developed AKI. This is as 
one might expect as we know this group had worse renal function at baseline and The 
London Chest Hospital Guidelines for prevent of contrast induced AKI (section 2.5) 
recommend NAC and fluids only for patients with GFR < 50 ml/min. 
 
3.6 Post procedural Blood Results 
In those patients who were in-patients following their study procedure it is routine clinical 
practice for a FBC and U and E to be checked prior to discharge. This time-point is 
between 12 and 24 hours following the procedure and the results are summarised in 
Table 23. 
Table 23: Pre-discharge blood results 
 No AKI outcome 
(n = 70) 
AKI outcome 
(n = 27) 
p value 
Haemoglobin (g/dl) 10.8 (10.0, 12.4) 10.8 (9.5, 12.4) 0.675 
Urea (mmol/l) 9.3 (6.7, 11.7) 11.4 (9.3. 17.0) 0.005 
Creatinine (µmol/l) 120 (102, 149) 137 (129, 167) 0.005 
eGFR (ml/min) 49 (39, 59) 42 (30, 46) 0.002 
 
The main difference is that renal function is significantly worse in the group who 
developed AKI at day 3. This group also had worse renal function at baseline as seen in 
section 3.4. 
 
 
153 
3.7 Day 3 Blood Results 
207 patients attended for Day 3 follow-up blood results. 1 patient did not attend 
and we were not able to obtain follow-up blood results from his GP. 39 (18.8%) 
developed AKI. The results are summarised in Table 24. 
Table 24: Day 3 Blood Results 
 No AKI outcome 
(n = 168) 
AKI outcome 
(n = 39) 
p value 
Haemoglobin (g/dl) 11.4 (10.6, 12.6) 10.1 (9.3, 11.4) 0.001 
Creatinine (µmol/l) 126 (104, 149) 183 (152, 213) < 0.001 
eGFR (ml/min) 49 (40, 55) 30 (25, 39) < 0.001 
1 patient required inotropic support but no patients required haemofiltration or 
haemodialysis. As would be expected, serum creatinine was significantly 
elevated in the AKI group at day 3 compared to the non-AKI group (188.3 µmol/l 
vs. 134.6 µmol/l, p <0.001). Haemoglobin was significantly lower in the AKI 
group at Day 3. Anaemia is known to be an important risk factor for the 
development of AKI (section 1.6.4).  
 
3.8 Discussion 
Diabetes mellitus is one of the main risk factors for the development of coronary 
artery disease (10). Once coronary artery disease has developed these patients 
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are then at high risk for the development of ACS (17-20;59). From the 
Framingham study (10) it is known that even after adjustment for other factors, 
diabetic patients have higher mortality rates and also a higher incidence of 
reinfarction and heart failure in both the acute and the post-infarct setting. 
Patients with diabetes and CKD are a particular challenge as they have a higher 
incidence of cardiovascular comorbidities than any other patient group and yet 
have been excluded from the majority of clinical trials to date (440-442). Due to 
their increased cardiovascular morbidity and mortality (7;13;443), there is 
frequently a need for patients with diabetes to undergo coronary angiography 
and PCI procedures. However when renal function is already impaired by 
pathological processes the kidney is far less able to tolerate the additional stress 
of excreting a contrast load (281). This risk is further amplified for patients with 
diabetes (268) as described in section 1.6. Therefore the patients who 
participated in our study were a high risk cohort for developing contrast induced 
AKI since in order to be eligible they had to have a confirmed diagnosis of 
diabetes and CKD (eGFR < 60 ml/min). 
It would be extremely useful to be able to identify those patients most at risk 
early, to allow possible therapeutic interventions to be initiated promptly. 
Possible interventions include more intensive i.v. hydration regimes, use of 
vasodilators such as dopamine, fenoldopam, endothelin receptor antagonists or 
aminophylline (329). Such attempts have to date been limited as the current 
‘gold standard’ biomarker serum creatinine does not start to rise until 48-72 
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hours post the injury event (265). Furthermore serum creatinine concentrations 
are influenced by a number of other factors including age, muscle mass, 
hydration and nutritional status (383). Additionally a rise in serum creatinine may 
not be clinically detectable until almost 50% of renal function has been lost and 
serum creatinine concentrations are not a reflection of acute GFR change in the 
acute setting since a period of hours-days must elapse before equilibrium 
between steady-state production and decreased creatinine excretion is achieved 
(380) (444). 
The incidence of contrast induced AKI in our cohort was 18.8% (n = 39). This 
included both unstable and elective patients with diabetes and CKD but due to 
other concurrent studies in the department patients with STEMI were excluded. 
Due to problems with inconsistent definitions of contrast induced AKI being used, 
it can be difficult to compare results from different studies in the medical 
literature. We used the definition that has been most widely used of a rise in 
serum creatinine of > 25% from baseline or an absolute rise of 44.5 µmol/l. It will 
be important for future studies that definitions become standardised as 
discussed in section 1.4.  
The majority of patients enrolled in our study had Type 2 diabetes, with only 3 
patients with Type 1 diabetes included. The mean duration of diabetes was 
approximately 14.5 years. Diabetes treatment with respect to diet, oral 
medication and insulin therapy was similar between those patients who 
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developed AKI. Reasonable glycaemic control was observed in the studied 
patients with median HbA1c of 7.4 in the non-AKI group and 7.6 in the AKI group 
(p = 0.785). There was no significant difference in median blood glucose levels 
at time of procedure 7.0 mmol/l vs. 7.5 mmol/l, respectively, (p = 0.106).  
A recent study by Stolker et al (445), showed that pre-procedural glucose levels 
are a risk marker for contrast induced AKI in patients without diabetes with acute 
MI (STEMI and NSTEMI) who underwent coronary angiography during their 
index admission. This was not observed in patients with diabetes possibly due to 
the higher risk for contrast induced AKI in these patients. The findings were valid 
even after adjustment for confounding variables such as impaired baseline renal 
function. In a previous study, fasting blood glucose was shown to be an 
independent predictor of contrast induced AKI in patients with the metabolic 
syndrome (446). Hyperglycaemia is commonly observed in critically ill patients 
and occurs in > 40% of patients without diabetes but with acute MI (447). The 
aetiology of hyperglycaemia in this setting is thought to be due to a number of 
factors including stress–related neuro-hormonal alterations, activation of the 
renin-angiotensin-aldosterone system, and expression of various cytokines 
(296). Hyperglycaemia may be acting as a ‘stress test’ for the failure of 
endogenous insulin reserves to adequately control blood glucose levels or be a 
consequence of insulin resistance (447). The results of the study by Stolker et al 
raises the possibility of interventions to treat blood glucose levels at the time of 
procedure such as intensive insulin regimes to reduce risk of contrast 
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induced AKI. Further studies will be necessary to ascertain if pre-procedural 
hyperglycaemia is a risk marker for contrast induced AKI in elective and general 
populations undergoing coronary imaging procedures using iodinated contrast 
media. 
The study presented in this thesis included a high proportion of patients of South 
Asian origin, reflective of the demographics of the local population and also the 
population of East London from which The London Chest Hospital received 
referrals. Patients of South Asian origin are known to be at high risk for 
development of diabetes, CKD and CHD, with these conditions often coexisting 
in the same patient; and this has been reported in a number of other studies 
(433-436). These patients do not have an increase in the rates of the traditional 
and modifiable risk factors for CHD of hypertension, hypercholesterolaemia and 
cigarette smoking. South Asian patients are observed to have an increase of 
other cardiovascular risk factors including central adiposity and physical 
inactivity. Other factors which have been implicated include reduced HDL 
cholesterol, hypertriglyceridaemia, hyperinsulinaemia, reduced beta cell function 
and various prothrombotic factors (448-450). Ethnicity did not have any influence 
on the development of contrast induced AKI (p = 0.838). 
Rates of use of ACE inhibitors (n = 127) and AIIRBs (n = 50) were high in this 
study (Table 19). There was no significant difference in use of ACE inhibitors (p 
= 0.482) or AIIRBs (p = 0.555) on patient outcome. In landmark clinical trials 
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pharmacological inhibition of the renin angiotensin system attenuated the decline 
in renal function associated with CKD (154-156;451-454). However these trials 
have several limitations and concerns arise regarding the general applicability of 
their findings to the ‘real-world’ particularly regarding older patients (> 65 years) 
with CKD (455-457).  
The Renin Angiotensin Aldosterone System (RAAS) blockade clinical trials 
generally enrolled younger patients with well-preserved baseline renal function, 
the exception to this being the RENAAL and IDNT trials which recruited patients 
with quite advanced CKD with baseline serum creatinine of 1.9 and 1.7 mg/dl, 
respectively (155;451). Furthermore there is little evidence that the benefits of 
reno-protection extend beyond blood pressure control. A post-hoc substudy 
analysis from the HOPE trial showed that patients in the ramipril arm achieved 
significantly lower 24 hour BP levels when compared to the control arm (457). In 
other trials which reported BP independent effects such as RENAAL (losartan) 
and IDNT (captopril), the treatment arms showed mean arterial BP values lower 
than the placebo arm of ≥ 3 mmHg (155;451). In the ONTARGET trial lower BP 
levels were reported in the combination arm (telmisartan and ramipril) vs. the 
monotherapy arm (454). Marked emphasis has been given to the magnitude of 
reduction of levels of proteinuria in patients studied as a definitive renal end-point 
although this has not been validated in any studies (456;458). Finally in many of 
the RAAS blockade trials, the rates of discontinuation of medication have been 
extremely high. In the RENAAL trial 46.5% of patients discontinued losartan 
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and 53.5% discontinued the placebo treatment (155). The implications of study 
drug discontinuation rates on statistical analysis and validity of study outcomes is 
hypothetical and is an area of strong debate even amongst experts in the area 
(455). 
Whether ACE inhibitors and AIIRBs should be discontinued prior to patients 
undergoing procedures involving iodinated contrast media remains an area of 
controversy. Some studies suggest that these drugs are of benefit and limit the 
effects of contrast induced AKI (269;459); others report that concurrent use of 
ACE inhibitors and AIIRBs exacerbates contrast induced AKI in patients with 
CKD (460-463). A recent post-hoc analysis from the Dialysis Versus Diuresis 
(DVD) Trial of 412 patients (29.1% diabetic) with serum creatinine ≥ 1.3 mg/dl 
and ≤ 3.5 mg/dl, demonstrated that patients treated with either ACE inhibitors or 
AIIRBs prior to exposure to contrast developed significantly higher rates of 
contrast induced AKI within 72 h (464). Following adjustment for confounding co-
morbidities, treatment with either an ACE inhibitor or AIIRB was an independent 
risk predictor for development of contrast induced AKI (11.9% vs. 4.3%, p = 
0.006). Multivariate analyses using logistic regression identified RAAS blockade 
to be an independent risk predictor for contrast induced AKI (OR 3.082, 95%CI 
1.234 – 7.698, p = 0.016). Komenda et al (463) found that renal outcomes were 
improved when ACE inhibitors were withheld from patients for 2 days prior to 
coronary angiography. A trial by Gupta et al (459) which concluded that captopril 
was reno-protective administered the first dose of the drug just 1 h prior to 
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coronary angiography. It would appear unlikely that this would have allowed 
sufficient patients drug exposure prior to contrast being administered. Other 
limitations of this study include small size (n = 71) and that use of peri-procedural 
i.v. fluid regimes (a therapy that is known to be beneficial in preventing contrast 
induced AKI) was not standardised and was therefore at the operator’s 
discretion. Rosenstock et al (465) also reported that the withholding ACE 
inhibitors or AIIRBs in patients with CKD prior to coronary angiography and 
contrast exposure was not beneficial. A major limitation of this study was that 
these drugs were only withheld for 24 h prior to contrast exposure. In patients 
with significant CKD, knowledge of pharmacokinetics would indicate that 24 h 
was an inadequate time period for the effect of RAAS blockade to disappear 
(466;467). This therefore could explain the failure of this study to demonstrate 
any benefit associated with withholding ACE inhibitors or AIIRBs prior to contrast 
exposure. This would also support the findings of Komenda et al (463) as 
previously discussed in this section, where withholding ACE inhibitors or AIIRBs 
for a longer time period was associated with improved renal outcomes.  
On balance it would appear that the results in the literature are predominantly in 
favour of discontinuing RAAS blockade prior to exposure to iodinated contrast 
media for patients with CKD (315;460-464). However the limitations of small 
case series and post-hoc analyses should be recognised and this should drive 
the establishment of large scale multi-centre randomised trials to confirm these 
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findings. 
There was a significant trend towards patients who developed AKI having a 
higher baseline NYHA Class (p = 0.048). This is based on patient reported 
symptoms and therefore is subjective but this was further supported by objective 
data on LV function from both imaging reports and LV gram data performed at 
the time of procedure (section 3.5). LV function was significantly worse in the 
patients who developed AKI (p = 0.027), with higher proportions of patients 
having moderate or severe LV dysfunction. Heart failure is a well-recognised risk 
factor for the development of contrast induced AKI (310). It is thought that this 
results in decreased renal blood flow, leading to increased viscosity, 
predisposing to medullary hypoxia and ischaemia (296). It may be difficult to 
adequately hydrate these patients prior to procedure and there may also be high 
rates of concomitant use of nephrotoxic medications such as ACE inhibitors / 
AIIRBs and diuretics.  
This is further supported by the higher rate of loop diuretic prescription in the 
patients who developed AKI as reported in section 3.3. There is no evidence in 
the literature to date of any interaction between the biomarkers studied and loop 
diuretics and whilst these agents might ‘dilute’ the baseline concentration, a delta 
would still be observed following development of AKI.  
Since the volume of contrast used is an important predictor for the development 
of AKI (237;326) and with the wide availability of non-invasive imaging 
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techniques for assessing LV function including nuclear imaging, 
echocardiography, cardiac MRI, it could be argued as to whether it is appropriate 
for patients with CKD to undergo an LV gram at the time of their angiography or 
PCI procedure. There are currently no formal guidelines regarding performance 
of LV gram at our institution and this is therefore at operator discretion. The 
minimum contrast volume for an LV gram using pressure injection systems (as 
are found in the majority of cardiac catheterisation laboratories in the United 
Kingdom) is 25 ml whilst a manual injection can be done with 10 ml. It has been 
suggested that for patients with CKD the volume of contrast (ml) should not 
exceed twice the baseline level of eGFR (307). In our cohort the median volumes 
of contrast used were 140 ml and 180 ml in the non-AKI and AKI groups 
respectively. This is compared to a median baseline eGFR of 54 ml/min and 42 
ml/min. Since our institution is a tertiary referral centre and also a teaching 
hospital, these high contrast volumes may be reflective of the complexity of the 
cases referred and also of the training of junior operators. 
Use of both NAC and i.v. fluids was significantly higher in the patients who 
developed AKI (p = 0.036 and 0.051). At first glance this might seem counter-
intuitive but the AKI group had worse renal function at baseline (Table 20) and 
The London Chest Hospital Guidelines for Prevention of Contrast Induced AKI, 
recommend NAC and fluids only for patients with eGFR < 50 ml/min. Therefore 
patients in the study with eGFR 51-60 ml/min did not receive these agents. This 
appears to be a rather arbitrary cut-off as CKD Stage 3 or moderate CKD is 
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defined as eGFR 30 – 59 ml/min. Following the completion of this study, the 
hospital guidelines are currently under review and it has been proposed that use 
of NAC and i.v. hydration is extended to patients with eGFR 51-60 ml/min. 
Limitations of the Study and Further Work 
This was a single centre study performed in a tertiary referral cardiac unit. There 
may therefore have been an element of selection bias with a tendency to more 
complex cases being referred from peripheral hospitals. Our reported rate of 
contrast induced AKI and the relatively high volumes of contrast used in the 
study may be reflective of this.  
A pragmatic approach with regard to i.v. hydration prior to the coronary 
angiogram or PCI procedure has had to be taken in order to ensure efficient use 
of both hospital beds and laboratory time and work flow. This generally precludes 
patients being admitted the night before their procedure for i.v. hydration if they 
have eGFR < 50 ml/min. The hospital guidelines recommend a minimum of 2 h 
of i.v. fluids in these patients prior to procedure and do not monitor urine output. 
As discussed in section 1.7, the majority of trials looking at i.v. hydration regimes 
have included a minimum of 6 hours of i.v. fluids prior to procedure.  
The study included only elective and unstable patients with diabetes and CKD. 
STEMI patients were excluded due to other studies which were occurring in the 
department. To be truly reflective of a ‘real-world’ population with diabetes 
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and CKD undergoing coronary angiography or PCI it would be important for 
these patients to be included in further studies. The protocol was for patients to 
be followed up until Day 3 post procedure. Although data were collected on the 
outcome of all contrast induced AKI events it would be extremely interesting to 
follow up the patients over a longer term basis to ascertain the prognosis of 
developing contrast induced AKI on future morbidity and mortality. 
Patients were referred from at least 5 peripheral hospitals all with their own 
clinical laboratories. There can be some variation in the assays used to report 
serum creatinine at different institutions. All patients who participated in the study 
were invited back to The London Chest Hospital for an appointment for a Day 3 
blood test. However due to logistical reasons a number of patients were not able 
to do this and therefore results were obtained from their local hospital or general 
practitioner which may have led to us not correctly identifying all cases of 
contrast induced AKI.  
The Hospital Guidelines are currently under review and some suggestions for 
further consideration are documented in Chapter 7.  
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Chapter 4: Renal Angiogram Data, Mehran Risk Score 
and SYNTAX Score Data 
4.1 Renal Angiogram data 
There is a paucity of data in the medical literature with regard to structural renal disease 
and the development of contrast induced AKI. Structural renal artery disease is likely to 
result in diminished perfusion of the kidney and therefore might render it more 
vulnerable to contrast induced AKI. (Hypoperfusion of the kidney is a known risk factor 
for the development of AKI (section 1.6)). We therefore included renal angiography in 
the study protocol, to be performed at the operator’s discretion.  
56 patients underwent a renal angiogram at the time of the procedure. This was 
performed using a technique of selective intubation of the left and right renal arteries 
using a multi-purpose catheter. This was a minimal additional dye load as with selective 
intubation of the renal vessels an adequate image can be obtained with 2 ml of contrast 
agent. There are no established scoring systems for assessing severity of reno-vascular 
disease. We therefore scored the anatomy in a similar manner to that we use for 
coronary lesions as normal, mild stenosis, moderate stenosis and severe stenosis. The 
results are summarised in Table 25. 
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Table 25: Renal angiogram data 
 
No AKI Outcome 
 
AKI Outcome 
 
p value 
Renal angiogram (%) n = 44 (26.2) n = 12 (30.8) 0.562 
    Normal 38 (86.4) 7 (58.3) 
0.11 
 
 
Mild stenosis 2 (4.6) 2 (16.7) 
Moderate stenosis 1 (2.3) 0 (0) 
Severe stenosis 3 (6.8) 3 (25.0) 
There was no significant difference in anatomical severity of renal artery disease 
between the 2 groups. 7 patients (12.5%) had moderate or severe renal artery stenosis. 
Of these 1 had a critical restenosis in a previous renal artery stent that due to language 
difficulties was not known about at the time of procedure. She underwent a balloon 
angioplasty to this lesion with excellent angiographic result. All patients with moderate to 
severe renal artery stenosis were referred to our renal colleagues for advice regarding 
further management. 
We then looked at the usage of ACE inhibitors, AIIRBs and diuretics in these patients. 
The results are summarised in Table 26. 
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Table 26: Prescription of ACE inhibitors, Angiotensin II Receptor Blockers and 
Diuretics in patients who underwent renal angiography 
Renal artery score Not on ACE-I (%) On ACE-I (%) p value 
Normal 15 (83.3) 30 (79.0) 
0.464 
Mild stenosis 0 (0) 4 (10.5) 
Moderate stenosis 0 (0) 1 (2.6) 
Severe stenosis 3 (16.7) 3 (7.9) 
 
Renal artery score Not on AIIRB (%) On AIIRB (%) p value 
Normal 36 (83.7) 9 (69.2) 
0.219 
Mild stenosis 3 (7.0) 1 (7.7) 
Moderate stenosis 0 (0) 1 (7.7) 
Severe stenosis 4 (9.3) 2 (15.4) 
 
Renal artery score Not on Loop diuretic (%) On Loop diuretic (%) p value 
Normal 2 1(84.0) 24 (77.4) 
0.623 
Mild stenosis 1 (4.0) 3 (9.7) 
Moderate stenosis 1 (4.0) 0 (0) 
Severe stenosis 2 (8.0) 4 (12.9) 
    
Renal artery score Not on Thiazide On Thiazide p value 
Normal 40 (83.3) 5 (62.5) 
0.305 
Mild stenosis 3 (6.3) 1 (12.5) 
Moderate stenosis 1 (2.1) 0 (0) 
Severe stenosis 4 (8.3) 2 (25.0) 
7 patients with moderate to severe renal artery stenosis were taking ACE-inhibitors or 
AIIRBs and 6 were taking a diuretic agent. 2 patients with mild renal artery stenosis and 
1 patient with severe renal artery stenosis taking ACE inhibitors developed AKI. 1 
patient with severe renal artery stenosis on an AIIRB developed AKI. All the patients on 
an ACE inhibitor or AIIRB with renal artery stenosis who developed AKI were also taking 
a diuretic. 
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4.2 The Mehran Risk Score 
The Mehran risk score has been well validated in a general population undergoing 
coronary angiography and PCI procedures (326) as described in Section 1.6, (Table 9). 
From this original general population data it was shown to have good discriminant power 
for identifying contrast induced AKI with a C statistic of 0.69. To the best of our 
knowledge it has not been formally assessed in a high risk patient subset such as ours, 
that is in patients with diabetes and CKD. We therefore sought to evaluate its 
performance in our study population. The results are summarised in Table 27. 
Table 27: Mehran Risk Score Data 
 No AKI Outcome 
 
AKI Outcome 
 
p value 
Mehran Risk Score, mean 
(SD) 
11.1 (3.8) 13.7 (4.2) < 0.001 
Risk of AKI %, median, IQR 14 (14, 26.1) 26.1 (26.1, 57.3) < 0.001 
Risk of dialysis %, median, 
IQR 
0.12 (0.12, 1.09) 1.09 (1.09, 12.6) < 0.001 
The mean Mehran risk score was significantly higher in the AKI group (p < 0.001). The 
incidence of AKI in our study population was 18.8%. No patients required 
haemodialysis. Overall the Mehran risk score had good discriminant power in our study 
population for identifying contrast induced AKI with a C statistic = 0.69. 
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4.3 The SYNTAX Score and Clinical SYNTAX Score 
The SYNTAX score is an anatomical score of severity of coronary artery disease and is 
described in detail in Section 2.1. We aimed to establish if there was a relationship 
between severity of coronary artery disease and development of contrast induced AKI 
(Table 28). 
Table 28: The SYNTAX score and Clinical SYNTAX Score data 
 No AKI Outcome 
 
AKI Outcome 
 
p value 
SYNTAX Score, mean (SD) 19.1 (16.5) 25.0 (20.1) 0.091 
Clinical SYNTAX Score, median 
(IQR) 
35.4 (12.7, 101.2) 82.7 (26.0, 158.9) 0.036 
 
There was no significant difference between severity of coronary disease, assessed by 
the SYNTAX score between the 2 groups. However the Clinical SYNTAX Score (CSS) 
(described in detail in section 2.12.2) was significantly higher in the AKI group 35.4 vs. 
82.7 (p = 0.036). The CSS takes into account clinical factors including Age, eGFR and 
LV function in addition to the anatomical scoring of the SYNTAX Score. It is likely that 
this difference is driven by the more severe LV dysfunction and renal function observed 
in the AKI group which we have discussed already. The CSS had reasonable accuracy 
for predicting development of contrast induced AKI with a C statistic of 0.64.  
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4.4 Discussion 
4.4.1 Renal artery stenosis, ACE inhibitor prescription and AKI 
Development 
The association between accelerated renal failure in patients with CKD and renal artery 
stenosis receiving ACE-inhibitors or AIIRBs is well described in the medical literature 
(468-473). The majority of these data comes from case reports, small case series and 
retrospective studies and have suggested that such failure is reversible following drug 
withdrawal. The overall conclusion has been that it is necessary for an additional 
precipitating risk factor to be present in order for patients with renal artery stenosis 
treated with RAAS blockade to develop AKI (285;468-474). Risk factors that have been 
identified include other therapeutic agents such as diuretics and NSAIDs, described as 
‘the triple whammy effect’ (475). In the study presented here all of the patients with renal 
artery stenosis who developed AKI were also taking diuretic therapy. It has also been 
suggested that bilateral renal artery disease must be present in patients with dual 
kidneys for RAAS blockade to result in worsening renal failure. However it is possible for 
microvascular renal arteriolar narrowing to occur that is not visible either on direct renal 
angiography or magnetic resonance angiography (MRA) and can be identified only on 
renal artery biopsy (473). This microvascular renal narrowing can stimulate increased 
angiotensin II production in a similar manner to macroscopic renal artery stenosis 
(455;473). How patients with renal artery stenosis should be managed remains an area 
of debate. 
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Topol and Nissen coined the phrase ‘the oculo-stenotic’ reflex to describe the at the time 
widely held view that an angiographically severe stenosis must cause ischaemia and 
therefore revascularisation is necessary (476). Although quantitative angiography 
improves the accuracy of stenosis severity it does not improve the accuracy of 
diagnosing ischaemia (477). New technological developments such as Fractional Flow 
Reserve (FFR) have shown that > 1/3 of angiographically severe coronary stenoses are 
haemodynamically not significant and results correlate well with ischaemic findings on 
myocardial perfusion imaging (478). Renal artery stenosis severity has also been shown 
to poorly correlate with haemodynamic significance (479).  
A number of randomised trials (480-484) have shown that renal artery stenting based 
solely on angiographic severity of stenoses is not associated with improvement in either 
blood pressure or renal function or clinical events compared to medical therapy alone. 
Potential explanations for these findings include treatment of patients with anatomic 
stenosis but no renal ischaemia, baseline parenchymal renal disease precluding later 
improvement in hypertension and renal function and essential hypertension without a 
renovascular component (485). 
A recent study by Mangiacapra et al (486) has suggested that invasive assessment of 
renal ischaemia by measuring trans-lesional pressure gradient following administration 
of intra-arterial dopamine may predict blood pressure response following renal artery 
stenting and hence would identify patients who might benefit from this procedure. The 
study enrolled 53 hypertensive patients with unilateral renal artery stenosis. A dopamine 
induced mean pressure gradient of ≥ 20 mmHg before revascularisation was the only 
independent predictor of blood pressure improvement. The C statistic on ROC 
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analysis for predicting a decrease in systolic BP ≥ 20 mmHg at 3 months was 0.77, 
consistent with good accuracy. Mean number of medications per patient was reduced 
from 3.2 to 2.8 following stenting. However 18% of non-responders had a dopamine 
induced mean pressure gradient ≥ 20 mmHg, suggesting considerable heterogeneity in 
blood pressure response. 
There are a number of possible explanations for this variable blood pressure response, 
even when renal ischaemia is present. Patients with atherosclerotic renal artery stenosis 
may have indistinguishable levels of renin activity compared to hypertensive patients 
without renal artery stenosis (487;488). This suggests that most patients with 
hypertension and renal artery stenosis do not have renovascular hypertension. Possible 
aetiologies include essential hypertension associated with sympathetic/cerebral nervous 
system activation, vasoactive oxygen species, abnormalities in endothelial dependent 
relaxation or ischaemic and hypertensive intra-renal injury (489-491). Therefore patients 
with haemodynamically significant renal artery stenosis may not have renovascular 
hypertension so expecting that hypertension will be cured following stenting is probably 
unrealistic.  
Although marked clinical benefits may be achieved from even modest reductions in 
blood pressure (492), further studies in more patients are needed to assess suitability of 
patients with renal artery stenosis for revascularisation. Other methods available to 
assess the physiological impact of renal artery stenosis include nuclear scintigraphy, 
direct GFR measurement, FFR as well as translesional pressure gradients 
(477;479;486;493). This will allow objective assessment of renal ischaemia, confirm the 
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absence of irreversible renal injury and therefore proper assessment of the 
appropriateness for revascularisation to occur. 
The number of renal angiograms performed in this study was small and no physiological 
assessment of lesion severity was made at the time of procedure. There are a number 
of reasons for this: (i) It is difficult to catheterise the renal arteries from the radial route 
as catheters are a set length and in general they do not reach around the aortic arch to 
the appropriate level in the abdominal aorta. Approximately 50% of procedures in this 
study were performed by the radial route. (ii) Few operators in the cardiac catheter 
laboratories at our institution are familiar with this technique and therefore were not 
willing to perform peripheral arterial cannulation. (iii) This was not an essential part of 
the study protocol and was performed at the operator’s discretion. The study identified 7 
patients with moderate-severe renal artery stenosis and these patients were referred to 
our nephrology colleagues for further assessment. 
4.4.2 The Mehran risk score to predict development of contrast 
induced AKI 
Radiographic contrast media are responsible for 11% of cases of hospital acquired renal 
insufficiency and are the third most common cause of renal failure after impaired renal 
perfusion and nephrotoxic drugs (266). Out of all the procedures which utilise contrast 
media for imaging purposes coronary angiography and PCI are associated with the 
highest rates of contrast induced AKI (266). Patients with diabetes and CKD have 
increased cardiovascular morbidity and mortality (7;13;443) as described in sections 1.2 
and 1.3. These patients therefore frequently need to undergo coronary angiography 
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and PCI procedures. As mentioned before (section 1.6.4.1), when renal function is 
already impaired by pathological processes the kidney is far less able to tolerate the 
stress of excreting a contrast load (281). Therefore patients with diabetes and CKD are 
at particular risk for developing contrast induced AKI. 
It would be extremely useful to identify those patients most at risk early, to allow 
possible therapeutic interventions to be initiated promptly. Possible interventions include 
more intensive i.v. hydration regimes, use of vasodilators such as dopamine, 
fenoldopam, endothelin receptor antagonists and aminophylline (329). Such attempts to 
date have been limited as the current ‘gold standard’ biomarker of renal injury, serum 
creatinine does not rise until 48-72 hours post the injury event (265). For the reasons 
previously mentioned (section 1.8), an alternative marker of renal injury than creatinine 
is required. 
The Mehran risk score is a simple model that allows identification of patients at high risk 
for contrast induced AKI at the time of procedure and therefore could be incorporated 
into routine clinical practice (326). The score is described in detail in section 1.6.4.7. 
Briefly, 8357 patients from a database at the cardiac catheterisation laboratory at 
Columbia University Medical Centre in New York were randomly assigned to a 
development and validation dataset. The baseline clinical and procedural characteristics 
of 5571 patients in the development dataset were considered as candidate univariate 
predictors of contrast induced AKI. Multivariate logistic regression was then used to 
identify independent predictors of contrast induced AKI with a p value < 0.0001. Based 
on the odds ratio, 8 variables were identified (hypotension, intra-aortic balloon pump, 
congestive cardiac failure, CKD, diabetes mellitus, age > 75 years, anaemia and 
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volume of contrast). Each of these variables was assigned a weighted integer, the sum 
of the integers being the total risk score for each patient. This allows the patients to be 
stratified into a low risk (≤ 5), low-medium (6–10), medium-high (11-16) and high risk (≥ 
16) group (326). From this score, % risk of contrast induced AKI and risk of dialysis can 
be ascertained (Table 9) at time of procedure. The score had a good discriminative 
ability in identifying contrast induced AKI in a general population undergoing coronary 
angiography and PCI with a C statistic of 0.69.  
The score performed well in the study population of patients with diabetes and CKD 
described in this thesis. This was a medium-high risk group with mean risk score of 11.1 
in the patients who did not develop AKI and 13.7 in those who developed AKI. The rate 
of AKI in this population was 18.8%, which is within the range (14 - 26.1%) that the 
score identifies. However it would appear that the score over-estimates the risk of 
contrast induced AKI (Table 27) requiring dialysis as we had no such cases in our study 
population of 208 patients. The C statistic for the score in patients with diabetes and 
CKD was 0.69, again showing good discriminant accuracy. Identification of high risk 
patients early allows continuation of supportive care such as i.v. fluids and also permits 
closely tailored monitoring in appropriate patients whilst also facilitating prompt 
discharge of those at lower risk. This will create a more efficient work flow within 
cardiology departments, both in terms of cardiac catheter laboratory time but also with 
hospital bed management. Care can therefore be tailored on an individual basis based 
on the patient’s perceived risk.  
It would also be possible to use the scoring system in a pre-admission setting to select 
cases that might require senior (experienced) operators. A standard volume of 
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contrast could be included in this calculation such as 50 ml for a diagnostic angiogram 
and 200 ml for a PCI. Since currently treatment options for contrast induced AKI are 
rather limited and development of this complication is associated with a prolonged 
hospital stay and unfavourable in-hospital and 1 year outcomes, early identification of 
those at high risk with options such as increasing pre-procedure hydration by admitting 
these patients the night before procedure. This might also allow the allocation of limited 
resources such as haemofiltration to those most at risk. A single centre study reported 
that peri-PCI haemofiltration starting prior to PCI and extending for 24 h post PCI was 
effective in decreasing the incidence of contrast induced AKI in high risk patients (serum 
creatinine > 2 mg/dl or 176.8 µmol/l). Contrast induced AKI (defined as a rise from 
baseline serum creatinine of >25%) developed in 5% of patients who underwent 
haemofiltration compared to 50% in the control group who received i.v. hydration (p < 
0.001). Due to the high cost of haemofiltration compared to that of a saline infusion this 
approach has not become established in clinical practice (361).  
The Mehran risk score has a number of limitations. The inclusion of 2 procedural 
characteristics (IABP and contrast volume) limits the ability to apply the score prior to 
procedure. A volume of contrast can be estimated (as described above) depending on 
the type of procedure and use of IABP is rare in the elective setting so an assessment of 
the ‘minimum’ risk can be made. However the score does not include any data on i.v. 
hydration which is the one factor that has been shown to conclusively decrease rates of 
contrast induced AKI (section 1.7.1), nor does it include other important data such as 
presence of proteinuria, urine output and nephrotoxic medications. These are areas that 
could perhaps be investigated in further studies and might result in improved accuracy in 
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identifying high risk patients. 
4.4.3 The SYNTAX Score and Clinical SYNTAX score 
The SYNTAX score allows objective quantification of complexity of coronary artery 
disease, taking into account not just the number of significant lesions and their location 
but also the complexity of each lesion independently. Higher SYNTAX scores, indicative 
of more complex disease, are thought to present a bigger therapeutic challenge and to 
potentially herald a worse prognosis (421). The scoring algorithm is described in detail in 
section 2.12. The score has been divided into terciles to guide optimal revascularisation 
strategy with a low score (0 – 22) favouring PCI, a medium score (23 – 32) suggesting 
either PCI or CABG are reasonable choices and a high score (≥ 33) favouring CABG 
(26). The patients in this study who did not develop AKI had a mean SYNTAX score of 
19.1 whereas those who developed AKI had a mean score of 25.0 suggesting that their 
disease was more complex overall. Anatomical lesion scoring systems have been 
shown to have a lower ability to predict mortality than scoring systems that use clinical 
characteristics (424) and this led to the development of the Clinical SYNTAX Score 
(CSS) which was recently reported (431). The median CSS was 35.4 in the patients who 
did not develop AKI and 82.7 (p = 0.036) in those who did develop AKI. This difference 
is driven by the more severe LV dysfunction and baseline renal function of the patients 
who developed AKI described in chapter 3. The CSS classifies patients into terciles as 
described in section 2.12.2 and this would put the patients studied here into CSSHIGH 
(>27.5). It has been shown that such patients have higher mortality and 
revascularisation rates at 1 year (431). Although patients in this study were only followed 
up to day 3 and mortality and revascularisation rates were not assessed, further 
 
179 
projects could address this. Limitations of both scores are that it is extremely time 
consuming even using the online calculator to complete the algorithm, taking 
approximately 30 min for the average patient. There is also a definite ‘learning curve’ 
that needs to be overcome in order to be consistent with result reporting and even then 
there is only moderate intra-observer reproducibility as has been reported in the 
literature (494;495). These limitations are likely to limit the adoption of these scores into 
routine clinical practice. 
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Chapter 5: Materials and Methods for Biomarker ELISA 
Assays 
5.1 NGAL Assay 
(DuoSet ELISA Development System, R and D Systems, Oxford, United Kingdom; 
Catalogue Number DY1757) 
The DuoSet kit contains the basic components required for the development of 
sandwich ELISAs to measure natural or recombinant NGAL. The ELISA technique has 
been described in detail in section 2.9. Briefly, a monoclonal antibody specific for NGAL 
is coated onto a microtitre plate and left overnight. The following day the plate is washed 
with buffer and standards and samples are pipetted into the wells. Any NGAL present is 
bound by the immobilised antibody. After washing away any unbound substances, an 
enzyme linked monoclonal antibody specific for NGAL is added to the wells. Following a 
wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to 
the wells and colour develops in proportion to the quantity of NGAL bound in the initial 
step. Colour development is stopped and the intensity of colour is measured. 
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5.1.1 Solutions and Antibodies 
Phosphate Buffered Saline (PBS) 
Make up 2 litres of PBS with 2 sachets of Sigma PBS 7.4 (P3813) which consists of 137 
mM Na Cl, 2.7 mm K Cl, 8.1 mM Na2 HPO4, 1.5 mm KH2PO4, pH 7.2-7.4, 0.2 µm filtered. 
Reagent Buffer (R and D Systems Catalogue # DY 995) 
To 500 ml of Reagent Buffer add 5 g of Fraction V Bovine Serum Albumin (A-3294) to 
make a final solution which consists of 1% BSA in PBS, pH 7.2-7.4, 0.2 µm filtered  
Wash Buffer (R and D Systems Catalogue # WA 126) 
To 2 litres of PBS add 1 ml of neat Tween 20 (=0.05%) 
Capture Antibody (rat anti-human Lipocalin-2) 
To lyophilised antibody add 1 ml of PBS = 360 µg/ml. Then dilute 55 µl into 10 ml PBS 
to give working reagent of 2 µg/ml 
Standards/Calibrators (recombinant human Lipocalin-2) 
Make up stock calibrator: add 0.5 ml of reagent diluent to the supplied lyophilised 
calibrant = 90 ng/ml 
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Dilate stock calibrator 18 fold: 50 µl + 850 µl of reagent buffer = 5000 pg/ml. Then serial 
dilute down 1:2 to give calibrate equal to: 0, 78, 156, 313, 625, 1250, 2500, 5000 pg/ml. 
Detection Antibody (biotinylated goat anti-human Lipocalin-2) 
Add 1 ml of reagent diluents to lyophilised antibody. Add 55 µl of this to 10 ml of reagent 
diluent to give 100 ng/ml final concentration 
Streptavidin-HRP 
1 ml of streptavidin conjugated to horseradish-peroxidase supplied. Dilute 1 in 200 in 
Reagent Diluent – 50 microlitres in 10 ml. Protect from light 
Substrate Solution: 3,3’,5,5’ Tetramethylbenzidine (TMB) Liquid 
Substrate System (Sigma, Dorset, United Kingdom) 
The product is supplied as a ready to use peroxidase substrate containing 3,3’,5,5’ TMB 
in a mildly acidic buffer. Prior to reaction with peroxidase the substrate should be a 
colourless to light bluish-green solution. The substrate is a light sensitive and should be 
protected from direct sunlight or UV sources and stored at 2-8 °C. It should be brought 
to room temperature (~ 22-25°C) before use. 
Stop Solution (Sigma, Dorset, United Kingdom; Catalogue # 320501) 
2.5 mM Sulphuric acid (H2SO4) 
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5.1.2 NGAL General ELISA Protocol 
Plate Preparation 
1. Dilute the capture antibody to the working concentration in PBS without carrier 
protein. Immediately coat a 96-well microplate with 100 µl/well of the diluted 
Capture Antibody. Seal the plate and incubate overnight at room temperature. 
2. Aspirate each well and wash with Wash Buffer, repeating the process two times 
for a total of three washes. Wash by filling each well with 400 µl of Wash Buffer 
using a squirt bottle, manifold dispenser or autowasher. Complete removal of 
liquid at each stage is essential for good performance. After the last wash, 
remove any remaining Wash Buffer by aspirating or by inverting the plate and 
blotting it against clean paper towels. 
3. Block the plates by adding 300 µl of Reagent Diluent to each well. Incubate at 
room temperature for a minimum of 1 h. 
4. Repeat the aspiration/wash as in step 2. The plates are now ready for a sample 
addition. 
Assay Procedure 
1. Add 100 µl of sample or standards in Reagent Diluent, or an appropriate 
diluent/well. Cover with an adhesive strip and incubate at room temperature for 2 
h. 
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2. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
3. Add 100 µl of the Detection Antibody, diluted in Reagent Diluent to each well. 
Cover with a new adhesive strip and incubate for 2 h at room temperature. 
4. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
5. Add 100 µl of the working dilution of Streptavidin-HRP to each well. Cover the 
plate and incubate for 20 min at room temperature. Avoid placing the plate in 
direct light. 
6. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
7. Add 100 µl of Substrate Solution to each well. Incubate for 20 min at room 
temperature. Avoid placing the plate in direct light. Following reaction with 
peroxidase, a blue reaction product forms. 
8. Add 50 µl of Stop Solution to each well, yielding a yellow end product. Gently tap 
the plate to ensure thorough mixing. 
9. Determine the optical density of each well immediately using a microplate reader 
set to 450 nm. Wavelength correction was set to 650 nm 
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Figure 19: Standard Curve for NGAL Assays 
 
5.1.3 NGAL Assay Titrations 
Our study population only included diabetic patients with CKD. Serum and urine NGAL 
concentrations have not been evaluated in such a population post contrast 
administration and therefore we had to titrate the samples so that we could identify the 
most appropriate dilutions for performing sample analysis. We identified a dilution for 
serum samples of 1 in 200 and for urine of 1 in 20 as the most appropriate for our study 
population. All samples from an individual patient were measured in a single assay. The 
co-efficient of variation for intra-assay reproducibility for NGAL concentration was 7.2% 
in our laboratory and corresponds to that reported by the kit manufacturer. Sample 
assays were repeated across several different plates on different days to ensure 
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reproducibility of results although formal interassay variation was not calculated.  
5.2 Interleukin-18 Assay 
(DuoSet ELISA Development System, R and D Systems, Oxford, United Kingdom; 
Catalogue Number DY119) 
The DuoSet kit contains the basic components required for the development of 
sandwich ELISAs to measure natural or recombinant IL-18. The ELISA technique has 
been described in detail in section 2.9. Briefly, a monoclonal antibody specific for IL-18 
is coated onto a microtitre plate and left overnight. The following day the plate is washed 
with buffer and standards and samples are pipetted into the wells. Any IL-18 present is 
bound by the immobilised antibody. After washing away any unbound substances, an 
enzyme linked monoclonal antibody specific for IL-18 is added to the wells. Following a 
wash to remove any unbound antibody-enzyme reagent, a substrate solution is added to 
the wells and colour develops in proportion to the quantity of IL-18 bound in the initial 
step. Colour development is stopped and the intensity of colour is measured. 
 
188 
5.2.1 Solutions and Antibodies 
PBS 
Make up 2 litres of PBS with 2 sachets of Sigma PBS 7.4 (P3813) which consists of: 137 
mM Na Cl, 2.7 mm K Cl, 8.1 mM Na2 HPO4, 1.5 mm KH2PO4, pH 7.2-7.4, 0.2 µm filtered. 
Reagent Buffer (R and D Systems Catalogue # DY 995) 
To 500 ml Reagent Buffer add 5 g of Fraction V BSA (A-3294) to make a final solution 
which consists of 1% BSA in PBS, pH 7.2-7.4, 0.2 µm filtered  
Wash Buffer (R and D Systems Catalogue # WA 126) 
To 2 litres of PBS add 1 ml of neat Tween 20 (= 0.05%), pH 7.2-7.4 
Capture Antibody (mouse anti-human IL-18) 
To lyophilised antibody add 1 ml of PBS = 360 µg/ml. Then dilute 55 µl into 10 ml PBS 
to give working reagent of 2 µg/ml 
Calibrators/Standards (recombinant human IL-18) 
Make up stock calibrators: add 0.5 ml of reagent diluent to the supplied lyophilised 
calibrant = 250 ng/ml. Store as 50 µl aliquots. 
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Take 24 µl of stock calibrator and dilute with 976 µl of reagent buffer to give a high 
standard of 6000 pg/ml. Then serial dilute this 1:2 to give calibrants equal to: 0, 93.75, 
187.5, 375, 750, 1500, 3000, 6000 pg/ml. 
Detection Antibody (biotinylated goat anti-human Il-18) 
Add 1 ml of reagent diluent to lyophilised antibody. Add 55 µl of this to 10 ml of reagent 
diluent to give 200 ng/ml final concentration. 
Streptavidin-HRP 
1 ml of streptavidin conjugated to horseradish-peroxidase supplied. Dilute 1 in 200 in 
Reagent Diluent – 50 µl in 10 ml and protect from light. 
Substrate Solution: 3,3’,5,5’ Tetramethylbenzidine (TMB) Liquid 
Substrate System (Sigma, Dorset, UK) 
The product is supplied as a ready to use peroxidase substrate containing 3,3’,5,5’ TMB 
in a mildly acidic buffer. Prior to reaction with peroxidase the substrate should be a 
colourless to light bluish-green solution. The substrate is a light sensitive and should be 
protected from direct sunlight or UV sources and stored at 2-8 °C. It should be brought 
to room temperature (~ 22-25°C) before use. 
Stop Solution (Sigma, Dorset, UK; Catalogue # 320501) 
2.5 mM H2SO4 
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5.2.2 Interleukin-18 General ELISA Protocol 
Plate Preparation 
1. Dilute the Capture Antibody to the working concentration in PBS without carrier 
protein. Immediately coat a 96-well microplate with 100 µl/well of the diluted 
Capture Antibody. Seal the plate and incubate overnight at room temperature. 
2. Aspirate each well and wash with Wash Buffer, repeating the process two times 
for a total of three washes. Wash by filling each well with 400 µl of Wash Buffer 
using a squirt bottle, manifold dispenser or autowasher. Complete removal of 
liquid at each stage is essential for good performance. After the last wash, 
remove any remaining Wash Buffer by aspirating or by inverting the plate and 
blotting it against clean paper towels. 
3. Block the plates by adding 300 µl of Reagent Diluent to each well. Incubate at 
room temperature for a minimum of 1 h. 
4. Repeat the aspiration/wash as in step 2. The plates are now ready for a sample 
addition. 
Assay Procedure 
1. Add 100 µl of sample or standards in Reagent Diluent, or an appropriate 
diluent/well. Cover with an adhesive strip and incubate at room temperature for 2 
h. 
2. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
 
191 
3. Add 100 µl of the Detection Antibody, diluted in Reagent Diluent to each well. 
Cover with a new adhesive strip and incubate for 2 h at room temperature. 
4. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
5. Add 100 µl of the working dilution of Streptavidin-HRP to each well. Cover the 
plate and incubate for 20 min at room temperature. Avoid placing the plate in 
direct light. 
6. Repeat the aspiration/wash as in step 2 of Plate Preparation. 
7. Add 100 µl of Substrate Solution to each well. Incubate for 20 min at room 
temperature. Avoid placing the plate in direct light. 
8. Add 50 µl of Stop Solution to each well. Gently tap the plate to ensure thorough 
mixing. 
9. Determine the optical density of each well immediately using a microplate reader 
set to 450nm. Wavelength correction was set at 650 nm. 
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Figure: 20: Standard Curve for IL-18 assay 
 
5.2.3 Interleukin 18 Assay Titrations 
Our study population only included diabetic patients with CKD. Serum and urine IL-18 
concentrations have not been evaluated in such a population post contrast 
administration and therefore we had to titrate the commercial kits so that we could 
identify the most appropriate dilutions for performing sample analysis. We identified a 
dilution for serum samples of 1 in 200 and for urine of 1 in 5 or 1 in 50 as the most 
appropriate for our study population. All samples from an individual patient were 
measured in a single assay. The co-efficient of variation for intra-assay reproducibility 
for IL-18 concentration was 11.9% in our laboratory and corresponds to that reported by 
the kit manufacturer. Sample assays were repeated across several different plates on 
different days to ensure reproducibility of results although formal interassay variation 
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was not calculated. 
 
5.3 Receiver Operating Characteristic Curve Analysis 
Receiver Operating Characteristic (ROC) curves provide a statistical method of 
assessing the diagnostic accuracy of a test (or biomarker) that has a continuous 
spectrum of test results. The ROC curve is a graphical display of the ‘trade-off’ between 
the true-positive rate (sensitivity) and false positive rate (1-specificity) corresponding to 
all possible binary tests that can be formed from this continuous biomarker (496). Every 
classification rule or cut-off level generates a point on the curve. The closer the curve 
follows the left hand border and then the top border of the ROC space, the more 
accurate the test. The closer the curve is to the 45° diagonal, the less accurate the test 
is (497). This is shown in Figure 21. 
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Figure 21: Receiver Operating Characteristic Curves  
 
Adapted from Soreide J Clin Pathol 2009 (497). 3 curve plots and their respective area under the curve (AUC) are shown. 
The diagnostic accuracy of marker C (white area) is better than that of B and A as the AUC of C > B > A. X represents the 
best cut-off point for each biomarker. 
The traditional ROC curve arises when a continuous value is measured in each subject. 
The classification is positive if the value is above a threshold. As the threshold varies, a 
new classification rule is created and the resulting plot is a single curve. The optimal 
ROC curve is therefore the line connecting the points highest and farthest to the left 
upper corner and captures the trade-off between sensitivity and specificity over a 
continuous range (497). 
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5.3.1 Area under the ROC curve 
The area under the curve (AUC) is also known as the C statistic and can range in value 
from 0.5 – 1. A C statistic of 0.5 (refers to the 45° line in the ROC plot) is no better than 
random chance and therefore the marker has no predictive ability. A C statistic of 1 
refers to perfect discrimination/accuracy.  
The AUC is a measure of the overall diagnostic accuracy of a test and the cut-off value 
providing the highest sensitivity and specificity is calculated (Figure 21). 
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Chapter 6: Biomarker Panel Results 
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Chapter 6: Biomarker Panel Assays and ROC Analysis 
6.1 NGAL as a biomarker of AKI in the Study Population   
6.1.1 Serum NGAL results 
We measured our biomarker panel at baseline, 2 h post procedure, 4 h post procedure 
and 12-24 h post procedure. The results for serum NGAL (units = µg/litre) are shown in 
Figure 22. 
Figure 22: Box-plot of serum NGAL results as baseline, 2 hours, 4 hours and 12-24 
hours showing development of AKI versus no AKI.  
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In the AKI group a significant absolute rise in serum NGAL is seen as early as 2 h post 
procedure compared to baseline (p = 0.023), and this persists at 4 h (p = 0.005) and 12-
24 h (p = 0.017). However there is little evidence of an association between an increase 
in the absolute value of serum NGAL in the study population as a whole as evidenced 
by the odds ratio (Table 29). The large range of values and the wide variability within the 
study population even at baseline mean that a small absolute change in the levels of the 
biomarker may be lost due to a ‘high signal to noise’ ratio and therefore we looked at % 
rises from baseline in our biomarkers rather than absolute values (Table 30). 
Table 29: Odds ratio for risk of developing contrast AKI for serum NGAL 
Biomarker  OR 95% CI p value 
Serum NGAL Baseline (per 100 
units) 207 1.07 0.89 1.29 0.458 
Serum NGAL 2h (per 100 units) 198 1.09 0.92 1.28 0.342 
Serum NGAL 4h (per 100 units) 182 1.06 0.94 1.20 0.348 
Serum NGAL 12-24h (per 100 
units) 71 1.23 0.91 1.67 0.186 
 
Table 30: Absolute and Percentage changes from baseline in serum NGAL 
Table 30a) Serum NGAL in AKI patients 
Baseline 
Median (IQR) 
2 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
198 (167, 316) 230 (189, 292) 0.023 14.6 (-3.4, 28.7) 0.004 
     
Baseline 
Median (IQR) 
4 hours 
Median (IQR) p value 
% Change p value 
Median (IQR) 
 198 (167, 316) 261 (202, 379) 0.005 22.0 (6.8, 52.4) 0.001 
     
Baseline 
Median (IQR) 
12-24 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
198 (167, 316) 270 (200, 407) 0.017 26.1 (-4.0, 79.4) 0.019 
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Table 30b) Serum NGAL in non-AKI patients 
Baseline 
Median (IQR) 
2 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
180 (120, 266) 197 (129, 278) 0.008 7.4 (-15.1, 38.6) 0.001 
     
Baseline 
Median (IQR) 
4 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
180 (120, 266) 207 (144, 307) 0.002 12.1 (-13.7, 43.4) <0.001 
     
Baseline 
Median (IQR) 
12-24 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
180 (120, 266) 252 (178, 329) 0.018 17.0 (-7.6, 41.4) 0.001 
 
Receiver Operating Characteristic Curves were constructed to assess how discriminant 
serum NGAL concentrations at different time-points are for the development of AKI. The 
results are summarised in Figure 23. 
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Figure 23: Receiver Operating Characteristic Curves for serum NGAL 
 
The respective C statistics for serum NGAL concentrations at baseline, 2 h, 4 h 
and 12-24 h are 0.6128, 0.6340, 0.6244, 0.5819. 
 
6.12 Urine NGAL results 
The box-plot results for urine NGAL concentrations at the different time-points are 
summarized in Figure 24. 
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Figure 24: Box-plot of urine NGAL results* at baseline, 2 hours, 4 hours and 12-24 
hours showing development of AKI versus no AKI. (NGAL units =ng/µg creatinine)   
*These results are corrected for urine creatinine excretion 
 
Urine NGAL concentrations did not change significantly in the study population during 
the first 24 hours. The odd ratio data are shown in Table 31. 
Table 31: Odds ratio for risk of developing contrast AKI for urine NGAL 
Biomarker  OR 95% CI p value 
Urine NGAL Baseline (per 100 
units) 202 0.99 0.81 1.21 0.934 
Urine NGAL 2h (per 100 units) 188 1.01 0.85 1.20 0.936 
Urine NGAL 4h (per 100 units) 181 1.02 0.83 1.25 0.866 
Urine NGAL 12-24h (per 100 units) 74 0.95 0.76 1.19 0.667 
 
202 
The absolute and percentage changes in urine NGAL are shown in Table 32. 
Table 32 Absolute and Percentage changes from baseline in urine NGAL 
Table 32a) Urine NGAL in AKI patients 
Baseline 
Median (IQR) 
2 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
39.1 (18.2, 113.2) 31.9 (11.9, 154.9) 0.675 -23.8 (-65.5, 69.4) 0.912 
     
Baseline 
Median (IQR) 
4 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
39.1 (18.2, 113.2) 37.8 (12.7, 104.4) 0.347 -16.1 (-54.3, 67.2) 0.891 
     
Baseline 
Median (IQR) 
12-24 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
39.1 (18.2, 113.2) 44.7 (27.6, 91.1) 0.177 49.6 (-25.1, 85.3) 0.102 
 
Table 32b) Urine NGAL in non AKI patients 
Baseline 
Median (IQR) 
2 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
38.8 (16.0, 95.3) 26.4 (9.8, 101.1) <0.001 -27.8 (59.4, 19.9) 0.007 
     
Baseline 
Median (IQR) 
4 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
38.8 (16.0, 95.3) 28.7 (10.6, 92.7) 0.001 -29.3 (-64.7, 39.3) 0.079 
     
Baseline 
Median (IQR) 
12+ hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
38.8 (16.0, 95.3) 47.2 (20.9, 162.1) 0.845 -5.1 (-51.4, 71.4) 0.254 
 
Receiver Operating Characteristic Curves were constructed to assess how discriminant 
urine NGAL concentrations at different time-points are for the development of AKI. The 
results are summarised in Figure 25. 
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Figure 25: Receiver Operating Characteristic Curves for Urine NGAL 
 
The respective C statistics for urine NGAL at baseline, 2 h, 4 h and 12-24 h are 0.5048, 
0.5107, 0.5277, 0.4881. 
 
6.2 Interleukin-18 as a biomarker of AKI in the study population 
6.2.1 Serum IL-18 results 
The results for serum IL-18 are shown on a box-plot in Figure 26. 
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Figure 26: Box plot of serum IL-18 results as baseline, 2 hours, 4 hours and 12-24 
hours showing development of AKI versus no AKI.   (units = µg/litre) 
 
In the AKI group a significant absolute rise in serum IL-18 is seen as early as 2 h post 
procedure compared to baseline (p <0.001), and this persists at 4 h (p = 0.042) but is 
not seen at 12-24 h (p = 0.485). However there is little evidence of an association 
between an increase in the absolute value of serum IL-18 in the study population as a 
whole as evidenced by the odds ratio (Table 33).  
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Table 33: Odds ratio for risk of developing contrast AKI for serum IL-18 
Biomarker n OR 95% CI p value 
Baseline serum IL-18 206 1.01 1.00 1.01 0.159 
Serum IL-18 2 h 201 1.01 1.00 1.03 0.069 
Serum IL-18 4 h 182 1.00 0.99 1.02 0.619 
Serum IL-18 12 -24 h 75 1.01 0.99 1.03 0.460 
Again the large range of values and the wide variability within the study population even 
at baseline mean that a small absolute change in the levels of the biomarker may be lost 
due to a ‘high signal to noise’ ratio and therefore as previously described (section 6.1) 
we looked at % rises from baseline in our biomarkers rather than absolute values (Table 
34).  
Table 34: Absolute and Percentage changes from baseline in serum IL-18. 
Table 30a) Serum IL-18 in AKI patients 
Baseline 
Median (IQR) 
2 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
57.3 (30.9, 77.2) 52.9 (32.5, 63.5) <0.001 -6.9 (-16.9, 2.1) 0.022 
     
Baseline 
Median (IQR) 
4 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
57.3 (30.9, 77.2) 47.0 (27.6, 62.6) 0.042 -6.7 (-18.8, 10.3) 0.265 
     
Baseline 
Median (IQR) 
12+ hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
57.3 (30.9, 77.2) 51.3 (34.9, 61.2) 0.485 4.4 (-4.6, 23.3) 0.199 
Table 30b) Serum IL-18 
Baseline 
Median (IQR) 
2 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
42.4 (30.8, 56.9) 39.9 (28.5, 53.1) <0.001 -5.8 (-15.2, 5.5) <0.001 
     
Baseline 
Median (IQR) 
4 hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
42.4 (30.8, 56.9) 40.6 (29.5, 54.0) 0.01 -6.3 (-15.7, 7.9) 0.034 
     
Baseline 
Median (IQR) 
12+ hours 
Median (IQR) 
p value 
  
% Change 
Median (IQR) 
p value 
  
42.4 (30.8, 56.9) 44.4 (34.9, 57.4) 0.113 3.1 (-5.5, 22.0) 0.061 
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Receiver Operating Characteristic Curves were constructed to assess how discriminant 
serum IL-18 concentrations at different time-points are for the development of AKI. The 
results are summarised in Figure 27. 
Figure 27: Receiver Operating Characteristic curves for serum IL-18 
 
The respective C statistics for serum IL-18 at baseline, 2 h, 4 h and 12-24 h are: 0.624, 
0.612, 0.533 and 0.535. 
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6.2.3 Urine IL-18 results 
The box-plot results for urine IL-18 concentrations at the different time-points are 
summarized in Figure 28. 
Figure 28: Box-plot of urine IL-18 results at baseline, 2 h, 4 h and 12-24 h showing 
development of AKI versus no AKI.   
 
(units = ng/µg Cr– results are corrected for urine creatinine excretion 
When we looked at absolute values in the AKI group there was no significant change 
from baseline at any time-point. However when we looked at percentage rise from 
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baseline within these patients, a significant rise was seen at 2 h (p < 0.001), and this 
persisted at 4 h (p = 0.02) and 12-24 h (p = 0.049). There was no significant change in 
urine IL-18 concentrations in the whole study population over 24 hours. The odds ratio 
data for urine IL-18 are summarised in Table 35. 
Table 35: Odds ratio for urine IL-18 and risk of AKI in the study population 
Biomarker n OR 95% CI p value 
Baseline IL-18 urine 200 0.63 0.33 1.21 0.164 
IL-18 urine 2 h 195 0.98 0.87 1.12 0.807 
IL-18 urine 4 h 182 0.97 0.84 1.12 0.684 
IL-18 urine 12-24 h 80 1.01 0.84 1.21 0.932 
Absolute and percentage changes in urine IL-18 from baseline are summarised in Table 
36. 
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Table 36: Absolute and Percentage Changes from Baseline in Urine IL-18 
Table 36a) Urine IL-18 in AKI patients 
Baseline 
Median (IQR) 
2 hours 
Median (IQR) 
p value 
 
% Change 
Median (IQR) 
p value 
 
14.3 (6.1, 64.0) 39.0 (15.8, 82.2) 0.116 119.4 (-17.5, 387.5) <0.001 
     
Baseline 
Median (IQR) 
4 hours 
Median (IQR) 
p value 
 
% Change 
Median (IQR) 
p value 
 
14.3 (6.1, 64.0) 48.8 (17.0, 80.4) 0.278 24.5 (-31.8, 394.6) 0.02 
     
Baseline 
Median (IQR) 
12-24 hours 
Median (IQR) 
p value 
 
% Change 
Median (IQR) 
p value 
 
14.3 (6.1, 64.0) 29.6 (2.2, 55.6) 0.277 28.9 (-24.3, 222.1) 0.049 
Table 36b) Urine IL-18 in non-AKI patients 
Baseline 
Median (IQR) 
2 hours 
Median (IQR) p value 
0.081 
% Change 
Median (IQR) p value 
<0.001 41.7 (5.1, 95.0) 34.9 (16.0, 92.2) 19.5 (-28.6, 221.0) 
     
Baseline 
Median (IQR) 
4 hours 
Median (IQR) p value 
0.233 
% Change 
Median (IQR) p value 
<0.001 41.7 (5.1, 95.0) 37.9 (11.2, 85.3) 20.7 (-28.3, 175.2) 
     
Baseline 
Median (IQR) 
12+ hours 
Median (IQR) p value 
% Change 
Median (IQR) p value 
41.7 (5.1, 95.0) 25.7 (7.7, 56.3) 0.156 -21.9 (-57.4, 115.7) 0.425 
Receiver Operating Characteristic Curves were constructed to assess how discriminant 
urine IL-18 concentrations at different time-points are for the development of AKI. The 
results are summarised in Figure 29. 
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Figure 29: Receiver Operating Characteristic Curves for urine IL-18 
 
The respective C statistics for urine IL-18 at baseline, 2 h, 4 h and 12-24 h are: 0.416, 
0.485, 0.505 and 0.498. 
 
6.3 Exploratory analysis 
We had found that the Mehran risk score had a C statistic = 0.69 in our study population 
for predicting the development of AKI. We therefore aimed to determine if a combination 
of our biomarkers could improve this further. An exploratory analysis was performed 
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looking at different % rises in our biomarkers at different time points and calculating an 
odds ratio for development of contrast induced AKI. The marker time –points with the 
highest odds ratios are shown in Table 37. 
 
Table 37: Exploratory analysis for % rises in biomarkers 
Variable OR 95% CI p value 
Serum NGAL 4 h 5% change 2.60 1.11 6.11 0.028 
IL-18 urine 2 h 20% change 2.21 1.01 4.82 0.046 
IL-18 urine 2 h 30% change 2.10 0.98 4.51 0.058 
IL-18 urine 12 h 10% change 2.41 0.87 6.64 0.09 
Serum NGAL 4 h 20% change 1.88 0.89 3.96 0.097 
IL-18 urine 2h 5% change 1.90 0.86 4.23 0.114 
IL-18 urine 12 h 5% change 2.24 0.81 6.18 0.119 
IL-18 urine 2 h 10% change 1.75 0.80 3.82 0.16 
Serum NGAL 4 h 10% change 1.70 0.79 3.66 0.179 
Serum NGAL 2 h 10% change 1.62 0.79 3.34 0.188 
Urine NGAL 2 h 20% change 1.68 0.76 3.72 0.201 
We then combined these combinations with the Mehran risk score to see if it improved 
the C statistic further and the results are shown in Table 38. 
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Table 38: Improvement in C statistic on combining The Mehran risk score and 
our biomarker profiles. 
 
N AUC 95% CI 
Mehran risk score only 207 0.65 0.60 0.78 
IL-18 urine 2h 5% & urine NGAL 2h 20% + Mehran risk score 181 0.76 0.67 0.85 
IL-18 urine 2h 20% & urine NGAL 2h 20% + Mehran risk score 181 0.77 0.68 0.86 
IL-18 urine 12h 5% & serum NGAL 4h 10% + Mehran risk score 74 0.74 0.59 0.88 
IL-18 urine 12h 5% & serum NGAL 4h 20% + Mehran risk score 74 0.74 0.60 0.88 
 
Next we added in albumin : creatinine ratio and protein : creatinine ratio data in addition 
to our biomarker results and the Mehran risk score and this resulted in a further 
improvement in the C statistic (Table 39).  
Table 39: Further improvement in C statistic on combining The Mehran risk score 
and our biomarker profiles. 
Biomarkers N AUC 95% CI 
IL-18 urine 2h 5% & NGAL urine 2h 20% + Mehran risk score 
plus albumin:creatinine ratio & protein: creatinine ratio 
180 0.79 0.70 0.87 
IL-18 urine 2h 20% & NGAL urine 2h 20% + CIN score 
plus albumin:creatinine ratio & protein: creatinine ratio 
180 0.79 0.71 0.87 
 
 
The Clinical SYNTAX Score had a C statistic of 0.64 for predicting contrast induced AKI 
in our study population. The results of a similar exploratory analysis combining the CSS 
with our biomarker data are shown in Table 40. 
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Table 40: The Clinical Syntax Score combined with biomarker data 
Biomarker N AUC 95% CI 
Clinical SYNTAX score 136 0.64 0.51 0.78 
     
IL-18 urine 2h 5% & NGAL urine 2h 20% + CSS score 
plus albumin:creatinine and protein: creatinine 
ratio 
117 0.76 0.65 0.88 
     
IL-18 urine 2h 20% & NGAL urine 2h 20% + CSS 
score plus albumin:creatinine and protein: 
creatinine ratio 
117 0.78 0.66 0.89 
 
The addition of the CSS to the biomarker data resulted in further modest improvement in 
the C statistic. 
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6.4 Discussion 
The current Western World epidemics of obesity, diabetes and hypertension are key 
players in the epidemic of combined CKD and cardiovascular disease (1;2;4;498). The 
marked increase in cardiovascular mortality in patients with CKD is often attributed to an 
increased burden of traditional cardiac risk factors such as diabetes, hypertension, 
smoking and dyslipidaemia (105;118). However, patients with CKD have higher rates of 
cardiovascular morbidity and mortality than are predicted by the Framingham model of 
cardiovascular risk (116;117). Other cardiovascular risk factors that have been identified 
to occur more frequently in patients with CKD than in the general population include 
anaemia, abnormal metabolism of calcium and phosphorous, inflammation and oxidative 
stress (103;107). Patients with diabetes and CKD are a particular challenge as they 
have a higher incidence of cardiovascular co-morbidities such as CHD and PVD than 
any other patient group with CKD (128;129). There is therefore frequently a need for 
patients with diabetes and CKD to undergo coronary angiography and PCI procedures. 
These patients are at high risk for developing contrast induced AKI as when renal 
function is already impaired, the kidney is much less able to tolerate the additional stress 
of excreting a contrast load (281). 
It would be extremely useful to identify those patients most at risk early, to allow 
possible therapeutic interventions to be instituted promptly. Possible interventions 
include more intensive i.v. hydration regimes, use of vasodilators such as dopamine, 
fenoldopam, endothelin receptor antagonists and aminophylline (329). To date such 
attempts have been limited as the current ‘gold standard’ biomarker serum creatinine 
does not start to rise until 48-72 hours post the injury event (265). Additionally, 
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serum creatinine levels are influenced by a number of other factors including age, 
muscle mass, hydration and nutritional status (383). Furthermore a rise in serum 
creatinine may not be clinically detectable until almost 50% of renal function has been 
lost. Serum creatinine concentrations are not a reflection of GFR change in the acute 
setting as it takes a period of hours-days to elapse before equilibrium is achieved 
between steady-state production and decreased creatinine excretion (380). A biomarker 
of AKI that is easily measured, unaffected by other biological variables and capable of 
both early detection and possibly also risk stratification would therefore be a major 
clinical advance in improving the care of these patients.  
A review of the literature was performed to identify novel biomarkers that might meet 
these parameters as discussed in sections 1.8 and 1.9. NGAL, IL-18 which are markers 
of structural injury and cystatin C which is a marker of functional renal injury were 
eventually selected. The aim was to identify a ‘renal injury risk panel’ in a similar manner 
to the well-established panel for identifying myocardial injury of creatinine kinase, 
creatinine kinase-MB and troponin. 
These 3 renal injury markers were chosen for a number of reasons. The available data 
suggested that all these markers rise rapidly following renal injury and therefore might 
facilitate earlier identification of patients at risk prior to hospital discharge, rather than 
having to bring patients back 48 - 72 hours following the procedure as is current 
practice. NGAL has been shown to rise within 2 hours of renal injury, interleukin-18 
within 4 hours and cystatin C within 8 - 24 hours (401). NGAL has been evaluated as a 
marker of AKI in a wide number of clinical settings including both children and adults 
post cardiac surgery, in the critical care unit and post contrast administration with 
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high accuracy (C statistic 0.78 – 0.99) (401;499;500). However there is very little data 
post contrast administration in patients with CKD (501). Interleukin-18 has been shown 
to be more specific for ischaemic AKI and other forms of acute tubular necrosis and 
does not appear to be affected by pre-renal azotaemia or CKD (380;406;407). From 
review of the medical literature it would appear that IL-18 had not been formally 
evaluated post contrast administration at the time the study commenced enrolment. 
Cystatin C has demonstrated excellent accuracy for predicting AKI early, prior to a 
clinical diagnosis being established (sensitivity 0.82, specificity 0.95), but the majority of 
studies have not reported C statistic data (401). Furthermore for both NGAL and cystatin 
C large scale immunoassays which can be performed in clinical laboratories have been 
developed, potentially allowing rapid translation of research methodologies into clinical 
practice (444;502).  
208 patients with diabetes and CKD undergoing coronary angiography or PCI at The 
London Chest Hospital between 14th August 2009 and 26th July 2010 were recruited. 39 
patients developed AKI at day 3. One patient required haemodynamic support with 
inotropes but no patients required renal replacement therapy in the form of dialysis or 
filtration.  
ROC curve analysis does not suggest that either NGAL or IL-18 are particularly 
beneficial markers in isolation, for identifying contrast induced AKI in a population with 
diabetes and CKD as our best C statistic for accurately detecting AKI was from serum 
NGAL 0.634 on a serum sample 2 h post procedure. Although a number of studies have 
reported on both serum and urine NGAL as a biomarker post contrast administration 
with higher accuracy (up to a C statistic of 0.92), these have been in very 
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homogeneous populations such as children undergoing coronary angiography 
(420;503). More heterogeneous populations similar to that described in this thesis have 
been evaluated such as adults undergoing cardiac surgery. Wagener et al showed that 
urine NGAL had a sensitivity of 0.68 and specificity of 0.69 in identifying ischaemic renal 
injury in patients post bypass surgery (400). Nickolas et al reported that in an adult 
population presenting to the emergency department, urine NGAL had a sensitivity of 
0.87 and specificity of 0.97 for identifying development of AKI (504). I was unable to 
identify any other studies in the medical literature reporting a C statistic for IL-18 post 
contrast administration. 
Very few studies in the literature have evaluated NGAL as a marker post contrast 
induced AKI in adult populations. These have all been very small studies and 3 of the 4 
come from a single research group in Poland. Of the Polish studies there are some 
methodological limitations and these are described below.  
The first study of 35 patients undergoing elective PCI excluded patients with CKD but 
included 12 patients with diabetes (505). Serum and urine NGAL were measured at 
baseline, 2 hours, 4 hours, 12 hours, 24 hours and 48 hours following PCI. The authors 
reported a significant rise in serum NGAL 2 hours and 4 hours following PCI and in urine 
NGAL 4 hours and 12 hours following PCI. They also found that baseline serum NGAL 
levels were significantly higher in patients with diabetes than in non-diabetics. However 
none of the patients in this study developed contrast induced AKI, that is to say the rise 
in NGAL concentrations was not associated with a rise in creatinine. The study used 2 
different contrast agents, one a LOCM (n = 28) and one HOCM (n =7) with no 
explanation given and the actual agents used were not identified.  
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The second study (n = 92), was described as evaluating NGAL in a population with CKD 
(501) although diabetic patients were excluded. However 52 of the patients included had 
an eGFR ≥ 60 ml/min, with only 15 patients included with an eGFR < 30 ml/min. The 
authors showed a relationship between baseline NGAL levels and serum creatinine 
concentrations. The patients included were all due to undergo coronary angiography but 
no procedural data are given and no data on rates of contrast induced AKI.  
The third study (n = 140) included patients with diabetes (n = 70) but excluded patients 
with CKD (414). 2 different contrast agents were used in this study IOCM, iodixanol in 
24 patients and LOCM, Iopromide in 116 patients. There are also conflicting data about 
the cessation of nephrotoxic drugs. It is stated early in the manuscript that all 
nephrotoxic medications were discontinued for 1 week prior to the procedure. 
Subsequently the authors state that agents such as metformin, diuretics and NSAIDs 
were discontinued 24 h prior to procedure. ACE inhibitors were either withdrawn at this 
time (if blood pressure permitted) or dosage halved. All patients received 2 litres of i.v. 
hydration in the peri-procedure period although the exact regime is not specified. The 
authors defined contrast induced AKI as a rise in serum creatinine of 25% from baseline 
and reported prevalence of 10% in non-diabetics and 14% in diabetics. Serum NGAL 
levels correlated with baseline creatinine and eGFR and were significantly elevated 2 
hours following contrast administration in patients who developed AKI. Urine NGAL was 
significantly higher in patients who developed AKI 4 hours following the procedure. The 
authors also evaluated a number of other biomarkers including serum cystatin C and 
serum and urine IL-18. A significant rise in serum cystatin C was seen at 8 hours and 24 
hours following the procedure. IL-18 apparently followed a similar pattern to cystatin C 
although no data were given for separate serum and urine values. These data are 
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difficult to interpret as actual p values are not given and no data on how the biomarkers 
performed compared to creatinine are provided.  
A final study from China has evaluated urine NGAL and IL-18 as markers of contrast 
induced AKI following coronary angiography procedures. 40 patients, of whom 
approximately 15% had diabetes were included in this study, all received LOCM, 
Iopamidol. A rate of contrast induced AKI (defined as a rise in serum creatinine of > 25% 
from baseline or an absolute rise of 44.2 µmol/l) of 8.7% was reported. The mean 
baseline eGFR was 91.8 ml/min in the patients who developed AKI compared to 113.8 
ml/min in the patients who did not develop AKI. For coronary angiography the mean 
contrast dosage was high at 155.4 ml and 111.9 ml respectively. Urine IL-18 and NGAL 
levels were measured 24 hours post procedure and were shown to be significantly 
increased in the patients who developed AKI (p < 0.05). The C statistic for urine IL-18 
was 0.749 and for urine NGAL 0.734, demonstrating good performance in diagnosing 
AKI at 24 hours post procedure. Patients were followed up for at least 17 months and 
assessed for major adverse cardiac events (MACE) including death and MI. Urine IL-18 
was shown to be an independent predictor of late MACE, relative risk = 2.09 (p < 0.01). 
The value of these markers probably best lies as part of a ‘renal injury risk panel’. From 
exploratory analysis we identified the highest odds ratios for predicting AKI and by 
combining with the Mehran risk score we were able to further improve the C statistic to 
0.77. Combining these data with urine albumin : creatinine ratio and protein : creatinine 
ratio improved this further to 0.79. However it could be argued that the Mehran risk 
score alone has reasonable discriminatory ability to identify patients with AKI in the 
study population with a C statistic of 0.69 and therefore are our biomarkers truly 
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adding benefit? One of the limitations of ROC analysis is that even biomarkers which 
can be shown to be effective, as independent predictors of an outcome when using 
logistic regression may struggle to show much increase in the AUC or C statistic of the 
ROC curve when the AUC for the previously used measurement was already high. This 
is discussed in more detail in the next section along with suggestions for further work. 
Limitations of the Study and Further Work 
There are some important limitations of NGAL as a biomarker of renal injury in our study 
population. NGAL has been shown to be expressed in atherosclerotic plaques (506) 
which may influence serum measurements and possibly be a confounder in patients 
with coronary artery disease. Furthermore serum measurements may be influenced by a 
number of other variables including chronic hypertension, CKD and anaemia 
(402;444;501;507). As described above serum creatinine concentrations correlate with 
NGAL levels and therefore CKD may act as a confounding variable. Finally defining AKI 
based on serum creatinine has limitations as it sets the biomarker assay for lack of 
accuracy due to either false positives (true tubular injury but no change in serum 
creatinine) or false negatives (absence of tubular injury but elevation in serum creatinine 
caused by e.g. pre-renal effects). 
Patients undergoing coronary angiography and PCI are not usually catheterised (unlike 
patients post CABG). There are therefore problems with the accuracy of timing of urine 
samples. Furthermore hydration status and use of medications such as diuretics may 
also influence biomarker concentration. Although we attempted to correct for the 
possibility of urine dilution by reporting urine NGAL and IL-18 samples adjusted for 
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urine creatinine concentration, this may be inaccurate in the AKI setting due to the 
abnormal creatinine kinetics known to occur in the early stages of AKI (508). 
The use of ROC curves and logistic regression is well established when testing 
biomarkers for their relationship with disease status and clinical outcomes (509). 
However, there are limitations to this approach, especially when attempting to use a new 
biomarker measurement to complement an established diagnostic test (510). 
One of these limitations is that even biomarkers which can be shown to be an effective, 
independent predictor of an outcome when using logistic regression may not show much 
increase in the AUC or C statistic of the ROC curve when the AUC for the previously 
used measurement was already high. In many ways this is not a surprising result, since 
a predictive model which performs well will generally be harder to improve upon (511). 
Given this, other approaches have been suggested for determining how well a predictive 
model performs (510;511). One method is to check the calibration of the model with 
regards to the predicted and observed rates of disease or events. After running a logistic 
regression model, the predicted probability of the outcome can be calculated for each 
individual, based on the coefficients from the model and the observed values of those 
variables for the individual. A predicted probability of 0 would mean the logistic model 
believed that individual had no chance of experiencing the outcome event, whilst a 
probability of 1 would mean they were thought to be certain to experience it. To check 
the model calibration one can then compare the observed and predicted event rates in 
different subgroups of our population. A common method is to split the population up 
into quartiles or quintiles, based on predicted risk, and then compare the level of 
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predicted risk in this group with the observed event rate. If the two values are similar in 
each subgroup then the model can be thought to be well calibrated (509). 
Another method that can be used are reclassification tables and the net reclassification 
improvement (NRI) (510;511). Using this technique, individuals are again put into groups 
based on their predicted probabilities, firstly using the existing diagnostic tool. The 
model is then rerun with the additional biomarker, with the grouping process repeated. It 
is then possible to calculate what percentage of individuals who did not have an event 
were reclassified into a lower risk group, and how many who did have an event had their 
risk group increased. The two percentages are then summed to give the NRI, with 
higher values indicating the new model was better as reclassifying individuals correctly. 
These methods are still relatively new, and not yet commonly seen in papers looking at 
risk prediction. However, they may present further opportunities for biomarker testing in 
this population in any future studies.  
The risk model that was identified on ROC analysis, (namely combining the Mehran 
score with NGAL and IL-18 to predict development of AKI) will need to be re-evaluated 
in a separate cohort prospectively to support the conclusions I have made from the 
development phase. Time constraints did not allow this to be performed as part of the 
body of work presented in this thesis but this can be validated by other members of the 
department. 
Due to time constraints on the study the cystatin C assays have not yet been performed. 
However it is intended that this work will be completed in our department in the next few 
months. Furthermore this work was planned as a long term programme of clinical 
research and the original ethics application covered a number of other biomarkers 
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discussed in section 1.9 including L-FABP, KIM-1 and NAG. Analysis of all of these was 
outside the scope of this PhD thesis. We now have a library with multiple aliquots of 
plasma, serum and urine for each patient, stored at -80 °C. As further putative 
biomarkers are identified in the medical literature we have an available library on which 
to assess their accuracy in patients with diabetes and CKD. 
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Chapter 7: Discussion 
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Chapter 7: General Discussion 
 
The Western World is in the middle of a worldwide epidemic of diabetes (1;2;512). 
Diabetes is one of the main risk factors for the development of coronary artery disease. 
Once coronary artery disease has developed these patients are then at high risk for 
developing ACS (17-19). From the Framingham study (10) it is well recognised that 
even after adjusting for other factors, diabetic patients have higher mortality rates and 
also a higher incidence of reinfarction in both the acute and post-infarct setting. Patients 
with diabetes and CKD are a particular challenge as they have a higher incidence of 
cardiovascular morbidities and mortalities than any other patient group and as a 
consequence of this, frequently need to undergo coronary angiography and PCI 
procedures (7;13;443). However when renal function is impaired by pathological 
processes, the kidney is far less able to tolerate the additional stress of excreting a 
contrast load (281), rendering these patients at particular risk for developing contrast 
induced AKI.  
Contrast induced AKI has received increasing recognition in the last few years as a 
result of increased understanding of its pathogenesis, possible new innovations in 
prevention and recognition that development of contrast induced AKI is associated with 
long term adverse events (268;269;278;283). It is the third most common cause of 
hospital acquired renal insufficiency after impaired renal perfusion and use of 
nephrotoxic medications (266). Coronary angiography and PCI are associated with the 
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highest rates of contrast induced AKI out of all procedures utilising contrast media (266).  
The definition of contrast induced AKI requires 3 necessary components (310): (i) an 
absolute or relative increase in serum creatinine compared to baseline values, (ii) a 
temporal relationship between the rise in serum creatinine and exposure to a contrast 
agent and (iii) exclusion of an alternative explanation for renal impairment. The definition 
most widely used in the literature was used in this study: that is a relative increase in 
serum creatinine of 25% or more from baseline or an absolute rise of 0.5 mg/dl (44.5 
µmol/l) (273). As discussed in section 1.4.2, the use of different definitions of contrast 
induced AKI has led to difficulties in comparing the results of studies in the literature. 
The advent of new proposed classifications of AKI such as the RIFLE and AKIN criteria 
(242;243;513) may complicate this further, so it will be important that any future studies 
incorporate standardised definitions as well to facilitate comparison of data. 
The increased incidence of adverse events following contrast induced AKI has primarily 
been derived from retrospective analyses of large databases or observational studies of 
patients who have undergone coronary angiography or PCI (268;278;281). ‘A cause and 
effect’ relationship cannot be derived from non-randomised studies. Patients with 
multiple cardiovascular risk factors prior to exposure to contrast media may be more 
likely to develop contrast induced AKI and independent of this may have more long term 
adverse events. The converse may also be true – that is to say the occurrence of 
contrast induced AKI may in some as yet undefined way alter the likelihood of adverse 
events. In other words, contrast induced AKI is on a pathophysiologic pathway that 
results in the development of adverse events (232). 
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Prospective randomised clinical trials allow the assessment of causal relationships. If 
there exists a causal association between long term adverse events and contrast 
induced AKI then a strategy that prevents AKI should reduce long term adverse events, 
as long as the strategy itself does not alter any other risk factors for those adverse 
events. In a randomised trial of 2 different treatments such as 2 different contrast agents 
or i.v. fluids vs. haemofiltration, the assumption is that the baseline risk factors for long 
term adverse events will be equally distributed between the 2 treatments being tested. 
Differences in the incidence of contrast induced AKI, if paralleled by differences in long 
term adverse events, would suggest that contrast induced AKI is part of a 
pathophysiologic pathway that leads to the development of those adverse events.  
Marenzi et al assessed 2 different haemofiltration protocols compared to i.v. fluid 
therapy in 92 patients with CKD undergoing coronary angiography. They showed that a 
strategy of pre and post procedure haemofiltration was not only associated with a 
significantly lower rate of contrast induced AKI (3% vs. 40% in the control group, p = 
0.013) but also significantly lower in-hospital mortality (0% vs. 20% in controls, p = 
0.03). The possibility that contrast induced AKI is associated with increased 
cardiovascular and renal events is further supported by recent data from Solomon et al 
(232;291). 294 patients with moderate to severe CKD undergoing coronary angiography 
were randomised to 2 different contrast media: LOCM non-ionic Iopamidol or IOCM non-
ionic iodixanol. Rates of long term adverse events were significantly higher in patients 
who developed AKI. Both these studies used a definition of AKI of an increase in serum 
creatinine > 25% from baseline. Further data from trials which are currently enrolling 
should provide further evidence (514).  
 
228 
It would be extremely useful to identify patients at high risk for the development of 
contrast induced AKI early, to allow possible therapeutic interventions to be initiated 
promptly. Possible interventions include more intensive i.v. hydration regimes, use of 
vasodilators such as dopamine, fenoldopam, endothelin receptor antagonists and 
aminophylline (329). Such attempts to date have been limited as the current ‘gold 
standard’ biomarker serum creatinine does not start to rise until 48-72 hours post the 
injury event (265). Furthermore serum creatinine concentrations are influenced by a 
number of other factors including age, muscle mass, hydration and nutritional status 
(383). Additionally a rise in serum creatinine may not be clinically detectable until almost 
50% of renal function has been lost and serum creatinine concentration may not be a 
reflection of acute GFR change in the acute setting since a period of hours-days must 
elapse before equilibrium between steady-state production and decreased creatinine 
excretion is achieved (380). A biomarker of AKI that is easily measured, unaffected by 
other biological variables and capable of both early detection and also risk stratification 
would therefore be a major clinical advance in improving the care of such patients. This 
concept led to the development of the study described in this thesis assessing novel 
biomarkers in patients with diabetes and CKD. This population was chosen because as 
discussed in section 1.6.4 they are an extremely high risk population for the 
development of contrast induced AKI (286). 
The rationale for the choice of biomarkers has already been described in sections 1.9 
and 6.4. Briefly, a literature review was performed to identify novel biomarkers that might 
meet the criteria described above. From this NGAL and interleukin-18 which are 
markers of structural renal injury and cystatin C which is a marker of functional renal 
injury were identified as promising candidates. These 3 markers were chosen for a 
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number of reasons. The available data at the time suggested that these markers all rose 
rapidly following renal injury and therefore might facilitate identification of patients at risk 
of contrast induced AKI prior to hospital discharge rather than having to bring back 
patients at 48-72 hours following the procedure as is current practice. NGAL had been 
shown to rise within 2 hours of renal injury, interleukin-18 within 4 hours and cystatin C 
within 8-24 hours (401). NGAL has been evaluated as a marker of kidney injury in a 
wide number of clinical settings including post cardiac surgery, critical care and post 
contrast administration and has been shown to have high accuracy for detecting AKI 
(383;499;500). The data post contrast administration have involved very small studies 
with some methodological concerns (414;420;501;505). Interleukin-18 had been shown 
to be more specific for ischaemic AKI and other forms of acute tubular necrosis and did 
not appear to be affected by pre-renal azotaemia or CKD (245;380;515). 2 small studies 
had evaluated IL-18 post contrast administration with some promising data although not 
in a population with CKD (414;420). Cystatin C had demonstrated excellent accuracy for 
predicting AKI early prior to a clinical diagnosis being established (409). Interpretation as 
to its accuracy as a biomarker of AKI was limited as the majority of studies had not 
reported c statistic data(401). The availability of large scale immunoassays for NGAL 
and cystatin C meant that the potential existed for rapid translation of research 
methodologies into clinical practice (444;502).  
Chapter 3 described the baseline demographics and procedural data of the population 
studied in detail. 208 patients with diabetes and CKD undergoing coronary angiography 
or PCI at The London Chest Hospital were recruited between 14th August 2009 and 26th 
July 2010. 39 patients (18.8%) developed AKI. One patient required haemodynamic 
support with inotropes but no patients required renal replacement therapy in the form 
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of dialysis or filtration. The study included a high proportion of patients of South Asian 
origin reflective of the demographics of the local population. These patients are known 
to be at high risk for development of diabetes, CKD and CHD with these conditions often 
co-existing in the same patients (433-436).  
Rates of use of ACE inhibitors and AIIRBs was high in the study population (Table 19), 
as would be expected. At the time of the study the hospital guidelines suggested that 
continuation of these agents should be considered on a case by case basis (331) (see 
Appendix). A detailed discussion of the available literature was performed in section 3.8 
and overall would appear to favour cessation of these agents at least 2 days prior to 
procedures involving the use of iodinated contrast media (315;460-464) . However it is 
recognised that the majority of these data came from small case series and post hoc 
analyses and therefore there is a need for large scale randomised clinical trials to 
address this definitively. 
Both symptomatic (NYHA Class, section 3.2) and objective data from imaging (section 
3.5) showed that there was a higher proportion of patients with moderate to severe LV 
dysfunction who developed AKI. Whilst not unexpected this highlighted parts of clinical 
practice that might need to be reviewed such as usage of ACE inhibitors/AIIRBs at time 
of procedure and also the ‘routine’ performance of LV grams in patients at high risk for 
contrast induced AKI. These have been incorporated into my recommendations as to 
the optimal management of these patients when undergoing coronary angiography or 
PCI described later in this chapter.  
The study provided further supporting evidence that co-prescription of diuretics with 
ACE inhibitors or AIIRBs in patients with renal artery stenosis should be avoided. 
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Although the data were limited as no physiological assessment of lesion severity was 
performed, it did provide further data supporting the discontinuation of ACE 
inhibitors/AIIRBs prior to procedure. It also identified 7 patients with moderate to severe 
renal artery stenosis who were referred to our nephrology colleagues for further 
assessment and optimisation. 
Although our ROC curve analysis did not suggest that either NGAL or IL-18 are 
particularly accurate markers in isolation for predicting AKI (Chapter 6), it was extremely 
interesting to see how well simple scoring systems can work in identifying patients at 
high risk for contrast induced AKI. The Mehran risk score described in 1.6.4.7 is a 
simple model that can be easily calculated at the time of procedure and had a good 
accuracy in identifying high risk patients with a C statistic of 0.69 in our study population. 
Advantages of this scoring system are that it takes minutes to perform and does not 
require any specialist training. It can also be adapted to allow use in the pre-admission 
setting by either using a fixed ‘average’ volume of contrast such as 100 ml for a 
coronary angiogram and 200 ml for a PCI; or alternatively estimating the volume of 
contrast used from the baseline GFR as described in section 1.6.4.4 since it has been 
suggested that these patients should not have a contrast volume used in their procedure 
that is greater than twice the value of the baseline eGFR (307). The Clinical SYNTAX 
Score performed similarly well in identifying patients at high risk for contrast induced AKI 
with a C statistic of 0.64. This has not been reported in the literature previously and 
although this scoring system is more complex and time consuming, with definite training 
required and intra-observer variability (as described in section 4.4.3), it provides 
additional useful information on the complexity of a patients coronary artery disease. 
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Whilst the CSS may be limited in clinical practice due to the problems outlined 
previously it will remain a useful research tool for risk - stratifying patients. 
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Possible amendments to the current hospital guidelines for 
patients at risk of contrast induced acute kidney injury 
From the new data available in the literature and from the work described in this thesis I 
have identified a number of areas to be considered for inclusion at the next review of the 
hospital guidelines for prevention of contrast induced kidney injury and these are listed 
below: 
1.  i.v. hydration and oral N-acetylcysteine to be prescribed to all patients with 
eGFR < 60 ml/min. i.v. hydration with 0.9% sodium chloride for a minimum of 2 
hours prior to procedure. Careful evaluation of oral intake and urine output post 
procedure with a low threshold for further post-procedure hydration. N-
acetylcysteine 600 mg po bd for 24 hours prior and 24 hours post procedure. 
2. Nephrotoxic medications such as ACE inhibitors, AIIRBs and diuretics to be 
discontinued at least 48 hours prior to procedure. Metformin can be discontinued 
at the same time point. If necessary for blood pressure control, consider 
increasing other medication dosage temporarily or prescribing an additional 
medication such as a calcium channel blocker, doxazosin or hydralazine. 
Medications to be restarted following a satisfactory day 3 serum creatinine level. 
3. The Mehran risk score to be calculated at pre-admission for elective patients or 
included in the appropriate pro-formas for hospital transfer/unstable patients.  
 
234 
High risk patients (Mehran risk score ≥ 16) to have a minimum of 6 h i.v. 
hydration and case to be performed by a senior operator. 
4. LV gram to be avoided in these patients unless absolutely necessary. Reason for 
performing the LV gram to be stated in the report / included in the cardiac 
catheter lab database. 
Limitations of the Study and Further Work 
Limitations of the study and suggestions for further work have been described in detail 
at the end of each results chapter (Chapter 3, Chapter 4 and Chapter 6). A few 
important points are mentioned here for completeness. 
This was a single-centre study in a highly selected population (diabetes and CKD) 
undergoing coronary angiography and PCI. All procedures were performed in a tertiary 
referral unit at a teaching hospital and therefore there may have been an element of 
selection bias with a tendency to more complex cases being referred from peripheral 
hospitals. The study excluded patients with STEMI. To be truly reflective of real-world 
clinical practice it would be important for these patients to be included in further studies. 
A pragmatic approach to i.v. hydration has been taken with the current guidelines in 
order to ensure efficient use of both hospital beds and laboratory time and work flow. If 
the suggested recommendations to the current renal guidelines were incorporated it 
would be interesting to audit the average length of stay of patients. It may be that by risk 
stratifying the patients, with those at most high risk having more intensive i.v. hydration 
with possibly pre-admission the night before that this significantly decreases the 
 
235 
rates of contrast induced kidney injury. This may be reflected in overall shorter 
admissions with lower rates of readmission. 
Although all patients were invited back to The London Chest Hospital for a day 3 blood 
test, a number were not able to attend for logistical reasons and therefore their results 
were obtained from their local hospital or GP. This may have led to lack of correct 
identification of all cases of contrast induced AKI.  
Patients in this study were only formally followed-up until Day 3 post procedure. Since 
contrast induced AKI has been shown to be associated with other adverse events, it 
would be extremely interesting to follow up these patients for a longer time period to 
further characterise this high risk population.  
The Mehran risk score has a number of limitations including in particular the lack of any 
data on hydration (discussed in section 4.4.2). Other parameters that could be 
investigated for inclusion in further studies include the presence of proteinuria, urine 
output and nephrotoxic medications. 
The NGAL and Interleukin-18 biomarker data were perhaps disappointing given the 
interest there has been in these in the medical literature. However if markers cannot 
identify accurately high risk patients then their usage in clinical practice is going to be 
severely limited. It may be that combination of these tubular markers with a marker of 
glomerular injury such as cystatin C may improve the diagnostic performance. It is 
intended that the cystatin C assays will be completed in the department in the next few 
months. Finally the model developed in the work presented in this thesis for predicting 
AKI (urine NGAL, IL-18 and the Mehran risk score) requires prospective validation in 
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a separate cohort. From the work in this thesis a library with multiple aliquots of plasma, 
serum and urine has been collated and stored at -80 °C for each patient. As further 
putative biomarkers are identified in the medical literature this will facilitate rapid 
assessment of their accuracy in a cohort of patients with diabetes and CKD. 
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NYHA Classification 
The New York Heart Association (NYHA) Functional Classification provides a 
simple means of classifying the extent of heart failure (516). It places patients into 
one of four categories based on the degree of limitation during physical activity; the 
limitations/symptoms are in regards to normal breathing and varying degrees in 
shortness of breath and or angina pain and are classified as follows: 
NYHA I  No symptoms and no limitation in ordinary physical activity, e.g. 
shortness of breath when walking, climbing stairs etc. 
NYHA II  Mild symptoms (mild shortness of breath and/or angina) and slight 
limitation during ordinary activity. 
NYHA III  Marked limitation in activity due to symptoms, even during less-than-
ordinary activity, e.g. walking short distances (20–100 m). Comfortable only at rest. 
NYHA IV  Severe limitations. Experiences symptoms even while at rest. Mostly 
bedbound patients. 
CCS Classification 
The Canadian Cardiovascular Society (CCS) Angina grading scale (517) is 
commonly used to classify the severity of angina symptoms: 
Class I – Angina only during strenuous or prolonged physical activity 
Class II – Slight limitation, with angina only during vigorous physical activity 
Class III – Symptoms with everyday living activities, i.e., moderate limitation 
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Class IV – Inability to perform any activity without angina or angina at rest, i.e., 
severe limitation 
Haemoglobin A1c conversion 
To convert from the well-known Diabetes Control and Complications Trials (DCCT) 
units of % to the International Federation of Clinical Chemistry (IFCC) units of 
mmol/mol use the following equation (438):  
IFCC-HbA1c (mmol/mol) = [DCCT-HbA1c (%) - 2.15] × 10.929 
For simplicity some common values are tabulated below:  
DCCT HbA1c (%) IFCC HbA1c (mmol/mol) 
4 20 
5 31 
6 42 
6.5 48 
7 53 
7.5 59 
8 64 
9 75 
10 86 
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Cockcroft Gault Formula 
This estimates Creatinine clearance (eCCr) in ml/min as follows: 
 
Where Constant is 1.23 for men and 1.04 for women (220) 
 
Modification of Diet in Renal Disease (MDRD) Formula 
The most commonly used formula is the ‘4-variable MDRD,’ which estimates GFR 
using four variables: serum creatinine, age, race, and gender. This uses the 
following equation (creatinine µmol/l)(221): 
eGFR = 32788 X Serum creatinine-1.154 x Age-0.203 x [1.212 if Black] x [0.742 if 
Female] 
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Barts and The London Heart Centre Guidelines for the 
Prevention of Contrast Nephropathy in Patients Undergoing 
Coronary Angiography or Angioplasty 
 
The guidelines are included overleaf. 
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Introduction 
 
Patients undergoing exposure to intravenous contrast are at risk of developing contrast 
nephropathy.  Patients with contrast nephropathy have an adverse prognosis and in those 
that go on to require dialysis the prognosis is very poor.   The main risk factors for 
contrast nephropathy are: 
 
 Renal impairment (creatinine clearance <50ml/min) 
 
 Dose of intravenous contrast 
 
 Diabetes mellitus + renal impairment (diabetes with normal renal function is not a risk) 
 
 Age >70 years 
 
 Co-administration of nephrotoxic drugs 
 
 Volume depletion 
 
 
The principal risk factor is the degree of renal impairment.  Patients with a creatinine 
clearance of >50 ml/min do not require special measures and can be treated with free 
clear oral fluids prior to the procedure.  There is evidence that patients with creatinine 
clearance  50 ml/min benefit from specific measures to reduce the risk of contrast 
nephropathy.  These are: 
 
 Intravenous hydration therapy with normal saline or sodium bicarbonate (most protocols 
state 12 hours pre and post – shorter durations have not been studied) 
 
 The use of iso-osmolar contrast agents 
 
 N Acetyl cysteine  (evidence of benefit is weaker and controversy surrounds its use, but it 
is well tolerated and non-toxic) 
 
The evidence base for all of these measures is not of the highest quality and we have 
interpreted the evidence, in collaboration with our renal colleagues, to maximise both 
patient protection and operational effectiveness of the unit. 
 
 
Iso-osmolar contrast agents should be used in all patients 
 
 
 
Before Procedure 
 
The creatinine clearance for all patients undergoing angiography or 
angioplasty must be known 
 
This will normally be provided direct from the biochemistry laboratory.  If it is not, then 
it can be calculated using the Cockcroft-Gault formula (see appendix 1).   If for any 
reason only the serum creatinine is available then a threshold for treatment of 120 can be 
used (this is NOT ideal and the degree of renal impairment may be underestimated in, for 
example, small elderly females with apparently ‘normal’ serum creatinine).   
 
n.b. Estimation of renal function is not necessary prior to true emergency procedures 
such as primary PCI for acute STEMI 
 
 
Patients with Creatinine Clearance > 50ml/min  
 
 No special measures. Free clear fluids until procedure.   
 
 
Patients with Creatinine Clearance   50ml/min 
 
 If the patient is under the care of a renal physician then they should be consulted for 
advice before the procedure if possible  
 
 Stop potentially nephrotoxic drugs if possible (e.g. NSAID’s, ACE-inhibitors) 
 
 IV fluid hydration 
1 litre of 0.9% sodium chloride starting at least 2 hours prior to the procedure, 
over an 8 hour period.  In addition, free access to clear oral fluids should be 
available before and after the procedure. 
 
 Oral N-Acetylcysteine 
600mg orally twice daily for a total of 4 doses. The first dose should be taken at 
least 2 hours before the procedure.  N-Acetylcysteine (NAC) should be 
administered orally as sachets. These must be dissolved in water before 
administration and three sachets are needed for each 600mg dose (200mg per 
sachet). At the time of writing, NAC sachets are unlicensed in England and 
obtained as a “named patient” item, so the name of each patient receiving them 
must be recorded.  Drug interactions, contraindications, precautions and adverse 
effects of NAC are listed in appendix 2. 
 
 
 
 
 
 
 
 
During Procedure 
 
 
Patients with Creatinine Clearance > 50ml/min  
 
 No special measures.  
 
 
Patients with Creatinine Clearance  50ml/min 
 
 Use contralateral femoral artery if renal transplant in situ 
 
 Consider carefully the need for left ventriculography 
 
 Limit contrast dose as far as possible 
 
 
 
After Procedure 
 
 
Patients with Creatinine Clearance > 50ml/min  
 
 No special measures.  
 
 
Patients with Creatinine Clearance  50ml/min 
 
 Continue intravenous hydration as above for a total of 8 hours 
 
 Ensure N-Acetylcysteine is administered as above 
 
 Arrange for repeat creatinine clearance (or serum creatinine) to be measured in 4 days 
and check result. 
 
 Repeat administration of contrast agents should be delayed for at least 10 days unless 
required in an emergency. 
 
 
 
Appendix 1  The Cockroft Gault formula 
 
 
 
For Males: 
 
 
1.23 X (140-age) X Weight (kg) 
Creatinine (mol/l) 
 
 
 
 
 
For Females: 
 
1.04 X (140-age) X Weight (kg) 
Creatinine (mol/l) 
 
 
 
 
The creatinine clearance can be calculated easily on-line using the website 
www.nephron.com.  Other formulas are also available which do not require the body 
weight (e.g. MDRD). 
 
 
 
 
 
 
 
 
Appendix 2 – N-Acetylcysteine 
 
Drug Interactions 
 
 Carbamazepine - Decreased levels (rarely) 
 Glyceryl Trinitrate - Risk of hypotension and increased temporal artery dilation. 
 Tetracycline – NAC impairs absorption. Take at least 2 hours apart. 
 Antitussives – Dangerous congestion of secretions may occur if cough reflex is impaired. 
 
 
Contraindications and precautions 
 
 NAC is contraindicated in patients with hypersensitivity or previous anaphylactic reaction to 
NAC. 
 Use with caution in asthmatic patients. 
 Use with caution in patients with a history of peptic ulcereration (because drug induced 
nausea and vomiting may increase risk of GI haemorrhage) 
 Use with caution in pregnancy and lactation. For further information contact a specialist 
physician or Medicines Information on extension 14-7487/7489. 
 In the case of patients with the hereditary metabolic disease phenylketonuria, it should be 
noted that NAC sachets contain aspartame (25mg in each sachet – equivalent to 14mg 
phenylalanine). 
 Patients who suffer from the rare hereditary fructose intolerance should not take this 
medicine, as it contains sorbitol, and sorbitol is converted to fructose. 
 When treating diabetic patients, it should be noted that about 0.7g carbohydrate is supplied as 
sorbitol per sachet of granules. 
 
 
Possible Adverse Effects 
 
 Nausea, vomiting and other GI symptoms. 
 Hypersensitivity reactions including bronchospasm, pruritis, rashes, angioedema, 
hypertension and hypotension 
 Rarely: 
o Flushing 
o Sweating 
o Liver function disturbances 
o Syncope  
o Blurred vision 
o Seizures  
o Tachycardia 
o Mild fever  
o Arthralgia 
o Acidosis  
o Cardiac or respiratory  
o arrest  
o Generalised urticaria 
o Stomatitis 
o Tinnitus 
 
 
 
  
 
 
  
 
Corrected Calcium 
The amount of total calcium varies with the level of serum albumin, a protein to which 
calcium binds. The biologic effect of calcium is determined by the amount of ionized 
calcium, rather than the total calcium. When albumin levels are abnormal a corrected 
calcium can be derived: 
Corrected calcium (mmol/L) = measured total calcium (mmol/L) + 0.02 (40 - 
serum albumin [g/L]),  
 
where 40 represents the average albumin level in g/L 
i.e. each 1 g/L decrease of albumin, will decrease 0.02 mmol/L in measured serum 
calcium and thus 0.02 must be added to the measured value to take this into account 
and get a corrected calcium. When there is hypoalbuminaemia (a lower than normal 
albumin), the corrected calcium level is higher than the total calcium. Most clinical 
laboratories in the United Kingdom report the corrected value alongside the serum 
calcium automatically. 
 
  
Syntax Score Algorithm Definitions 
 
(Adapted from Sianos et al EuroIntervention 2005 (421)). 
  
Patient CRF and Patient Information Sheet 
These are included overleaf: 
 
BIOMARKERS Pt ID: __ __ __ __ __ __ 
 
  Page 1 of 12 
PATIENT DETAILS 
 
1 Patient’s name:   
      
2 Hospital / Unit number:   
      
3 Address:   Street:   
      
4 City:   
      
5 Postal code:   
      
6 Country:   
      
7 Telephone number:   
    
8 NHS Number:   
 
DETAILS OF NEXT OF KIN 
 
9 Relative or friend name:   
      
10 Address:   Street:   
      
11 City:   
      
12 Postal code:   
      
13 Country:   
      
14 Telephone number:   
 
 
FOLLOW-UP SCHEDULE 
 
15 Date of consent  __ __ / __ __ /__ __ __ __ Done 
      
16 Date of procedure  __ __ / __ __ /__ __ __ __ [    ] 
      
17 Date of planned 3 day follow-up  __ __ / __ __ /__ __ __ __ [    ] 
 
Instructions, definitions and reminders: opposite page: 2  
 
 
 
♥ Ethnicity 
1 Caucasian 
2 South Asian 
3 East Asian 
4 Afro Caribbean 
5 African 
6 Other 
 
♥ Smoking history 
1. Current smoker (within past 3 months) 
2. Ex-smoker (stopped smoking for greater than 3 months) 
3. Never smoked 
 
♥ History of Hypertension: - Blood pressure > 130/85 untreated 
 
♥ History of Hyperlipidaemia: - Total cholesterol > 5.0 untreated 
 
♥ History of Renal Failure: - eGFR < 60 ml/min 
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Baseline Demographics and Medical history 
 
1 Date of assessment (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
      
2 Date of birth (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
      
3 Gender  Male [    ] Female [    ] 
      
4 Ethnicity (Enter code) ♥    
 
DIABETES STATUS 
 
5 Type of diabetes  Type 1 [    ] Type 2 [    ] 
      
6 How is the diabetes treated (tick all that apply)  
[    ]  Insulin 
 
[    ] Oral hypoglycaemic medication 
 
[    ] Diet controlled 
      
7 Date of diagnosis of diabetes (mm/yyyy)  __ __ /__ __ __ __ 
      
8 Diagnosis made on BM on arrival (AMI only)  Yes [    ] No [    ] 
      
9 Smoking history ♥  Current [    ] Ex [    ] Never [    ] 
     
10 Family history of ischaemic heart disease   Yes [    ] No [    ] 
     
11 History of hypertension ♥  Yes [    ] No [    ] 
     
12 If Yes, hypertension treated with medication?   Yes [    ] No [    ] NA [    ] 
     
13 History of hyperlipidaemia ♥  Yes [    ] No [    ] 
     
14 If Yes, hyperlipidaemia treated?   Yes [    ] No [    ] NA [    ] 
     
15 History of renal failure ♥  Yes [    ] No [    ] 
     
16 If Yes, on haemodialysis?   Yes [    ] No [    ] NA [    ] 
     
17 History of cerebrovascular disease  Yes [    ] No [    ] 
     
18 History of carotid artery disease  Yes [    ] No [    ] 
     
19 History of peripheral vascular disease  Yes [    ] No [    ] 
     
20 History of chronic lung disease  Yes [    ] No [    ] 
     
21 Angina   Yes [    ] No [    ] 
     
22 Previous Myocardial Infarction (mm/yyyy)  Yes [    ] __ __ /__ __ __ __ No [    ] 
     
23 Valvular Heart Disease  Yes [    ] No [    ] 
 
Instructions, definitions and reminders: opposite page: 3 
 
 
♥ Type of PCI procedure (enter code): 
1. Elective 
2. Urgent 
3. Emergency  
 
♥ CCS Class 
 
0.  No chest pain:   No limitation of physical activity by pain. 
I.  Pain on moderate exertion:   Ordinary physical activity, such as walking or climbing stairs 
does not  cause angina.  Pain with strenuous, rapid or prolonged exertion. 
II.   Pain limitation of normal daily activities:   Comfortable at rest, but ordinary physical 
activity, such as walking rapidly or climbing stairs, exercise after meals, in wind or cold weather 
causes anginal pain. 
III.   Marked pain limitation of ordinary physical activity:  Pain on walking on the level or 
climbing one flight of stairs. 
IVa.   Unstable: Pain on any activity or rest pain:    Symptom deterioration now controlled on 
additional oral medical therapy. 
IVb.  Unstable: Pain on any activity or rest pain:   Continued pain symptoms despite maximal 
oral medical therapy.  
IVc.  Unstable: Pain on any activity or rest pain:   Continued pain symptoms despite IV 
therapy. 
 
♥ NYHA Class 
 
I.      No objective evidence of cardiovascular disease:    Patients with cardiac disease but 
without resulting limitation of physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnoea or anginal pain. 
II.      Objective evidence of minimal cardiovascular disease:   Patients with cardiac disease 
resulting in slight limitation of physical activity. Comfortable at rest, ordinary physical activity 
results in fatigue, palpitation, dyspnoea or anginal pain. 
III.     Objective evidence of moderately severe cardiovascular disease:   Patients with 
cardiac disease resulting in marked limitation of physical activity. Comfortable at rest, less than 
ordinary physical activity causes fatigue, palpitation, dyspnoea or anginal pain. 
IV.    Objective evidence of severe cardiovascular disease:    Patients with cardiac disease 
resulting in inability to carry on any physical activity without discomfort. Symptoms of heart 
failure or the anginal syndrome may be present even at rest. If any physical activity is 
undertaken, discomfort is increased. 
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CLINICAL EXAMINATION AT BASELINE 
 
1 Height (cm)   __  __  __  
     
2 Weight (kg)  __  __  __ . __  
     
3 Systolic blood pressure (mmHg)  __ __ __  
     
4 Diastolic blood pressure (mmHg)  __ __ __  
     
5 Pulse (bpm)  __ __ __  
     
6 Temperature (°C)  __ __. __  
     
7 Clinical evidence of heart failure  Yes [    ] No [    ] 
      
MODE OF PRESENTATION 
 
     
8 Type of PCI procedure ♥    
     
9 Silent ischaemia  Yes [    ] No [    ] 
     
10 Previous PCI  Yes [    ] No [    ] 
     
11 Previous CABG  Yes [    ] No [    ] 
     
12 CCS class ♥    
     
13 NYHA class ♥    
      
 
Notes 
 
 
 
Instructions, definitions and reminders: opposite page: 4 
 
 
♥ Medications at Baseline:  Please include all medication taken regularly by the patient prior 
to this admission to hospital 
 
♥ Heparin:  LMWH – Low molecular weight heparin; UFH – Unfractionated heparin 
 
♥ Dihydropyridine calcium antagonists: e.g.Nifedipine, Amlodopine 
 
♥ Non - Dihydropyridine calcium antagonists: e.g. Diltiazem, Verapamil 
 
♥ Potassium channel activators: e.g. Nicorandil 
 
♥ Loop diuretics: e.g.Furosemide, Bumetanide 
 
♥ Thiazide diuretics: e.g. Bendrofluazide, Metolazone 
 
♥ Sulphonylureas: e.g. Glibenclamide, Gliclazide, Tolbutamide 
 
♥ Thiazolidinediones: e.g. Pioglitazone, Rosiglitazone 
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MEDICATIONS AT BASELINE♥ 
 
1 Aspirin  Yes [    ] No [    ] 
      
2 Clopidogrel  Yes [    ] No [    ] 
      
3 Warfarin  Yes [    ] No [    ] 
      
4 Other anticoagulant, please specify   Yes [   ] _______________ No [   ] 
      
5 Heparin ♥  LMWH [    ] UFH [    ] No [    ] 
     
6 Beta-blockers  Yes [    ] No [    ] 
      
7 Dihydropyridine calcium-channel antagonists ♥  Yes [    ] No [    ] 
      
8 Non – dihydropyridine calcium-channel antagonists ♥  Yes [    ] No [    ] 
     
9 Nitrates  Yes [    ] No [    ] 
      
10 Potassium channel activators ♥  Yes [    ] No [    ] 
      
11 Lipid lowering agent (tick all that apply)  Statins [    ] Other [    ] No [    ] 
      
12 ACE inhibitors  Yes [    ] No [    ] 
      
13 Angiotensin-II antagonists  Yes [    ] No [    ] 
      
14 Loop diuretics ♥  Yes [    ] No [    ] 
      
15 Thiazide diuretics ♥  Yes [    ] No [    ] 
     
16 Digoxin  Yes [    ] No [    ] 
      
17 Amiodarone  Yes [    ] No [    ] 
     
18 Thyroxine  Yes [    ] No [    ] 
    
19 Metformin  Yes [    ] No [    ] 
    
20 Sulphonylureas ♥  Yes [    ] No [    ] 
    
21 Thiazolidinediones ♥  Yes [    ] No [    ] 
    
22 Insulin  Yes [    ] No [    ] 
    
23 Any other cardiovascular medication  NA [   ] 
      
24 Any other diabetic medication  NA [   ] 
Instructions, definitions and reminders: opposite page: 5 
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BLOOD RESULTS AT BASELINE 
 
1 Random glucose  Yes [    ] __ __ . __ __mmol/L NA [   ] 
      
2 Fasting glucose  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
      
3 HbA1C (units %)  Yes [    ] __ __ . __ __ % NA [   ] 
     
4 HbA1C (units mmol/mol)  Yes [    ] __ __ . __ __ mmol/mol NA [   ] 
     
5 Haemoglobin  Yes [    ] __ __ . __ g/dL NA [   ] 
     
6 White cell count  Yes [    ] __ __ . __ x 10
9
/L NA [   ] 
      
7 Platelets  Yes [    ] __ __ __ . __ x 10
9
/L NA [   ] 
     
8 INR  Yes [    ] __ __ . __ __ NA [   ] 
      
9 CRP  Yes [    ] __ __ __ . __ __ mg/L NA [   ] 
    
10 Sodium  Yes [    ] __ __ __ mmol/L NA [   ] 
    
11 Potassium  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
      
12 Urea  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
      
13 Creatinine  Yes [    ]  __ __ __µmol/L NA [   ] 
      
14 Corrected Calcium  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
      
15 Phosphate  Yes [    ]  __ . __ __ mmol/L NA [   ] 
      
16 Albumin  Yes [    ] __ __   mmol/L NA [   ] 
      
17 ALP  Yes [    ] __ __ __ Units NA [   ] 
      
18 ALT  Yes [    ] __ __ __ Units NA [   ] 
      
19 Creatinine Kinase  Yes [    ] __ __ __ __ NA [   ] 
      
20 Troponin T  Yes [    ] __ __ __ NA [   ] 
     
21 Cholesterol  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
     
22 LDL  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
     
23 HDL  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
      
24 Triglyceride  Yes [    ] __ . __ __ mmol/L NA [   ] 
      
25 Haematocrit  Yes [    ] __ __ . __ % NA [   ] 
      
26 Screening Creatinine  Yes [    ]  __ __ __µmol/L NA [   ] 
      
27 Screening GFR  Yes [    ]  __ __. __ ml/min NA [   ] 
      
Instructions, definitions and reminders: opposite page: 6 
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TIMING OF BASELINE SAMPLES 
 
1 Date of sample (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
      
2 Time sample taken (hh:mm)   __ __ : __ __ 
 
 
 
URINE RESULTS AT BASELINE 
 
 
      
16 Urine : albumin   Yes [    ] __ __ __ . __mg/L NA [   ] 
      
3 Albumin : Creatinine ratio  Yes [    ] __ __ . __ __mmol/L NA [   ] 
      
4 Urine : Creatinine  Yes [    ] __ __ . __ __mmol/L NA [   ] 
      
5 Urine : Protein   Yes [    ] __ __ . __ __g/L NA [   ] 
      
6 Protein : Creatinine ratio  Yes [    ] __ __ . __ __mg/mmol NA [   ] 
      
7 eGFR  Yes [    ] __ __ . __ __ml/min NA [   ] 
      
 
BIOMARKER RESULTS AT BASELINE 
 
SERUM AND PLASMA RESULTS AT BASELINE 
 
   SERUM PLASMA 
8 NGAL  Yes [    ] _ _ . _ _  NA [   ] Yes [    ] _ _ . _ _  NA [   ] 
    
9 Cystatin C  Yes [    ] _ _ . _ _  NA [   ] Yes [    ] _ _ . _ _  NA [   ] 
     
 
URINE BIOMARKERS AT BASELINE 
 
10 NGAL  Yes [    ] __ __ . __ _ NA [   ] 
      
11 Cystatin C  Yes [    ] __ __ . __ __ NA [   ] 
      
12 KIM -1  Yes [    ] __ __ . __ _ NA [   ] 
      
13 Interleukin-18  Yes [    ] __ __ . __ _ NA [   ] 
      
14 NAG  Yes [    ] __ __ . __ _ NA [   ] 
      
15 FAB-P  Yes [    ] __ __ . __ __ NA [   ] 
Instructions, definitions and reminders: opposite page: 7 
 
♥ LV function 
1 Normal 
2 Mild Impairment 
3 Moderate Impairment 
4 Severe Impairment 
 
♥ Appearance of renal arteries 
1 No objective evidence of atherosclerotic disease 
2 Mild atherosclerotic disease 
3 Moderate atherosclerotic disease 
4 Severe atherosclerotic disease 
 
♥ Type of contrast used 
1 Visipaque 
2 Ultravist 
3 Other 
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PROCEDURE DETAILS 
 
1 Date of procedure (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
      
2 AMI  Yes [    ] No  [    ] 
      
3 STEMI
 
 Yes [    ] No  [    ] 
      
4 Staged procedure  Yes [    ] No  [    ] 
      
5 Point of access  Radial [    ] Femoral [    ] 
      
6 LV gram performed  Yes [    ] No  [    ] 
      
7 Echo performed  Yes [    ] No  [    ] 
      
8 If Yes, date of echo (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
      
9 If Yes, Ejection fraction (%)   __ __  
      
10 LV function ♥     
      
11 Renal angiogram  Yes [    ] No  [    ] 
      
12 Appearance of renal arteries ♥    
      
13 N-acetylcysteine pre-procedure  Yes [    ] No  [    ] 
      
14 Intravenous fluids pre-procedure  Yes [    ] No  [    ] 
      
15 Total procedure time (minutes)  __ __ __  
      
16 Fluoro time (minutes)  __ __ __  
      
17 Type of contrast used ♥    
      
18 Volume of contrast used (ml)  __ __ __  
      
19 IABP inserted  Yes [    ] No  [    ] 
       
RISK SCORING 
 
20 SYNTAX Score    
      
21 CIN Score    
      
22 Risk CIN  __ __ %  
      
23 Risk of haemodialysis  __ __ . __ __ %  
      
24 Procedure performed  Angio [    ] PCI [    ] Both [    ] 
       
 
Instructions, definitions and reminders:     opposite page: 8 
 
 
 
 
 
 
 
 
    SYNTAX SCORE segment numbers 
 
 Give the TIMI flow at the beginning and end of PCI  
 procedure – select one only (Enter code) 
 Contrast Flow 
0 No flow 
1 Small amount of flow, incomplete opacification  
of distal vessel 
2 Slow filling but complete opacification of distal vessel 
3 Prompt antegrade flow and rapid clearing 
 
 Estimate the stenosis at the beginning and end of 
the PCI procedure e.g. 50%, 75% 
 Type of stent implanted – select one only (Enter 
code) 
1. Cypher 
2. Endeavour 
3. Taxus 
4. Promus 
5. Other 
 
 PCI procedure performed – select one only  
(Enter code) 
1. Attempted but failed to succeed at lesion 
2. PTCA only (includes cutting balloon) 
3. Bare metal stent only implanted 
4. Drug eluting stent only implanted 
5. Bare metal stent and drug eluting stent implanted 
 PCI procedural success – select one only  
(Enter code) 
1. Good 
2. Failure 
3. Sub-optimal 
4. Not treated 
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TARGET LESIONS  
 
 
  
Segment 
number  
TIMI pre-
procedure 
 
Stenosis pre 
procedure  
TIMI post-
procedure  
Stent 
implanted 
(Yes/No) 
Type of stent 
implanted  
Stent Length 
(mm) 
Stent 
Diameter 
(mm) 
Stenosis post 
procedure 
 
Procedure 
performed 
 
Procedural 
success 
 
  
  
 
 
     
  
1 Lesion 1            
  
  
 
 
     
  
2 Lesion 2            
  
  
 
 
     
  
3 Lesion 3            
  
  
 
 
     
  
4 Lesion 4            
  
  
 
 
     
  
5 Lesion 5            
  
  
 
 
     
  
6 Lesion 6            
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TIMING OF SAMPLES TAKEN AT 2 HOURS 
 
1 Date of sample (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
      
2 Time sample taken (hh:mm)   __ __ : __ __ 
 
BIOMARKER RESULTS AT 2 Hours 
 
SERUM AND PLASMA RESULTS AT 2 Hours 
 
   SERUM PLASMA 
3 NGAL  Yes [    ] _ _ . _ _  NA [   ] Yes [    ] _ _ . _ _  NA [   ] 
    
4 Cystatin C  Yes [    ] _ _ . _ _  NA [   ] Yes [    ] _ _ . _ _  NA [   ] 
 
URINE BIOMARKERS AT 2 Hours 
 
5 NGAL  Yes [    ] __ __ . __ _ NA [   ] 
      
6 Cystatin C  Yes [    ] __ __ . __ __ NA [   ] 
      
7 KIM -1  Yes [    ] __ __ . __ _ NA [   ] 
      
8 Interleukin-18  Yes [    ] __ __ . __ _ NA [   ] 
      
9 NAG  Yes [    ] __ __ . __ _ NA [   ] 
      
10 FAB-P  Yes [    ] __ __ . __ __ NA [   ] 
 
TIMING OF SAMPLES TAKEN AT 4 HOURS 
 
11 Date of sample (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
      
12 Time sample taken (hh:mm)   __ __ : __ __ 
 
BIOMARKER RESULTS AT 4 Hours 
 
SERUM AND PLASMA RESULTS AT 4 Hours 
 
   SERUM PLASMA 
13 NGAL  Yes [    ] _ _ . _ _  NA [   ] Yes [    ] _ _ . _ _  NA [   ] 
    
14 Cystatin C  Yes [    ] _ _ . _ _  NA [   ] Yes [    ] _ _ . _ _  NA [   ] 
 
URINE BIOMARKERS AT 4 Hours 
 
15 NGAL  Yes [    ] __ __ . __ _ NA [   ] 
      
16 Cystatin C  Yes [    ] __ __ . __ __ NA [   ] 
      
17 KIM -1  Yes [    ] __ __ . __ _ NA [   ] 
      
18 Interleukin-18  Yes [    ] __ __ . __ _ NA [   ] 
      
19 NAG  Yes [    ] __ __ . __ _ NA [   ] 
      
20 FAB-P  Yes [    ] __ __ . __ __ NA [   ] 
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TIMING OF SAMPLES TAKEN AT PRE-DISCHARGE 
 
1 Date of sample (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
      
2 Time sample taken (hh:mm)   __ __ : __ __ 
 
BIOMARKER RESULTS AT PRE-DISCHARGE 
 
 
SERUM RESULTS AT PRE-DISCHARGE 
 
   SERUM PLASMA 
3 NGAL  Yes [    ] _ _ . _ _  NA [   ] Yes [    ] _ _ . _ _  NA [   ] 
    
4 Cystatin C  Yes [    ] _ _ . _ _  NA [   ] Yes [    ] _ _ . _ _  NA [   ] 
     
 
 
URINE BIOMARKERS AT PRE-DISCHARGE 
 
5 NGAL  Yes [    ] __ __ . __ _ NA [   ] 
      
6 Cystatin C  Yes [    ] __ __ . __ __ NA [   ] 
      
7 KIM -1  Yes [    ] __ __ . __ _ NA [   ] 
      
8 Interleukin-18  Yes [    ] __ __ . __ _ NA [   ] 
      
9 NAG  Yes [    ] __ __ . __ _ NA [   ] 
      
10 FAB-P  Yes [    ] __ __ . __ __ NA [   ] 
 
 
BLOOD RESULTS PRE-DISCHARGE 
 
11 Haemoglobin  Yes [    ] __ __ . __ g/dL NA [   ] 
     
12 White cell count  Yes [    ] __ __ . __ x 10
9
/L NA [   ] 
      
13 Platelets  Yes [    ] __ __ __ . __ x 10
9
/L NA [   ] 
     
14 Sodium  Yes [    ] __ __ __ mmol/L NA [   ] 
    
15 Potassium  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
      
16 Urea  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
      
17 Creatinine  Yes [    ]  __ __ µmol/L NA [   ] 
      
18 Creatinine Kinase  Yes [    ] __ __ __ __ NA [   ] 
      
19 Troponin  Yes [    ] __ __ __ NA [   ] 
      
20 eGFR  Yes [    ] __ __ . __ ml/min NA [   ] 
Instructions, definitions and reminders: opposite page: 11 
 
 
♥ Complications 
 
Please complete an SAE form if the patient has any event requiring hospitalisation or prolonging 
length of stay during hospitalisation at time of index procedure. 
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DISCHARGE DETAILS 
 
1 Referral for further PCI  Yes [    ] No  [    ] 
     
2 Referral for CABG  Yes [    ] No  [    ] 
      
3 Did the patient have any complications ♥  Yes [    ]  Complete SAE No  [    ] 
      
4 Status of patient on leaving hospital  Alive [    ] Dead  [    ] 
 
 
INVESTIGATOR’S DECLARATION 
By signing below, I declare that the information presented in this Case Record Form accurately reflects 
the medical records on the date specified. 
 
5 Date form completed (dd/mm/yyyy)  __ __ / __ __ / __ __ __ __ 
    
6 Name of person completing form (capitals)   
      
7 Signature of person completing form   
 
BIOMARKERS Pt ID: __ __ __ __ __ __ 
 
 
♥ Contrast Induced Nephropathy 
 
Contrast Induced Nephropathy is defined as a creatinine increase of ≥  44µmol/l from baseline. 
 
♥ Other Serious Adverse Event (SAE) 
 
Please complete an SAE form if the patient has any event requiring hospitalisation or prolonging 
length of stay during hospitalisation at time of index procedure. 
 
 
 
BIOMARKERS Pt ID: __ __ __ __ __ __ 
 
 
3 DAY FOLLOW UP 
 
1 Date of follow up (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
     
 
SERIOUS ADVERSE EVENTS SINCE DISCHARGE 
 
2 Contrast Nephropathy event ♥  Yes [    ] Complete SAE report No [    ] 
     
3 Other SAE event
 ♥  Yes [    ] Complete SAE report No [    ] 
 
TIMING OF SAMPLES TAKEN AT 3 DAY FOLLOW UP 
 
4 Date of sample (dd/mm/yyyy)  __ __ / __ __ /__ __ __ __ 
      
5 Time sample taken (hh:mm)   __ __ : __ __ 
 
BLOOD RESULTS AT 3 DAY FOLLOW UP 
 
6 Haemoglobin  Yes [    ] __ __ . __ g/dL NA [   ] 
     
7 White cell count  Yes [    ] __ __ . __ x 10
9
/L NA [   ] 
      
8 Platelets  Yes [    ] __ __ __ . __ x 10
9
/L NA [   ] 
     
9 Sodium  Yes [    ] __ __ __ mmol/L NA [   ] 
    
10 Potassium  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
      
11 Urea  Yes [    ] __ __ . __ __ mmol/L NA [   ] 
      
12 Creatinine  Yes [    ] __ __ __ µmol/L NA [   ] 
      
16 eGFR  Yes [    ] __ __ . __ ml/min NA [   ] 
 
 
INVESTIGATOR’S DECLARATION 
By signing below, I declare that the information presented in this Case Record Form accurately reflects 
the medical records on the date specified. 
 
13 Date form completed (dd/mm/yyyy)  __ __ / __ __ / __ __ __ __ 
    
14 Name of person completing form (capitals)   
      
15 Signature of person completing form   
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Development of a biomarker panel for the 
earlier prediction of contrast nephropathy 
post percutaneous coronary intervention in 
patients with diabetes mellitus 
 
Patient Information Sheet 
 
You are being asked to take part in this study because you are 
an adult who is about to undergo a planned procedure on 
your heart blood vessels (percutaneous coronary intervention 
- angioplasty and coronary stenting) 
 
Part 1 
 
Invitation 
You are being invited to take part in a research study. Before you 
decide it is important for you to understand why the research is 
being done and what it will involve. Please take time and read the 
following information carefully. Talk to others about the study if you 
wish. 
 
 Part 1 Tells you about the purpose of this study and 
what will happen to you if you take part. 
 Part 2 This gives you more detailed information 
about the conduct of the study 
 
Ask if there is anything that is not clear or if you would like more 
information. Take time to decide whether or not you wish to take 
part. 
Barts and The London NHS Trust (BLT) is the Sponsor of this 
research. 
 
What is the purpose of the study? 
Patients living with diabetes mellitus have double the risk of kidney 
failure compared to patients without diabetes following use of dye 
in many x-rays and procedures to diagnose and treat narrowing of 
the arteries (blood vessels) in the heart that can lead to angina or a 
heart attack. Heart disease is the commonest cause of death in 
patients with diabetes. People with diabetes are more likely to 
need these tests/treatments. By identifying those at greater risk of 
kidney complications we may be able to make these 
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tests/treatments safer and offer them to more patients with 
diabetes 
 
Why have I been chosen? 
You have been asked to take part in this study because you are an 
adult who is about to undergo a planned procedure (percutaneous 
coronary intervention – angioplasty and coronary stenting) to look 
at the blood vessels (arteries) of the heart and treat any 
narrowings found.  
 
The percutaneous coronary intervention procedure that you are 
undergoing as part of your planned care requires the use of x-rays 
to look at your blood vessels and as such there is a risk arising 
from the use of ionising radiation. The dose from the x-ray 
exposure for the whole procedure is about the same dose that you 
will get from 5 years of natural background radiation and is 
considered to be of low risk. 
 
Do I have to take part? 
No – it is up to you to decide whether or not you want to take part. 
If you do, you will be given this information sheet to keep and be 
asked to sign the agreement to research section on the consent 
form. You are still free to withdraw at any time and without giving a 
reason. Your involvement in the study will not affect your planned 
procedure in any way. Nor will it influence the standard of care that 
you will receive in hospital. 
 
Before you can begin the study 
You may read the full study protocol as well as this Information 
Sheet which gives you many details about the study. The recruiting 
investigator will tell you about the study and any risks. You will be 
told exactly what the study involves and what will be required of 
you. You are encouraged to ask questions of the investigators 
conducting the recruitment interview until you are satisfied that you 
fully understand the nature of the study and the requirements. 
 
What do I have to do? 
If you agree to take part and to sign the research section of your 
Consent Form, we will review your medical records and collect 
data relating to your health, diagnosis and planned treatment. 
 
In relation to the study, we only request that you agree to us taking 
some blood and urine samples before / during and at time intervals 
after (2 hours, 4 hours, 8-12 hours, pre-discharge) the procedure. 
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These samples will have no impact on your planned treatment or 
health. 3 days after the procedure we request that you come back 
to The London Chest Hospital for a final blood test. The total blood 
volume will not exceed 145ml and the total urine volume will not 
exceed 500ml. Having this amount of blood taken is not associated 
with any medical problems. 
 
What are the alternatives for diagnosis or treatment? 
Your doctor will have already discussed your treatment with you. If 
you have any concerns about your planned treatment please 
discuss them with the medical team. 
 
What are the other possible disadvantages or risks of taking 
part? 
We do not believe that there are any disadvantages or risks in you 
taking part. 
 
Expenses and Payments 
There will be no payment in exchange for your participation in this 
study or for the donation of your blood and urine samples. 
 
What are the possible benefits of taking part? 
None although you will be contributing to our understanding of the 
reasons for kidney problems developing in patients with diabetes 
and this knowledge may help other patients, like yourself in the 
future. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the 
study or any possible harm you might suffer will be addressed. The 
detailed information on this is given in Part 2. If you have a 
complaint please contact the following in the first instance: 
Dr Katie Qureshi, Specialist Registrar in Cardiology 
Dr Akhil Kapur, Consultant Cardiologist 
 
Will my taking part in the study be kept confidential? 
Yes. All information about your participation in this study will be 
kept confidential 
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Contact Details: 
If you require any further information please contact: 
Dr Katie Qureshi,    Dr Akhil Kapur, 
Specialist Registrar,   Consultant Cardiologist, 
Department of Cardiology,   Department of Cardiology, 
St. James’ Building,    St. James’ Building 
The London Chest Hospital,   The London Chest Hospital, 
Barts and The London NHS Trust,  Barts and The London NHS Trust, 
Bonner Road,      Bonner Road, 
London,     London, 
E2 9JX     E2 9JX 
Tel: 0208 983 2477    0208 983 2413 
Mob: 07592 745217   
Fax: 0208 983 2381    0208 983 2381 
E-mail: drkatiequreshi@yahoo.co.uk  akhil.kapur@bartsandthelondon.nhs.uk 
E-mail: katie.qureshi@bartsandthelondon.nhs.uk 
 
This completes Part 1 of the Information Sheet. If the information 
in Part1 has interested you and you are considering participation, 
please continue to read the information in Part 2 before making 
any decision. 
 
Part 2 
 
What will happen if I don’t want to carry on with the study? 
If you withdraw from the study we will need to use the data 
collected up to your withdrawal. Any blood and urine samples that 
can still be identified as yours will be destroyed if you wish. 
 
What if there is a problem? 
Barts and The London NHS Trust has agreed that if you are 
harmed as a result of your participation in the study, you will be 
compensated, provided that, on the balance of probabilities, an 
injury was caused as a direct result of the intervention or 
procedures you received during the course of the study. These 
special compensation arrangements apply where an injury is 
caused to you that would not have occurred if you were not in the 
trial. These arrangements do not affect your right to pursue a claim 
through legal action. 
 
Complaints: 
If you have a concern about any aspect of this study, you should 
ask to speak to the Research Team who will do their best to 
answer your questions (Dr Katie Qureshi 07592 745217, 0208 983 
2477, Dr Akhil Kapur 0208 983 2477). 
If you remain unhappy and wish to complain formally you can do 
this by contacting : The Patient Advisory Liaison Service (PALS) if 
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you have any concerns regarding the care you have received, or 
as an initial point of contact if you have a complaint. Please 
telephone 0207 377 6335, minicom 0207 943 1350, or email 
pals@bartsandthelondon.nhs.uk . You can also visit the PALS 
office by asking at any hospital reception. 
 
Will my taking part in this study be kept confidential? 
All the information obtained about you in the course of the study is 
confidential and will be kept in a secure, locked room. The 
investigators performing the study and a study monitor will have 
access to the data collected in this study. They may also be looked 
at by representatives of regulatory authorities and by authorised 
people from Bart’s and The London NHS Trust to check that the 
study is being performed correctly. All will have a duty of 
confidentiality to you as a research participant and nothing that 
could reveal your identity will be disclosed outside the research 
site.  
 
What will happen to any samples I give? 
All your blood and urine samples will be analysed at the William 
Harvey Research Institute at Barts and The London School of 
Medicine. Some will be tested immediately, while others will be 
stored for later use in the project. Once the results have been 
obtained, if there is any left, it will be destroyed. 
 
Will any genetic tests be done? 
No genetic tests will be performed on your samples 
 
What will happen to the results of the research study? 
Results from this study may be published or presented at meetings 
and in scientific journals. 
 
Who has reviewed the study? 
This study has been given a favourable ethical opinion for conduct 
in the NHS by East London and The City Research Ethics 
Committee 1 (NRES 09/H0703/29). 
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